US20190070182A1 - Uses of pyrimido-pyridazinones to treat cancer - Google Patents

Uses of pyrimido-pyridazinones to treat cancer Download PDF

Info

Publication number
US20190070182A1
US20190070182A1 US16/179,274 US201816179274A US2019070182A1 US 20190070182 A1 US20190070182 A1 US 20190070182A1 US 201816179274 A US201816179274 A US 201816179274A US 2019070182 A1 US2019070182 A1 US 2019070182A1
Authority
US
United States
Prior art keywords
pyridazin
amino
phenyl
oxo
dihydropyrimido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/179,274
Inventor
Sanjeeva P. Reddy
Sandeep Gupta
Roger Astbury Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asana Biosciences LLC
Original Assignee
Asana Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asana Biosciences LLC filed Critical Asana Biosciences LLC
Priority to US16/179,274 priority Critical patent/US20190070182A1/en
Publication of US20190070182A1 publication Critical patent/US20190070182A1/en
Assigned to ASANA BIOSCIENCES, LLC reassignment ASANA BIOSCIENCES, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GUPTA, SANDEEP, REDDY, SANJEEVA P., SMITH, ROGER ASTBURY
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

  • ibrutinib is an orally bioavailable and highly specific inhibitor of Bruton tyrosine kinase (BTK) that was recently approved for treatment of patients with recurrent chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Ibrutinib has also shown efficacy in subsets of patients with diffuse large B cell lymphoma (DLBCL) and Waldenstrom macroglobulinaemia (WM).
  • BTK Bruton tyrosine kinase
  • the present invention provides a method of treating cancer, which includes administering a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein R 1 and R 2 are defined herein, to a subject in need thereof.
  • Another aspect of the present invention is directed to a method of inhibiting growth and proliferation of cancer cells in vitro or in vivo, which includes contacting the cells with an amount of the compound of formula (I) effective to inhibit the growth or proliferation of the cancer cells.
  • a further aspect of the present invention is directed to a method of inhibiting tumor growth, which includes contacting the tumor with an amount of the compound of formula (I) effective to inhibit the growth of the tumor.
  • cancers, cancer cells and tumors treatable in accordance with the methods of the present invention include non-solid tumors, e.g., hematopoietic cancers such as leukemias, multiple myelomas and lymphomas, and solid tumors.
  • the hematopoietic cancer is a B-cell lymphoma, e.g., diffuse large B-cell lymphoma, mantle cell lymphoma, or follicular lymphoma.
  • the leukemia is acute myeloid leukemia (AML), e.g., human erythroleukemia.
  • the subject with hematopoietic cancer is or has become refractory to treatment with Ibrutinib.
  • the solid tumor is a tumor of the bladder, colon, liver, kidney, lung, breast, ovary or cervix.
  • the compound of formula (I) is 2-(1-(4-((4-(4-hydroxypiperidin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile (also described herein as ASN002 or compound 189) or a pharmaceutically acceptable salt or ester thereof.
  • FIG. 1 is a graph that shows that ASN002 induced apoptosis in a DLBCL cell line, Pfeiffer, using a caspase 3/7 assay. The data show that after a 24-hour treatment, the EC 50 of ASN002 was 120 nM.
  • FIG. 2 is a bar graph showing that ASN002 exhibited strong antiproliferative activity in several hematological malignant cell lines, wherein the data were generated in a cell line panel representing leukemia, lymphoma, and multiple myelomas.
  • FIG. 3 is a graph showing that ASN002 inhibited tumor growth in a DLBCL xenograft mouse model (derived from Pfeiffer cell line).
  • FIG. 4 is a graph showing that compound ASN002 inhibited tumor growth in another DLBCL xenograft mouse model (derived from SU-DHL-6 cell line).
  • FIG. 5 is a graph showing that ASN002 inhibited tumor growth in a mouse model of multiple myeloma (derived from H929 cell line).
  • FIG. 6 is a graph showing that ASN002 delayed the hind limb paralysis in a mouse model of human erythroleukemia (derived from HEL cell line).
  • R 1 is NR 4 R 5 , optionally substituted C 1 to C 6 alkoxy, optionally substituted C 6 to C 14 aryl, optionally substituted heteroaryl, optionally substituted 3-10 membered monocyclic or bicyclic cycloalkyl, or optionally substituted 3-10 membered monocyclic or bicyclic heterocyclyl.
  • the 3-4 membered cycloalkyl and heterocyclyl are saturated.
  • the hydrogen atoms on the same carbon atom of the cycloalkyl or heterocyclyl are optionally replaced with an optionally substituted 3-6 membered cycloalkyl or heterocyclyl to form a spirocycloalkyl or spiroheterocyclyl.
  • the hydrogen atoms on the same atom of the cycloalkyl or heterocyclyl are optionally replaced with O to form an oxo substituent.
  • the compound of Formula (I) is provided wherein R 1 is NR 4 R 5 , optionally substituted C 1 to C 6 alkoxy, optionally substituted C 6 to C 14 aryl, optionally substituted heteroaryl, optionally substituted 3-10 membered monocyclic or bicyclic cycloalkyl, or optionally substituted 3-10 membered monocyclic or bicyclic heterocyclyl.
  • R 1 is NR 4 R 5 , optionally substituted C 1 to C 6 alkoxy, optionally substituted C 6 to C 14 aryl, optionally substituted heteroaryl, optionally substituted 3-10 membered monocyclic or bicyclic cycloalkyl, or optionally substituted 3-10 membered monocyclic or bicyclic heterocyclyl.
  • the 3-4 membered cycloalkyl and heterocyclyl rings are saturated.
  • Hydrogen atoms on the same carbon atom of the cycloalkyl or heterocyclyl are optionally replaced with an optionally substituted 3-6 membered cycloalkyl or heterocyclyl to form a spirocycloalkyl or spiroheterocyclyl.
  • hydrogen atoms on the same atom of the cycloalkyl or heterocyclyl are optionally replaced with O to form an oxo substituent.
  • R 2 is phenyl or 5-6 membered heteroaryl containing at least one N or NH in the backbone, wherein R 2 is optionally substituted with one or more R 19 and when R 2 is 4-pyridyl, the 4-pyridyl lacks a carbonyl substituent at the 2 nd position.
  • R 19 is NR 4 R 5 , (C 1 to C 6 alkyl)NR 4 R 5 , C 1 to C 6 alkyl, C(O)NR 4 R 5 , C 3 to C 8 cycloalkyl substituted with one or more R 21 , or heterocyclyl substituted with one or more R 21 .
  • R 21 is (C 1 to C 6 alkyl)CN, (C 1 to C 6 alkyl)C(O)OH, (C 1 to C 6 alkyl)C(O)NH 2 , (C 1 to C 6 alkyl)C(O)NHCH 2 CH 2 OH, or (C 1 to C 6 alkyl)C(O)N(CH 2 CH 2 OH) 2 .
  • R 4 and R 5 are independently selected from among H, C 1 to C 6 alkyl, C 1 to C 6 hydroxyalkyl, and (C 1 to C 6 alkyl)N(C 1 to C 6 alkyl)(C 1 to C 6 alkyl).
  • R 4 and R 5 are joined to form an optionally substituted 3-8 membered heterocyclyl optionally further containing one or more O, S(O) n , or NR 9 .
  • R 9 is H, OH, (C 1 to C 6 alkyl)C(O)OH, (C 1 to C 6 alkyl)C(O)NH 2 , (C 1 to C 6 alkyl)C(O)NHCH 2 CH 2 OH, (C 1 to C 6 alkyl)C(O)N(CH 2 CH 2 OH) 2 , C(O)(C 1 to C 6 alkyl)NH 2 , C(O)(C 1 to C 6 alkyl)OH, C 1 to C 6 hydroxyalkyl, or C 1 to C 6 alkyl and n is 0 to 2.
  • R 9 is CH 2 CH 2 OH.
  • Hydrogen atoms on the same carbon atom of the heterocyclyl are optionally replaced with a 3-6 membered cycloalkyl or heterocyclyl optionally substituted with one or more R 20 to form a spirocycloalkyl or spiroheterocyclyl.
  • R 20 is C(O)O(C 1 to C 6 alkyl), C(O)OH, (C 1 to C 6 alkyl)C(O)OH, (C 1 to C 6 alkyl)C(O)NH 2 , (C 1 to C 6 alkyl)C(O)NHCH 2 CH 2 OH, or (C 1 to C 6 alkyl)C(O)N(CH 2 CH 2 OH) 2 .
  • hydrogen atoms on the same atom of any of the heterocyclyls or cycloalkyls of R 9 are optionally replaced with O to form an oxo substituent; or a pharmaceutically acceptable salt or ester thereof.
  • the compound of Formula (I) is provided wherein R 1 is NR 4 R 5 , C 1 to C 6 alkoxy, optionally substituted phenyl, heteroaryl, optionally substituted 3-10 membered cycloalkyl, or optionally substituted 3-10 membered monocyclic or bicyclic heterocyclyl. Hydrogen atoms on the same carbon atom of the cycloalkyl or heterocyclyl are optionally replaced with an optionally substituted 3-6 membered cycloalkyl or heterocyclyl to form a spirocycloalkyl or spiroheterocyclyl.
  • R 2 is phenyl or pyrazole, wherein R 2 is optionally substituted with one or more R 19 .
  • R 19 is NR 4 R 5 , (C 1 to C 6 alkyl)NR 4 R 5 , C 1 to C 6 alkyl, C(O)NR 4 R 5 , C 3 to C 8 cycloalkyl substituted with one or more R 21 , or heterocyclyl substituted with one or more R 21 .
  • R 21 is (C 1 to C 6 alkyl)CN, (C 1 to C 6 alkyl)C(O)OH, (C 1 to C 6 alkyl)C(O)NH 2 , (C 1 to C 6 alkyl)C(O)NHCH 2 CH 2 OH, (C 1 to C 6 alkyl)C(O)N(CH 2 CH 2 OH) 2 .
  • R 4 and R 5 are (a) independently selected from among H, C 1 to C 6 alkyl, C 1 to C 6 hydroxyalkyl, and (C 1 to C 6 alkyl)N(C 1 to C 6 alkyl)(C 1 to C 6 alkyl) or (b) joined to form an optionally substituted 3-8 membered heterocyclyl optionally further containing one or more O, S(O) n , or NR 9 .
  • R 9 is H, OH, C 1 to C 6 hydroxyalkyl, (C 1 to C 6 alkyl)C(O)OH, (C 1 to C 6 alkyl)C(O)NH 2 , (C 1 to C 6 alkyl)C(O)NHCH 2 CH 2 OH, (C 1 to C 6 alkyl)C(O)N(CH 2 CH 2 OH) 2 , C(O)(C 1 to C 6 alkyl)NH 2 , C(O)(C 1 to C 6 alkyl)OH, or C 1 to C 6 alkyl and n is 0 to 2.
  • R 9 is CH 2 CH 2 OH.
  • R 20 is C(O)O(C 1 to C 6 alkyl), C(O)OH, (C 1 to C 6 alkyl)C(O)OH, (C 1 to C 6 alkyl)C(O)NH 2 , (C 1 to C 6 alkyl)C(O)NHCH 2 CH 2 OH, or (C 1 to C 6 alkyl)C(O)N(CH 2 CH 2 OH) 2 .
  • hydrogen atoms on the same atom of the heterocyclyl (b) or cycloalkyl are optionally replaced with O to form an oxo substituent; or a pharmaceutically acceptable salt or ester thereof.
  • the compound of Formula (I) is provided wherein R 1 is NR 4 R 5 , C 1 to C 6 alkoxy, phenyl optionally substituted with C(O)O(C 1 to C 6 alkyl), C(O)OH, O(C 1 to C 3 perfluoroalkyl), C 1 to C 6 alkoxy, halogen, CH 2 -heterocyclyl, or CH 2 CN, 5-8 membered cycloalkyl, heteroaryl, or 3-10 membered monocyclic or bicyclic heterocyclyl optionally substituted with (C 1 to C 6 alkyl)C(O)OH, C 1 to C 6 alkyl, CN, C(O)OH, or (C 1 to C 6 alkyl)CN.
  • Hydrogen atoms on the same carbon atom of the cycloalkyl or heterocyclyl are optionally replaced with an optionally substituted 3-6 membered cycloalkyl or heterocyclyl to form a spirocycloalkyl or spiroheterocyclyl.
  • hydrogen atoms on the same atom of the cycloalkyl or heterocyclyl are optionally replaced with O to form an oxo substituent.
  • R 2 is phenyl or pyrazole, wherein R 2 is optionally substituted with one R 19 .
  • R 19 is NR 4 R 5 , (C 1 to C 6 alkyl)NR 4 R 5 , C 1 to C 6 alkyl, C(O)NR 4 R 5 , C 3 to C 8 cycloalkyl substituted with one or more R 21 , or heterocyclyl substituted with one or more R 21 .
  • R 21 is (C 1 to C 6 alkyl)CN, (C 1 to C 6 alkyl)C(O)OH, (C 1 to C 6 alkyl)C(O)NH 2 , (C 1 to C 6 alkyl)C(O)NHCH 2 CH 2 OH, or (C 1 to C 6 alkyl)C(O)N(CH 2 CH 2 OH) 2 .
  • R 4 and R 5 are (a) independently selected from among H, C 1 to C 6 alkyl, C 1 to C 6 hydroxyalkyl, and (C 1 to C 6 alkyl)N(C 1 to C 6 alkyl)(C 1 to C 6 alkyl).
  • R 4 and R 5 may also be (b) joined to form a 5-8 membered heterocyclyl optionally further containing one or two O, S(O) n , or NR 9 .
  • R 9 is H, OH, C 1 to C 6 hydroxyalkyl (C 1 to C 6 alkyl)C(O)OH, C(O)(C 1 to C 6 alkyl)NH 2 , C(O)(C 1 to C 6 alkyl)OH, (C 1 to C 6 alkyl)C(O)NH 2 , (C 1 to C 6 alkyl)C(O)NHCH 2 CH 2 OH, (C 1 to C 6 alkyl)C(O)N(CH 2 CH 2 OH) 2 , or C 1 to C 6 alkyl and n is 0 to 2.
  • R 9 is CH 2 CH 2 OH.
  • Hydrogen atoms on the same carbon atom of the heterocyclyl are optionally replaced with a 3-5 membered cycloalkyl optionally substituted with one or more R 20 to form a spirocycloalkyl.
  • R 20 is C(O)O(C 1 to C 6 alkyl), C(O)OH, (C 1 to C 6 alkyl)C(O)OH, (C 1 to C 6 alkyl)C(O)NH 2 , (C 1 to C 6 alkyl)C(O)C(O)C(O)NHCH 2 CH 2 OH, or (C 1 to C 6 alkyl)C(O)N(CH 2 CH 2 OH) 2 .
  • hydrogen atoms on the same atom of the heterocyclyl (b) or cycloalkyl (b) are optionally replaced with O to form an oxo substituent; or a pharmaceutically acceptable salt or ester thereof.
  • Some compounds useful in the practice of the invention possess one or more chiral centers, and the present invention includes use of each separate enantiomer of such compounds as well as mixtures of the enantiomers. Where multiple chiral centers exist in compounds of the present invention, the invention includes uses of compound(s) with each possible combination of chiral centers within a compound, as well as all possible enantiomeric and diastereomeric mixtures thereof. All chiral, diastereomeric, and racemic forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials.
  • the number of carbon atoms present in a given group is designated “C x -C y ”, where x and y are the lower and upper limits, respectively.
  • a group designated as “C 1 -C 6 ” contains from 1 to 6 carbon atoms.
  • the carbon number as used in the definitions herein refers to carbon backbone and carbon branching, but does not include carbon atoms of the substituents, such as alkoxy substitutions and the like.
  • the nomenclature of substituents that are not explicitly defined herein are arrived at by naming from left to right the terminal portion of the functionality followed by the adjacent functionality toward the point of attachment.
  • arylalkyloxycabonyl refers to the group (C 6 -C 14 aryl)-(C 1 -C 6 alkyl)-O—C(O)—.
  • Terms not defined herein have the meaning commonly attributed to them by those skilled in the art.
  • Alkyl refers to a hydrocarbon chain that may be a straight chain or branched chain, containing the indicated number of carbon atoms, for example, a C 1 -C 12 alkyl group may have from 1 to 12 (inclusive) carbon atoms in it.
  • Examples of C 1 -C 6 alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, and isohexyl.
  • C 1 -C 8 alkyl groups include, but are not limited to, methyl, propyl, pentyl, hexyl, heptyl, 3-methylhex-1-yl, 2,3-dimethylpent-2-yl, 3-ethylpent-1-yl, octyl, 2-methylhept-2-yl, 2,3-dimethylhex-1-yl, and 2,3,3-trimethylpent-1-yl.
  • An alkyl group can be unsubstituted or substituted with one or more of halogen, NH 2 , (alkyl)NH, (alkyl)(alkyl)N—, —N(alkyl)C(O)(alkyl), NHC(O)(alkyl), —NHC(O)H, —C(O)NH 2 , —C(O)NH(alkyl), —C(O)N(alkyl)(alkyl), CN, OH, alkoxy, alkyl, C(O)OH, —C(O)O(alkyl), —C(O)(alkyl), aryl, heteroaryl, heterocyclyl, cycloalkyl, haloalkyl, aminoalkyl-, —OC(O)(alkyl), carboxyamidoalkyl-, and NO 2 .
  • halogen NH 2 , (alkyl)NH, (alkyl)(alkyl)
  • Alkoxy refers to the group R—O— where R is an alkyl group, as defined above.
  • Exemplary C 1 -C 6 alkoxy groups include but are not limited to methoxy, ethoxy, n-propoxy, 1-propoxy, n-butoxy and t-butoxy.
  • An alkoxy group can be unsubstituted or substituted with one or more of halogen, OH, alkoxy, NH 2 , (alkyl)amino-, di(alkyl)amino-, (alkyl)C(O)N(C 1 -C 3 alkyl)-, (alkyl)carboxyamido-, HC(O)NH—, H 2 NC(O)—, (alkyl)NHC(O)—, di(alkyl)NC(O)—, CN, C(O)OH, (alkoxy)carbonyl-, (alkyl)C(O)—, aryl, heteroaryl, cycloalkyl, haloalkyl, amino(C 1 -C 6 alkyl)-, (alkyl)carboxyl-, carboxyamidoalkyl-, or NO 2 .
  • Aryl refers to an aromatic 6 to 14 membered hydrocarbon group.
  • Examples of a C 6 -C 14 aryl group include, but are not limited to, phenyl, ⁇ -naphthyl, ⁇ -naphthyl, biphenyl, anthryl, tetrahydronaphthyl, fluorenyl, indanyl, biphenylenyl, and acenanaphthyl.
  • Examples of a C 6 -C 10 aryl group include, but are not limited to, phenyl, ⁇ -naphthyl, ⁇ -naphthyl, biphenyl, and tetrahydronaphthyl.
  • An aryl group can be unsubstituted or substituted with one or more of alkyl, halogen, haloalkyl, alkoxy, haloalkoxy, OH, hydroxyalkyl, —O-(hydroxyalkyl), —O-(alkyl)-C(O)OH, -(alkyl)-(alkoxy)-halogen, NH 2 , aminoalkyl-, dialkylamino-, C(O)OH, —C(O)O-(alkyl), —OC(O)(alkyl), —O-(alkyl)-N(alkyl)(alkyl),N-alkylamido-, —C(O)NH 2 , (alkyl)amido-, NO 2 , (aryl)alkyl, alkoxy, aryloxy, heteroaryloxy, (aryl)amino, (alkoxy)carbonyl-, (alkyl)amido-, (alky
  • bicycle or “bicyclic” as used herein refers to a molecule that features two fused rings, which rings are a cycloalkyl, heterocyclyl, or heteroaryl.
  • the rings are fused across a bond between two atoms.
  • the bicyclic moiety formed therefrom shares a bond between the rings.
  • the bicyclic moiety is formed by the fusion of two rings across a sequence of atoms of the rings to form a bridgehead.
  • a “bridge” is an unbranched chain of one or more atoms connecting two bridgeheads in a polycyclic compound.
  • the bicyclic molecule is a “spiro” or “spirocyclic” moiety.
  • the spirocyclic group is a carbocyclic or heterocyclic ring which bound through a single carbon atom of the spirocyclic moiety to a single carbon atom of a carbocyclic or heterocyclic moiety.
  • the spirocyclic group is a cycloalkyl and is bound to another cycloalkyl.
  • the spirocyclic group is a cycloalkyl and is bound to a heterocyclyl.
  • the spirocyclic group is a heterocyclyl and is bound to another heterocyclyl.
  • the spirocyclic group is a heterocyclyl and is bound to a cycloalkyl.
  • (Aryl)alkyl refers to an alkyl group, as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with an aryl group as defined above.
  • (C 6 -C 14 aryl)alkyl-moieties include benzyl, benzhydryl, 1-phenylethyl, 2-phenylethyl, 3-phenylpropyl, 2-phenylpropyl, 1-naphthylmethyl, 2-naphthylmethyl and the like.
  • An (aryl)alkyl group can be unsubstituted or substituted with one or more of of halogen, CN, NH 2 , OH, (alkyl)amino-, di(alkyl)amino-, (alkyl)C(O)N(alkyl)-, (alkyl)carboxyamido-, HC(O)NH—, H 2 NC(O)—, (alkyl)NHC(O)—, di(alkyl)NC(O)—, CN, OH, alkoxy, alkyl, C(O)OH, (alkoxy)carbonyl-, (alkyl)C(O)—, aryl, heteroaryl, cycloalkyl, haloalkyl, amino(alkyl)-, (alkyl)carboxyl-, carboxyamidoalkyl-, or NO 2 .
  • (Alkoxy)carbonyl- refers to the group alkyl-O—C(O)—.
  • Exemplary (C 1 -C 6 alkoxy)carbonyl- groups include but are not limited to methoxy, ethoxy, n-propoxy, 1-propoxy, n-butoxy and t-butoxy.
  • An (alkoxy)carbonyl group can be unsubstituted or substituted with one or more of halogen, OH, NH 2 , (alkyl)amino-, di(alkyl)amino-, (alkyl)C(O)N(alkyl)-, (alkyl)carboxyamido-, HC(O)NH—, H 2 NC(O)—, (alkyl)NHC(O)—, di(alkyl)NC(O)—, CN, alkoxy, C(O)OH, (alkoxy)carbonyl-, (alkyl)C(O)—, aryl, heteroaryl, cycloalkyl, haloalkyl, amino(alkyl)-, (alkyl)carboxyl-, carboxyamidoalkyl-, or NO 2 .
  • (Alkyl)amido- refers to a —C(O)NH— group in which the nitrogen atom of said group is attached to a C 1 -C 6 alkyl group, as defined above.
  • Representative examples of a (C 1 -C 6 alkyl)amido- group include, but are not limited to, C(O)NHCH 3 , —C(O)NHCH 2 CH 3 , —C(O)NHCH 2 CH 2 CH 3 , C(O)NHCH 2 CH 2 CH 2 CH 3 , —C(O)NHCH 2 CH 2 CH 2 CH 2 CH 3 , —C(O)NHCH(CH 3 ) 2 , C(O)NHCH 2 CH(CH 3 ) 2 , —C(O)NHCH(CH 3 )CH 2 CH 3 , —C(O)NH—C(CH 3 ) 3 and C(O)NHCH 2 C(CH 3 ) 3 .
  • (Alkyl)amino- refers to an —NH group, the nitrogen atom of said group being attached to a alkyl group, as defined above.
  • Representative examples of an (C 1 -C 6 alkyl)amino- group include, but are not limited to CH 3 NH—, CH 3 CH 2 NH—, CH 3 CH 2 CH 2 NH—, CH 3 CH 2 CH 2 CH 2 NH—, (CH 3 ) 2 CHNH—, (CH 3 ) 2 CHCH 2 NH—, CH 3 CH 2 CH(CH 3 )NH— and (CH 3 ) 3 CNH—.
  • An (alkyl)amino group can be unsubstituted or substituted on the alkyl moiety with one or more of halogen, NH 2 , (alkyl)amino-, di(alkyl)amino-, (alkyl)C(O)N(alkyl)-, (alkyl)carboxyamido-, HC(O)NH—, H 2 NC(O)—, (alkyl)NHC(O)—, di(alkyl)NC(O)—, CN, OH, alkoxy, alkyl, C(O)OH, (alkoxy)carbonyl-, (alkyl)C(O)—, aryl, heteroaryl, cycloalkyl, haloalkyl, amino(alkyl)-, (alkyl)carboxyl-, carboxyamidoalkyl-, or NO 2 .
  • halogen NH 2 , (alkyl)amino-, di(alky
  • Aminoalkyl- refers to an alkyl group, as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with —NH 2 ; one or both H of the NH 2 may be replaced by a substituent.
  • Alkylcarboxyl- refers to an alkyl group, defined above that is attached to the parent structure through the oxygen atom of a carboxyl (C(O)—O—) functionality.
  • Examples of (C 1 -C 6 alkyl)carboxyl- include acetoxy, propionoxy, propylcarboxyl, and isopentylcarboxyl.
  • (Alkyl)carboxyamido- refers to a —NHC(O)— group in which the carbonyl carbon atom of said group is attached to a C 1 -C 6 alkyl group, as defined above.
  • Representative examples of a (C 1 -C 6 alkyl)carboxyamido- group include, but are not limited to, —NHC(O)CH 3 , —NHC(O)CH 2 CH 3 , —NHC(O)CH 2 CH 2 CH 3 , NHC(O)CH 2 CH 2 CH 2 CH 3 , —NHC(O)CH 2 CH 2 CH 2 CH 2 CH 3 , —NHC(O)CH(CH 3 ) 2 , NHC(O)CH 2 CH(CH 3 ) 2 , —NHC(O)CH(CH 3 )CH 2 CH 3 , —NHC(O)—C(CH 3 ) 3 and NHC(O)CH 2 C(CH 3 ) 3 .
  • (Aryl)amino refers to a radical of formula (aryl)-NH—, wherein aryl is as defined above.
  • (Aryl)oxy refers to the group Ar—O— where Ar is an aryl group, as defined above.
  • Cycloalkyl refers to a non-aromatic, saturated, partially saturated, monocyclic, bicyclic or polycyclic hydrocarbon 3 to 12 membered ring system.
  • Representative examples of a C 3 -C 12 cycloalkyl include, but are not limited to, cyclopropyl, cyclopentyl, cycloheptyl, cyclooctyl, decahydronaphthalen-1-yl, octahydro-1H-inden-2-yl, decahydro-1H-benzo[7]annulen-2-yl, and dodecahydros-indacen-4-yl.
  • C 3 -C 10 cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, decahydronaphthalen-1-yl, and octahydro-1H-inden-2-yl.
  • Representative examples of a C 3 -C 8 cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and octahydropentalen-2-yl.
  • a cycloalkyl can be unsubstituted or substituted with one or more of halogen, NH 2 , (alkyl)NH, (alkyl)(alkyl)N—, —N(alkyl)C(O)(alkyl), —NHC(O)(alkyl), —NHC(O)H, —C(O)NH 2 , —C(O)NH(alkyl), —C(O)N(alkyl)(alkyl), CN, OH, alkoxy, alkyl, C(O)OH, —C(O)O(alkyl), —C(O) alkyl), aryl, heteroaryl, cycloalkyl, haloalkyl, aminoalkyl-, —OC(O)(alkyl), carboxyamidoalkyl-, and NO 2 . Additionally, each of any two hydrogen atoms on the same carbon atom of the carbocyclic ring can be replaced by an
  • Halo or “halogen” refers to —F, —Cl, —Br and —I.
  • C 1 -C 6 haloalkyl refers to a C 1 -C 6 alkyl group, as defined above, wherein one or more of the C 1 -C 6 alkyl group's hydrogen atoms has been replaced with F, Cl, Br, or I. Each substitution can be independently selected from F, Cl, Br, or I.
  • C 1 -C 6 haloalkyl- group include, but are not limited to, —CH 2 F, —CCl 3 , —CF 3 , CH 2 CF 3 , —CH 2 Cl, —CH 2 CH 2 Br, —CH 2 CH 2 I, —CH 2 CH 2 CH 2 F, —CH 2 CH 2 CH 2 Cl, —CH 2 CH 2 CH 2 CH 2 Br, —CH 2 CH 2 CH 2 CH 2 I, CH 2 CH 2 CH 2 CH 2 CH 2 Br, —CH 2 CH 2 CH 2 CH 2 CH 2 I, —CH 2 CH(Br)CH 3 , —CH 2 CH(Cl)CH 2 CH 3 , —CH(F)CH 2 CH 3 and —C(CH 3 ) 2 (CH 2 Cl).
  • Heteroaryl refers to a monocyclic, bicyclic, or polycyclic aromatic ring system containing at least one ring atom selected from the heteroatoms oxygen, sulfur and nitrogen.
  • Examples of C 1 -C 9 heteroaryl groups include furan, thiophene, indole, azaindole, oxazole, thiazole, isoxazole, isothiazole, imidazole, N-methylimidazole, pyridine, pyrimidine, pyrazine, pyrrole, N-methylpyrrole, pyrazole, N-methylpyrazole, 1,3,4-oxadiazole, 1,2,4-triazole, 1-methyl-1,2,4-triazole, 1H-tetrazole, 1-methyltetrazole, benzoxazole, benzothiazole, benzofuran, benzisoxazole, benzimidazole, N-methylbenzimidazole, azabenzimidazole, in
  • Bicyclic C 1 -C 9 hetroaryl groups include those where a phenyl, pyridine, pyrimidine or pyridazine ring is fused to a 5 or 6-membered monocyclic heteroaryl ring having one or two nitrogen atoms in the ring, one nitrogen atom together with either one oxygen or one sulfur atom in the ring, or one O or S ring atom.
  • monocyclic C 1 -C 4 heteroaryl groups include 2H-tetrazole, 3H-1,2,4-triazole, furan, thiophene, oxazole, thiazole, isoxazole, isothiazole, imidazole, and pyrrole.
  • a heteroaryl group can be unsubstituted or substituted with one or more of C 1 -C 6 alkyl, halogen, haloalkyl, OH, CN, hydroxyalkyl, NH 2 , aminoalkyl-, dialkylamino-, C(O)OH, —C(O)O-(alkyl), —OC(O)(alkyl), N-alkylamido-, —C(O)NH 2 , (alkyl)amido-, —NO 2 , (aryl)alkyl, alkoxy, aryloxy, heteroaryloxy, (aryl)amino, (alkoxy)carbonyl-, (alkyl)amido-, (alkyl)amino, aminoalkyl-, alkylcarboxyl-, (alkyl)carboxyamido-, (aryl)alkyl-, (aryl)amino-, cycloalkenyl, di(alky
  • Heterocycle refers to monocyclic, bicyclic, polycyclic, or bridged head molecules in which at least one ring atom is a heteroatom.
  • a heterocycle may be saturated or partially saturated.
  • Exemplary C 1 -C 9 heterocyclyl groups include but are not limited to aziridine, oxirane, oxirene, thiirane, pyrroline, pyrrolidine, dihydrofuran, tetrahydrofuran, dihydrothiophene, tetrahydrothiophene, dithiolane, piperidine, 1,2,3,6-tetrahydropyridine-1-yl, tetrahydropyran, pyran, thiane, thiine, piperazine, azepane, diazepane, oxazine, 5,6-dihydro-4H-1,3-oxazin-2-yl, 2,5-diazabicyclo[2.2.1]heptane, 2,
  • C 1 heterocyclyl radicals would include but are not limited to oxaziranyl, diaziridinyl, and diazirinyl
  • C 2 heterocyclyl radicals include but are not limited to aziridinyl, oxiranyl, and diazetidinyl
  • C 9 heterocyclyl radicals include but are not limited to azecanyl, tetrahydroquinolinyl, and perhydroisoquinolinyl.
  • a heterocyclyl group can be unsubstituted or substituted with one or more of alkyl, halogen, alkoxy, haloalkyl, OH, hydroxyalkyl, —C(O)-(hydroxyalkyl), NH 2 , aminoalkyl-, dialkylamino-, C(O)OH, —C(O)O-(alkyl), —OC(O)(alkyl), N-alkylamido-, —C(O)NH 2 , (alkyl)amido-, —C(O)-(alkyl)-CN, (alkyl)-CN, or NO 2 .
  • Heterocyclyl(alkyl)- refers to an alkyl group, as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with a heterocycle group as defined above.
  • Heterocyclyl(C 1 -C 6 alkyl)- moieties include 1-piperazinylethyl, 4-morpholinylpropyl, 6-piperazinylhexyl, and the like.
  • a heterocyclyl(alkyl) group can be unsubstituted or substituted with one or more of halogen, NH 2 , (alkyl)amino-, di(alkyl)amino-, (alkyl)C(O)N(alkyl)-, (alkyl)carboxyamido-, HC(O)NH—, H 2 NC(O)—, (alkyl)NHC(O)—, di(alkyl)NC(O)—, CN, OH, alkoxy, alkyl, C(O)OH, (alkoxy)carbonyl-, (alkyl)C(O)—, 4- to 7-membered monocyclic heterocycle, aryl, heteroaryl, or cycloalkyl.
  • Heteroaryl(alkyl) refers to a heteroaryl which is attached to an alkyl group and the heteroaryl is defined above.
  • “Hydroxyalkyl” refers to a alkyl group, as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with OH groups.
  • Examples of C 1 -C 6 hydroxyalkyl moieties include, for example, —CH 2 OH, CH 2 CH 2 OH, —CH 2 CH 2 CH 2 OH, —CH 2 CH(OH)CH 2 OH, —CH 2 CH(OH)CH 3 , —CH(CH 3 )CH 2 OH and higher homologs.
  • Perfluoroalkyl- refers to alkyl group, defined above, having two or more fluorine atoms. Examples of a C 1 -C 6 perfluoroalkyl- group include CF 3 , CH 2 CF 3 , CF 2 CF 3 and CH(CF 3 ) 2 .
  • Representative “pharmaceutically acceptable salts” include, e.g., water-soluble and water-insoluble salts, such as the acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, bromide, butyrate, calcium, chloride, choline, citrate, edisylate (camphorsulfonate), fumarate, gluconate, glucuronate, glutamate, hydrobromide, hydrochloride, lauryl sulfate, malate, maleate, mandelate, mesylate, palmitate, pantothenate, phosphate, potassium, propionate, p-toluenesulfonate, salicylate, sodium, stearate, succinate, and sulfate salts.
  • Representative pharmaceutically acceptable esters include acetyl, propionyl, benzoyl, nicotinoyl and phenylacetyl ester derivatives of compounds
  • the compound of formula (I) may be appropriately formulated into a desired dosage form, alone (neat) or optionally with other pharmaceutically inert or inactive ingredients. It may be used alone or in a composition suitable for in vitro applications.
  • the pharmaceutically inert or inactive ingredient includes one or more pharmaceutically acceptable carriers or excipients.
  • the present invention also contemplates combining the compound of Formula (I) with one or more therapeutic agents, e.g., anti-cancer agents (e.g., in the same dosage form or in the same treatment regimen).
  • a compound of Formula (I) may be combined with one or more inert/inactive ingredients and one or more therapeutic agents.
  • compositions of the invention contain an amount of a compound of Formula (I) that is effective for treating cancer in a subject, or inhibiting growth and proliferation of cancer cells (in vivo or in vitro) or inhibiting tumor growth (which may be referred to collectively as an “anti-cancer effect”).
  • the dosage of the compound of Formula (I) to achieve a therapeutic effect may depend on factors such as the formulation, pharmacological potency of the drug, age, weight and sex of the patient, condition being treated, severity of the patient's symptoms, specific compound of Formula (I), and route of delivery. Dosages may be adjusted depending, for example, on the response pattern of the patient.
  • the treatment and dosage of the compound of Formula (I) may be administered in unit dosage form and that one skilled in the art would adjust the unit dosage form accordingly to reflect the relative level of activity.
  • the decision as to the particular dosage to be employed (and the number of times to be administered per day) is within the discretion of the ordinarily-skilled physician, and may be varied by titration of the dosage to the particular circumstances to produce the desired therapeutic effect.
  • the effective amount of the compound of formula (I) to achieve an anti-cancer effect in a patient may range from about 1 to about 1000 mg daily dose, and in some embodiments from about 5 to about 500 mg daily dose, and in some other embodiments, from about 10 to about 100 mg daily dose.
  • the therapeutically effective amounts may be provided on regular schedule, i.e., on a less than daily, daily, weekly, monthly, or yearly basis or on an irregular schedule with varying administration days, weeks, months, etc.
  • the therapeutically effective amount to be administered may vary.
  • the therapeutically effective amount for the first dose may be higher than the therapeutically effective amount for one or more of the subsequent doses.
  • the therapeutically effective amount for the first dose may be lower than the therapeutically effective amount for one or more of the subsequent doses.
  • Equivalent dosages may be administered over various time periods including, for example, about every 2 hours, about every 6 hours, about every 8 hours, about every 12 hours, about every 24 hours, about every 36 hours, about every 48 hours, about every 72 hours, about every week, about every 2 weeks, about every 3 weeks, about every month, about every 2 months, about every 3 months and about every 6 months.
  • the number and frequency of dosages corresponding to a completed course of anti-cancer therapy will be determined according to the judgment of a health-care practitioner.
  • the therapeutically effective amounts described herein refer to total amounts administered for a given time period such that if more than one compound of Formula (I) is administered, the therapeutically effective amounts correspond to the total amount administered.
  • the compound of Formula (I) may be administered by any medically acceptable route, taking into consideration the specific cancerous condition for which it has been selected.
  • the compounds of Formula (I) may be delivered orally, by injection (including intravascularly, e.g., intravenously or intra-arterially), inhalation (intranasally and intratracheally), ocularly, transdermally (via simple passive diffusion formulations or via facilitated delivery using, for example, iontophoresis, microporation with microneedles, radio-frequency ablation or the like), intravascularly, subcutaneously, intramuscularly, sublingually, intracranially, epidurally, rectally, and vaginally, among other routes.
  • the compound of Formula (I) may be administered by injection, orally or topically.
  • the compound of Formula (I) may be administered alone, i.e., neat. It may also be administered as a formulation that also contains a pharmaceutically acceptable carrier and/or excipient (collectively referred to as a “carrier”.
  • a pharmaceutically acceptable carrier and/or excipient collectively referred to as a “carrier”.
  • the amount of the pharmaceutical carrier is determined by factors that may include the solubility and chemical nature of the compound of Formula (I), chosen route of administration, and standard pharmacological practice.
  • the carriers may be in dry (solid) or liquid form.
  • Liquid pharmaceutical compositions are typically sterile solutions or suspensions. When liquid carriers are utilized for parenteral administration, they are desirably sterile liquids. Liquid carriers are typically utilized in preparing solutions, suspensions, emulsions, syrups and elixirs.
  • suitable liquid carriers may include, e.g., dimethylsulfoxide (DMSO), saline, buffered saline, cyclodextrin, hydroxypropylcyclodextrin (HP ⁇ CD), n-dodecyl- ⁇ -D-maltoside (DDM) and mixtures thereof.
  • DMSO dimethylsulfoxide
  • HP ⁇ CD hydroxypropylcyclodextrin
  • DDM n-dodecyl- ⁇ -D-maltoside
  • the compound of Formula (I) is dissolved a liquid carrier.
  • the compound of Formula (I) is suspended in a liquid carrier.
  • One of skill in the art of formulations would be able to select a suitable liquid carrier, depending on the route of administration.
  • the compound of Formula (I) may alternatively be formulated in a solid carrier of which a variety of solid carriers and excipients are known to those of skill in the art.
  • the composition may be compacted into a unit dose form, i.e., tablet or caplet.
  • the composition may be added to unit dose form, i.e., a capsule.
  • the composition may be formulated for administration as a powder.
  • the solid carrier may perform a variety of functions, i.e., may perform the functions of two or more of the excipients described below.
  • a solid carrier may also act as a flavoring agent, diluent, lubricant, solubilizer, suspending agent, filler, glidant, compression aid, binder, disintegrant, or encapsulating material.
  • carriers include adjuvants, antioxidants, binders, buffers, coatings, coloring agents, compression aids, emulsifiers (e g., polyoxyethylene fatty acid esters), emollients, encapsulating materials, fillers, granulating agents, metal chelators, osmo-regulators, pH adjustors (e.g., sodium hydroxide), preservatives, sorbents, stabilizing agents, suspending agents, syrups, penetration enhancers (e.g., hydroxypolyethoxydodecane, DMSO, DMAC, DDM, etc.) and thickening agents (e.g., carboxypolymethylene or hydroxypropylmethylcellulose) and other viscosity regulators.
  • emulsifiers e g., polyoxyethylene fatty acid esters
  • emollients e.g., emollients
  • encapsulating materials fillers, granulating agents, metal chelators
  • the compound of formula (I) may be formulated to achieve a modified-release.
  • “Modified-release” as used herein refers to delivery of a compound of Formula (I) which is controlled, for example over a period of time, e.g., at least about 8 hours (e.g., extended delivery) to at least about 12 hours (e.g., sustained delivery). Otherwise, the formulations of the present invention may permit immediate release (e.g., therapeutic levels achieved in under about 1 hour, or in less than about 2 hours).
  • inventive methods may entail administering to a subject or contacting cancer cells or a tumor in need thereof a therapeutically effective amount of a compound of formula (I).
  • cancer refers to or describes the physiological condition in subjects in which a population of cells is characterized by unregulated cell growth.
  • the term “subject” refers to any animal (e.g., a mammal), including, for example, humans, non-human primates (e.g., monkeys, chimpanzees, baboons and gorillas), domestic animals (e.g., dogs and cats), rodents (e.g., mice, rats and guinea pigs), livestock (e.g., cows and swine), equines and the like, which is to be the recipient of a particular treatment or protocol described herein.
  • the terms “subject” and “patient” are used interchangeably herein in reference to a subject that is a human subject.
  • the mammal to be treated is human.
  • the cancer patient e.g., human cancer patient
  • the cancer patient has not been diagnosed with inflammation associated with or as a side effect of the cancer.
  • the terms “treat” and “treatment” refer to therapeutic treatment, including prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological change associated with cancer.
  • Beneficial or desired clinical results of the treating may include inhibition of growth and proliferation of cancer cells or inhibition of tumor growth.
  • Such results may also include diminishment of the extent of a disease or condition, stabilization of a disease or condition (i.e., where the disease or condition does not worsen), delay or slowing of the progression of a disease or condition, amelioration or palliation of the disease or condition, and remission (whether partial or total) of the disease or condition, whether detectable or undetectable.
  • Such results may further include prolonging survival as compared to expected survival if not receiving treatment.
  • Those in need of treatment include those already with the disease or condition as well as those prone to having the disease or condition or those in which the disease or condition is to be prevented.
  • contacting it is meant administering to a cancer subject or otherwise bringing a compound of formula (I) into contact with a tumor or a cancer cell (e.g., which cancer cell may be in vivo or in vitro) such that it can exert its intended effect.
  • therapy may be “first-line”, i.e., as an initial treatment in patients who have undergone no prior anti-cancer treatment regimens, either alone or in combination with other treatments; or “second-line”, as a treatment in patients who have undergone a prior anti-cancer treatment regimen, either alone or in combination with other treatments; or as “third-line”, “fourth-line”, etc. treatments, either alone or in combination with other treatments.
  • Therapy may also be given to patients who have had previous treatments which have been partially successful but are intolerant to the particular treatment. Therapy may also be given as an adjuvant treatment, i.e., to prevent reoccurrence of cancer in patients with no currently detectable disease or after surgical removal of tumor.
  • Cancers, cancer cells and tumors treatable in accordance with the methods of the present invention may include, by way of example, primary tumors and secondary or metastatic tumors (including those metastasized from lung, breast, or prostate), as well as recurrent or refractory tumors.
  • Recurrent tumors encompass tumors that appear to be inhibited by treatment with such agents, but recur up to five years, sometimes up to ten years or longer after treatment is discontinued.
  • Refractory tumors are tumors that have failed to respond or are resistant to treatment with one or more conventional therapies for the particular tumor type.
  • Refractory tumors include those that are hormone-refractory (e.g., androgen-independent prostate cancer; or hormone-refractory breast cancer, such as breast cancer that is refractory to tamoxifen); those that are refractory to treatment with one or more chemotherapeutic agents; those that are refractory to radiation; and those that are refractory to combinations of chemotherapy and radiation, chemotherapy and hormone therapy, or hormone therapy and radiation.
  • the inventive methods e.g., using ASN002 are directed to treating hematological cancer patients (e.g., leukemia and lymphoma patients) who are refractory to treatment with FDA-approved ibrutinib.
  • cancers, cancer cells and tumors treatable in accordance with the methods of the present invention include carcinomas, sarcomas, benign and malignant tumors, and malignancies.
  • Adult tumors/cancers and pediatric tumors/cancers are included.
  • the cancers may be vascularized, or not yet substantially vascularized, or non-vascularized tumors.
  • the cancers may be characterized by non-solid tumors, e.g., hematopoietic cancers such as leukemias and lymphomas (Hodgkins and non-Hodgkins) or solid tumors.
  • Representative examples of hematologic malignancies amenable to treatment in accordance with the present invention include lymphomas, multiple myelomas, and leukemias.
  • the hematologic malignancy is leukemia or lymphoma.
  • Leukemias treatable in accordance with the present invention include lymphocytic leukemias and chronic myeloid (myelogenous) leukemias. Specific examples include acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML) (e.g., HEL), chronic lymphocytic leukemia (CLL), and chronic myelogenous leukemia (CML). Other examples include T-cell acute lymphoblastic leukemia (T-ALL) and B-cell acute lymphoblastic leukemia (B-ALL).
  • ALL acute lymphocytic leukemia
  • AML acute myeloid leukemia
  • CLL chronic lymphocytic leukemia
  • CML chronic myelogenous leukemia
  • T-ALL T-cell acute lymphoblastic leukemia
  • B-ALL B-cell acute lymphoblastic leukemia
  • the hematologic malignancy is lymphoma (e.g., malignant neoplasms of lymphoid and reticuloendothelial tissues).
  • lymphomas treatable in accordance with the present invention include Burkitt's lymphoma, Hodgkins' lymphoma, non-Hodgkins' lymphomas, lymphocytic lymphomas such as small lymphocytic lymphoma (SLL), myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), indolent non-Hodgkin's lymphoma (iNHL), refractory iNHL, mantle cell lymphoma (MCL), follicular lymphoma (FL), Waldestrom's macroglobulinemia (WM), T-cell lymphoma, B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), lymphoplasmacytic lymphoma (LPL), and marginal zone lymph
  • SLL
  • the compound of formula (I) may be administered alone (monotherapy), in the form of a conjugate (e.g., chemically bonded to another moiety that targets cancer cells) or in combination with one or more therapeutically effective active agents (e.g., anti-cancer agents) or treatments (combination therapy).
  • the other therapeutically effective agent which is different from the compound of formula (I), may be incorporated into the same composition as the compound of formula (I), or may be administered as a separate composition.
  • the other therapeutically effective agent or treatment may be administered prior to, during and/or after the administration of the compound of formula (I).
  • the other therapeutically effective agent may be administered to augment the therapeutic effect of the compound of formula (I), or to diminish the negative side effects of the compound of formula (I).
  • anti-cancer therapeutically effective agents/treatments include surgery, radiation chemotherapeutic agents, cytokines, chemokines and biological agents such as antibodies and enzymes.
  • the source of the radiation can be either external (external beam radiation therapy—EBRT) or internal (brachytherapy—BT) to the patient being treated.
  • EBRT external beam radiation therapy
  • BT brachytherapy
  • the dose of anti-neoplastic agent administered depends on numerous factors, including, for example, the type of agent, the type and severity of tumor being treated and the route of administration of the agent. It should be emphasized, however, that the present invention is not limited to any particular dose. Radiation may also be used in conjunction with other antineoplastic agents.
  • chemotherapeutic agents which are typically small molecules
  • topoisomerase inhibitors e.g., inhibitors of topoisomerase I or topoisomerase II.
  • Topoisomerase I inhibitors such as irinotecan (CPT-II), aminocamptothecin, camptothecin, DX-8951f, and topotecan.
  • Topoisomerase II inhibitors include etoposide (VP-16), and teniposide (VM-26)), cyclophosphamide, Thiotepa, bysulfan, melphalan, dacarbazine, cytosine arabinoside, cyclophosphamide, actinomycin-D, methotrexate, gemcitabine, oxyplatin, fluorouracil (5-FU), leucourin (LU), cisplatin, irinotecan (CPT-II), paclitaxel, docetaxel, vinblastine, epothilone, carboplatin, pegylated adriamycin, anthracyclines (e.g., daunomycin and doxorubicin), vindesine, neocarzinostatin, cis-platinum, chlorambucil, cytosine arabinoside, 5-fluorouridine, ibrutinib,
  • Example 1 Exhibits Anti-Tumor Activity in Ibrutinib-Resistant Lymphoma Cells
  • ASN002 This activity of ASN002 was assessed using a diffuse large B-cell lymphoma (DLBCL) cell line, Pfeiffer (“Parental”); and an ibrutinib-resistant variant of the same cell line (“Ibrutinib-R”), which was developed by growing the cells in the presence of increasing concentrations of ibrutinib. Pools of ibrutinib-resistant cells were tested in this study.
  • the drug idelalisib (which was approved by the FDA in July 2015 for the treatment of B-cell blood cancers) was used for comparison as a reference compound.
  • Table A IC 50 is the half maximal inhibitory concentration). They show that ASN002 was significantly more potent in inhibiting tumor cell proliferation than either ibrutinib or idelalisib, in the Pfeiffer cell line and, in particular, the ibrutinib-resistant cell line.
  • Example 2 The Anti-Cancer Activity of ASN002 was Also Evaluated in Many Solid Tumor Cell Lines. IC 50 Values for the Antiproliferative Activity of ASN002 in these Cell Lines are Set Forth in TABLE B

Abstract

Disclosed are methods of treating cancer, which include administering a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or ester thereof, to a subject in need thereof.
Figure US20190070182A1-20190307-C00001
Also disclosed are methods of inhibiting growth and proliferation of cancer cells in vitro or in vivo, which include contacting the cells with an amount of the compound of formula (I) effective to inhibit the growth or proliferation of the cancer cells. Further disclosed are methods of inhibiting tumor growth, which include contacting the tumor with an amount of the compound of formula (I) effective to inhibit the growth of the tumor.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • The present application is a Continuation of U.S. application Ser. No. 15/365,222, filed Nov. 30, 2016, which claims the benefit of the filing date of U.S. Provisional Application No. 62/263,398, filed Dec. 4, 2015, the disclosure of which is incorporated herein by reference.
    • BACKGROUND OF THE INVENTION
  • The challenges of identifying clinically useful anti-cancer drugs and obtaining FDA approval for marketing can often be exacerbated by incidences of resistance of the drug in cancer patients. For example, ibrutinib is an orally bioavailable and highly specific inhibitor of Bruton tyrosine kinase (BTK) that was recently approved for treatment of patients with recurrent chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Ibrutinib has also shown efficacy in subsets of patients with diffuse large B cell lymphoma (DLBCL) and Waldenstrom macroglobulinaemia (WM). However, despite activity in multiple B-cell malignancies, cases of primary and secondary resistance have emerged along with predictions that the incidence of observed resistance will increase as clinical use expands over time. Zhang et al., Br. J. Haematol. 170(4):445-56 (2015). Although the suspected mechanism of resistance has been elucidated (a C481→S mutation in the BTK gene), further studies have shown that at least two other cellular mechanisms appear to override the inhibitory action of ibrutinib in resistant cancer cells, leading to proposals of using ibrutinib in combination with palbociclib or palbociclib followed by idelalisib. See, Sinha, “Overcoming Mantle Cell Lymphoma's Ibrutinib Resistance,” in JNCI, 106(11), 2014.
  • In view of the foregoing, a need remains for anti-cancer drugs that are efficacious and which could treat cancer patients, such as patients whose cancer has proven resistant or refractory to FDA-approved front-line therapy.
    • BRIEF SUMMARY OF THE INVENTION
  • In one aspect, the present invention provides a method of treating cancer, which includes administering a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein R1 and R2 are defined herein, to a subject in need thereof.
  • Figure US20190070182A1-20190307-C00002
  • Another aspect of the present invention is directed to a method of inhibiting growth and proliferation of cancer cells in vitro or in vivo, which includes contacting the cells with an amount of the compound of formula (I) effective to inhibit the growth or proliferation of the cancer cells.
  • A further aspect of the present invention is directed to a method of inhibiting tumor growth, which includes contacting the tumor with an amount of the compound of formula (I) effective to inhibit the growth of the tumor.
  • In some embodiments of the inventive methods, cancers, cancer cells and tumors treatable in accordance with the methods of the present invention include non-solid tumors, e.g., hematopoietic cancers such as leukemias, multiple myelomas and lymphomas, and solid tumors. In certain embodiments, the hematopoietic cancer is a B-cell lymphoma, e.g., diffuse large B-cell lymphoma, mantle cell lymphoma, or follicular lymphoma. In some embodiments, the leukemia is acute myeloid leukemia (AML), e.g., human erythroleukemia. In some embodiments, the subject with hematopoietic cancer is or has become refractory to treatment with Ibrutinib. In certain embodiments, the solid tumor is a tumor of the bladder, colon, liver, kidney, lung, breast, ovary or cervix. In some embodiments, the compound of formula (I) is 2-(1-(4-((4-(4-hydroxypiperidin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile (also described herein as ASN002 or compound 189) or a pharmaceutically acceptable salt or ester thereof.
  • Other aspects and advantages of the invention will be readily apparent from the following detailed description of the invention.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a graph that shows that ASN002 induced apoptosis in a DLBCL cell line, Pfeiffer, using a caspase 3/7 assay. The data show that after a 24-hour treatment, the EC50 of ASN002 was 120 nM.
  • FIG. 2 is a bar graph showing that ASN002 exhibited strong antiproliferative activity in several hematological malignant cell lines, wherein the data were generated in a cell line panel representing leukemia, lymphoma, and multiple myelomas.
  • FIG. 3 is a graph showing that ASN002 inhibited tumor growth in a DLBCL xenograft mouse model (derived from Pfeiffer cell line).
  • FIG. 4 is a graph showing that compound ASN002 inhibited tumor growth in another DLBCL xenograft mouse model (derived from SU-DHL-6 cell line).
  • FIG. 5 is a graph showing that ASN002 inhibited tumor growth in a mouse model of multiple myeloma (derived from H929 cell line).
  • FIG. 6 is a graph showing that ASN002 delayed the hind limb paralysis in a mouse model of human erythroleukemia (derived from HEL cell line).
    •  DETAILED DESCRIPTION
  • Compounds useful in the practice of the inventive methods may be represented by Formula (I):
  • Figure US20190070182A1-20190307-C00003
  • In this formula, R1 is NR4R5, optionally substituted C1 to C6 alkoxy, optionally substituted C6 to C14 aryl, optionally substituted heteroaryl, optionally substituted 3-10 membered monocyclic or bicyclic cycloalkyl, or optionally substituted 3-10 membered monocyclic or bicyclic heterocyclyl. In one aspect, the 3-4 membered cycloalkyl and heterocyclyl are saturated. In another aspect, the hydrogen atoms on the same carbon atom of the cycloalkyl or heterocyclyl are optionally replaced with an optionally substituted 3-6 membered cycloalkyl or heterocyclyl to form a spirocycloalkyl or spiroheterocyclyl. In a further aspect, the hydrogen atoms on the same atom of the cycloalkyl or heterocyclyl are optionally replaced with O to form an oxo substituent.
      • i. In another embodiment, R1 is N(C1 to C6 alkyl)(C1 to C6 alkyl) or C1 to C6 alkoxy.
      • ii. In still a further embodiment, R1 is N(CH(CH3)2)2, N(CH3)2, OCH2CH3, or OCH3.
      • iii. In another embodiment, R1 is optionally substituted phenyl.
      • iv. In still another embodiment, R1 is of the structure:
  • Figure US20190070182A1-20190307-C00004
        • wherein, R22, R23, R24, R25, and R26 are, independently, H, C(O)(C1 to C6 alkoxy), C(O)OH, O(C1 to C3 perfluoroalkyl), O(C1 to C6 perfluoroalkoxy), C1 to C6 alkoxy, halogen, (C1 to C6 alkyl)heterocyclyl, or (C1 to C6 alkyl)CN.
      • v. In a further embodiment, R1 is:
  • Figure US20190070182A1-20190307-C00005
      • vi. In yet another embodiment, R1 is optionally substituted 5-9 membered saturated heterocyclyl.
      • vii. In still a further embodiment, R1 is of the structure:
  • Figure US20190070182A1-20190307-C00006
        • wherein, R34, R35, R36, and R37 are, independently, H, C1 to C6 alkyl, or CN; Y is (C(R8)2)x, NR7(C(R8)2)x, O, (S═O), SO2, or NR7; R7 and R8 are, independently, H, C1 to C6 alkyl, C(O)OH, (C1 to C6 alkyl)CN, (C1 to C6 alkyl)C(O)OH, C(O)(C1 to C6 alkyl)CN, or CN; and x is 0 to 2.
      • viii. In another embodiment, R1 is:
  • Figure US20190070182A1-20190307-C00007
      • ix. In still a further embodiment, R1 is of the structure:
  • Figure US20190070182A1-20190307-C00008
        • wherein, f, g, h, j, and m are, independently, absent, (CH2), CH(R3), Z, or C═O; R3 is H, C(O)OH, or C(O)O(C1 to C6 alkyl); R45, R46, R47, and R48 are, independently, H or C1 to C6 alkyl; and Z is O, S, SO, SO2, or NH.
      • x. In yet another embodiment, R1 is:
  • Figure US20190070182A1-20190307-C00009
      • xi. In a further embodiment, R1 is a heteroaryl.
      • xii. In yet another embodiment, R1 is thiophene, benzooxole, or pyridine.
      • xiii. In still another embodiment, R1 is a monocyclic C3 to C8 cycloalkyl.
      • xiv. In yet a further embodiment, R1 is cycloheptyl or cyclohexyl, both optionally substituted with —N(C1 to C6 alkyl)(C1 to C6 alkyl).
      • xv. In another embodiment, R1 is piperidine substituted with C(O)(C1 to C6 alkyl)CN.
      • xvi. In still a further embodiment, R1 is:
  • Figure US20190070182A1-20190307-C00010
      • a. In one embodiment, R2 is phenyl substituted with C(O)NR4R5.
      • b. In another embodiment, R2 is phenyl substituted with
  • Figure US20190070182A1-20190307-C00011
      • c. In a further embodiment, R2 is phenyl substituted with NR4R5.
      • d. In yet another embodiment, R2 is phenyl substituted with (C1 to C6 alkyl)NR4R5.
      • e. In another embodiment, R2 is phenyl substituted with NR4R5 or (C1 to C6 alkyl)NR4R5 and R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 6-membered ring.
      • f. In still a further embodiment, R2 is phenyl substituted with NR4R5 or (C1 to C6 alkyl)NR4R5 and R4 and R5 are joined to form a heterocyclyl of the structure:
  • Figure US20190070182A1-20190307-C00012
        • wherein, R10, R11, R12, and R13 are, independently, H or C1 to C6 alkyl; R14 is halogen, OH, C(O)OH, C1 to C6 alkoxy, (C1 to C6 alkyl)halogen, (C1 to C6 alkyl)C(O)OH, C1 to C6 hydroxyalkyl, C3 to C8 cycloalkyl, (C1 to C6 alkyl)C(O)NH2, (C1 to C6 alkyl)C(O)NH(C1 to C6 hydroxyalkyl), (C1 to C6 alkyl)C(O)N(C1 to C6 hydroxyalkyl)2, (C1 to C6 alkyl)CN, (C1 to C6 alkyl)heteroaryl, or heteroaryl; and R18 is C1 to C6 hydroxyalkyl or (C1 to C6 alkyl)C(O)OH.
      • g. In yet a further embodiment, R2 is phenyl substituted with NR4R5 or (C1 to C6 alkyl)NR4R5 and wherein R4 and R5 are joined to form an optionally substituted piperidine or diazepane.
      • h. In another embodiment, R2 is phenyl substituted with NR4R5 or (C1 to C6 alkyl)NR4R5 and R4 and R5 are joined to form:
  • Figure US20190070182A1-20190307-C00013
    Figure US20190070182A1-20190307-C00014
      • i. In still a further embodiment, R2 is phenyl substituted with NR4R5 or (C1 to C6 alkyl)NR4R5 and R4 and R5 are joined to form a heterocyclyl of the structure:
  • Figure US20190070182A1-20190307-C00015
        • wherein, a, b, c, d, and e are, independently, absent, (CH2), CH(R3), Z, or C═O; R3 is H, C(O)OH, C1 to C6 hydroxyalkyl, or C(O)O(C1 to C6 alkyl); R10, R11, R12, and R13 are, independently, H or C1 to C6 alkyl; and Z is O, S, or NH.
      • j. In yet another embodiment, R2 is phenyl substituted with NR4R5 or (C1 to C6 alkyl)NR4R5 and R4 and R5 are joined to form:
  • Figure US20190070182A1-20190307-C00016
      • k. In a further embodiment, R2 is phenyl substituted with NR4R5 or (C1 to C6 alkyl)NR4R5 and R4 and R5 are taken together to form a heterocyclyl of the structure:
  • Figure US20190070182A1-20190307-C00017
        • wherein, R10, R11, R12, and R13 are, independently, H or C1 to C6 alkyl; Y is O or NR9; and R9 is H, C1 to C6 alkyl, OH, C(O)OH, C1 to C6 hydroxyalkyl, (C1 to C6 alkyl)NH2, (C1 to C6 alkyl)N(C1 to C6 alkyl)(C1 to C6 alkyl), (C1 to C6 alkyl)(C1 to C6 alkoxy), C(O)(C1 to C6 alkyl)NH2, (C1 to C6 alkyl)C(O)OH, C(O)(C1 to C6 hydroxyalkyl), C(O)(C1 to C6 alkyl)CN, (C1 to C6 alkyl)CN, (C1 to C6 alkyl)halogen, or (C1 to C6 alkyl)O(C1 to C6 alkyl)C(O)(C1 to C6 alkyl)NH2; wherein 2 hydrogen atoms attached to the same carbon atom are optionally replaced with ═O.
      • l. In yet another embodiment, R2 is phenyl substituted with NR4R5 or (C1 to C6 alkyl)NR4R5 and R4 and R5 are taken together to form an optionally substituted morpholine or piperazine.
      • m. In still a further embodiment, R2 is phenyl substituted with NR4R5 or (C1 to C6 alkyl)NR4R5 and R4 and R5 are taken together to form:
  • Figure US20190070182A1-20190307-C00018
      • n. In another embodiment, R2 is phenyl substituted with (C1 to C6alkyl)NR4R5.
      • o. In yet a further embodiment, R2 is phenyl substituted with (C1 to C6 alkyl)NR4R5 and R4 and R5 are (C1 to C6 hydroxyalkyl).
      • p. In still another embodiment, R2 is phenyl substituted with (C1 to C6 alkyl)NR4R5 and NR4R5 is:
  • Figure US20190070182A1-20190307-C00019
      • q. In a further embodiment, R2 is phenyl substituted with (C1 to C6 alkyl)NR4R5 and R4 and R5 are joined to form an optionally substituted 6-membered ring.
      • r. In yet another embodiment, R2 is phenyl substituted with (C1 to C6 alkyl)NR4R5 and NR4R5 are joined to form the 6-membered ring:
  • Figure US20190070182A1-20190307-C00020
        • wherein, R14 is H, OH, C(O)OH, C1 to C6 alkyl, or (C1 to C6 alkyl)CN.
      • s. In another embodiment, R2 is phenyl substituted with (C1 to C6 alkyl)NR4R5 and NR4R5 are joined to form the 6-membered ring:
  • Figure US20190070182A1-20190307-C00021
        • wherein, Y is O or NR9; and R9 is H, C1 to C6 alkyl, OH, C1 to C6 hydroxyalkyl, C(O)(C1 to C6 hydroxyalkyl), C(O)(C1 to C6 alkyl)CN, (C1 to C6 alkyl)CN, (C1 to C6 alkyl)NH2, (C1 to C6 alkyl)halogen, C(O)(C1 to C6 alkyl)CN or (C1 to C6 alkyl)O(C1 to C6 alkyl)C(O)(C1 to C6 alkyl)NH2.
      • t. In still a further embodiment, R2 is phenyl substituted with (C1 to C6 alkyl)NR4R5 and NR4R5 are joined to form the 6-membered ring
  • Figure US20190070182A1-20190307-C00022
        • wherein, a, b, c, d, and e are, independently, absent, (CH2), CH(R3), or O; and R3 is H or C(O)OH.
      • u. In yet another embodiment, R2 is a heteroaryl substituted with (C1 to C6 alkyl)NR4R5.
      • v. In still another embodiment, R2 is:
  • Figure US20190070182A1-20190307-C00023
      • w. In a further embodiment R2 is a heteroaryl substituted with NR4R5.
      • x. In still another embodiment, R2 is a heteroaryl substituted with NR4R5 and the heteroaryl is pyridine.
      • y. In yet a further embodiment, R2 is of the structure:
  • Figure US20190070182A1-20190307-C00024
      • z. In another embodiment, R2 is of the structure:
  • Figure US20190070182A1-20190307-C00025
        • wherein, R80 is OH, —(C1 to C6 alkyl)CN, C1 to C6 hydroxyalkyl, (C1 to C6 alkyl)C(O)NH2, (C1 to C6 alkyl)heterocycle or —(C1 to C6 alkyl) C(O)OH.
      • aa. In still a further embodiment, R2 is of the structure:
  • Figure US20190070182A1-20190307-C00026
        • wherein, p is 1 to 6; and R81 is H or C(O)OH.
      • bb. In another embodiment, R2 is of the structure:
  • Figure US20190070182A1-20190307-C00027
        • wherein, R90 is H, C1 to C6 alkyl, C(O)(C1 to C6 alkyl)CN, (C1 to C6 alkyl)C(O)OH, or C(O)C1 to C6 hydroxyalkyl.
      • cc. In yet another embodiment, wherein R2 is phenyl substituted with one or more C1 to C6 alkoxy, (C1 to C6 alkyl)halogen, C1 to C6 trifluoroalkoxy, (C1 to C6 alkyl)C(O)OH, halogen, optionally substituted C3 to C8 cycloalkyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, —O—(C1 to C6 alkyl)C(O)OH, —O—(C1 to C6 alkyl)NR4R5, —O(optionally substituted heterocycle), —O(C1 to C6 alkyl)N(C1 to C6 alkyl)(C1 to C6 alkyl), —O(C1 to C6 alkyl)NH2, C1 to C6 hydroxyalkyl, —O(C1 to C6 hydroxyalkyl), —O(C1 to C6 alkyl)C(O)OH, —C1 to C6 alkoxy-C1 to C6 alkoxy, —O(heterocycle)(C1 to C6 hydroxyalkyl), —SO2(C1 to C6 alkyl), or —(C1 to C6 alkyl)(C1 to C6 alkoxy)halogen.
      • dd. In a further embodiment, wherein R2 is of the structure:
  • Figure US20190070182A1-20190307-C00028
        • wherein, R6 is H, (C1 to C6 alkyl)C(O)OH, or (C1 to C6 alkyl)CN.
        • ee. In still another embodiment, R2 is of the structure:
  • Figure US20190070182A1-20190307-C00029
        • wherein, z is 1, 2, 3, 4, 5, or 6.
      • ff. In another embodiment, R2 is of the structure:
  • Figure US20190070182A1-20190307-C00030
        • wherein, R6 is H or (C1 to C6 alkyl)C(O)OH.
      • gg. In yet a further embodiment, R2 is —O(C1 to C6 alkyl)NR4R5.
      • hh. In still another embodiment, R2 is of the structure:
  • Figure US20190070182A1-20190307-C00031
        • wherein, y is 2 to 6; and R50 is H, OH, C1 to C6 alkyl, C1 to C6 hydroxyalkyl, or —(C1 to C6 alkyl)C(O)OH.
      • ii. In further embodiment, R2 is of the structure:
  • Figure US20190070182A1-20190307-C00032
        • wherein, m is 2 to 6; y is 0 or 1; Z is O or NR60; and R60 is H, C1 to C6 alkyl, C1 to C6 hydroxyalkyl, —(C1 to C6 alkyl)CN, —(C1 to C6 alkyl)C(O)OH, —(C1 to C6 alkyl)CONH2, or —C(O)(C1 to C6 alkyl)OH; wherein 2 hydrogen atoms attached to one carbon atom of the nitrogen-ring are replaced with an oxo or optionally substituted 3-8 membered spirocyclic ring.
      • jj. In yet another embodiment, R2 is of the structure:
  • Figure US20190070182A1-20190307-C00033
        • wherein, r is 2 to 6; and R70 is H, C(O)OH or C1 to C6 hydroxyalkyl.
      • kk. In still a further embodiment, R2 is:
  • Figure US20190070182A1-20190307-C00034
      • ll. In another embodiment, R2 is aryl substituted with —O—(C1 to C6 alkyl)-heterocycle.
      • mm. In a further embodiment, R2 is:
  • Figure US20190070182A1-20190307-C00035
  • In some embodiments, the compound of Formula (I) is provided wherein R1 is NR4R5, optionally substituted C1 to C6 alkoxy, optionally substituted C6 to C14 aryl, optionally substituted heteroaryl, optionally substituted 3-10 membered monocyclic or bicyclic cycloalkyl, or optionally substituted 3-10 membered monocyclic or bicyclic heterocyclyl. The 3-4 membered cycloalkyl and heterocyclyl rings are saturated. Hydrogen atoms on the same carbon atom of the cycloalkyl or heterocyclyl are optionally replaced with an optionally substituted 3-6 membered cycloalkyl or heterocyclyl to form a spirocycloalkyl or spiroheterocyclyl. In addition or alternatively, hydrogen atoms on the same atom of the cycloalkyl or heterocyclyl are optionally replaced with O to form an oxo substituent. R2 is phenyl or 5-6 membered heteroaryl containing at least one N or NH in the backbone, wherein R2 is optionally substituted with one or more R19 and when R2 is 4-pyridyl, the 4-pyridyl lacks a carbonyl substituent at the 2nd position. R19 is NR4R5, (C1 to C6 alkyl)NR4R5, C1 to C6 alkyl, C(O)NR4R5, C3 to C8 cycloalkyl substituted with one or more R21, or heterocyclyl substituted with one or more R21. R21 is (C1 to C6 alkyl)CN, (C1 to C6 alkyl)C(O)OH, (C1 to C6 alkyl)C(O)NH2, (C1 to C6 alkyl)C(O)NHCH2CH2OH, or (C1 to C6 alkyl)C(O)N(CH2CH2OH)2. R4 and R5 are independently selected from among H, C1 to C6 alkyl, C1 to C6 hydroxyalkyl, and (C1 to C6 alkyl)N(C1 to C6 alkyl)(C1 to C6 alkyl). Alternatively, R4 and R5 are joined to form an optionally substituted 3-8 membered heterocyclyl optionally further containing one or more O, S(O)n, or NR9. R9 is H, OH, (C1 to C6 alkyl)C(O)OH, (C1 to C6 alkyl)C(O)NH2, (C1 to C6 alkyl)C(O)NHCH2CH2OH, (C1 to C6 alkyl)C(O)N(CH2CH2OH)2, C(O)(C1 to C6 alkyl)NH2, C(O)(C1 to C6 alkyl)OH, C1 to C6 hydroxyalkyl, or C1 to C6 alkyl and n is 0 to 2. In one embodiment, R9 is CH2CH2OH. Hydrogen atoms on the same carbon atom of the heterocyclyl are optionally replaced with a 3-6 membered cycloalkyl or heterocyclyl optionally substituted with one or more R20 to form a spirocycloalkyl or spiroheterocyclyl. R20 is C(O)O(C1 to C6 alkyl), C(O)OH, (C1 to C6 alkyl)C(O)OH, (C1 to C6 alkyl)C(O)NH2, (C1 to C6 alkyl)C(O)NHCH2CH2OH, or (C1 to C6 alkyl)C(O)N(CH2CH2OH)2. Alternatively, or in addition, hydrogen atoms on the same atom of any of the heterocyclyls or cycloalkyls of R9 are optionally replaced with O to form an oxo substituent; or a pharmaceutically acceptable salt or ester thereof.
  • In some embodiments, the compound of Formula (I) is provided wherein R1 is NR4R5, C1 to C6 alkoxy, optionally substituted phenyl, heteroaryl, optionally substituted 3-10 membered cycloalkyl, or optionally substituted 3-10 membered monocyclic or bicyclic heterocyclyl. Hydrogen atoms on the same carbon atom of the cycloalkyl or heterocyclyl are optionally replaced with an optionally substituted 3-6 membered cycloalkyl or heterocyclyl to form a spirocycloalkyl or spiroheterocyclyl. In addition or alternatively, hydrogen atoms on the same atom of the cycloalkyl or heterocyclyl are optionally replaced with O to form an oxo substituent. R2 is phenyl or pyrazole, wherein R2 is optionally substituted with one or more R19. R19 is NR4R5, (C1 to C6 alkyl)NR4R5, C1 to C6 alkyl, C(O)NR4R5, C3 to C8 cycloalkyl substituted with one or more R21, or heterocyclyl substituted with one or more R21. R21 is (C1 to C6 alkyl)CN, (C1 to C6 alkyl)C(O)OH, (C1 to C6 alkyl)C(O)NH2, (C1 to C6 alkyl)C(O)NHCH2CH2OH, (C1 to C6 alkyl)C(O)N(CH2CH2OH)2. R4 and R5 are (a) independently selected from among H, C1 to C6 alkyl, C1 to C6 hydroxyalkyl, and (C1 to C6 alkyl)N(C1 to C6 alkyl)(C1 to C6 alkyl) or (b) joined to form an optionally substituted 3-8 membered heterocyclyl optionally further containing one or more O, S(O)n, or NR9. R9 is H, OH, C1 to C6 hydroxyalkyl, (C1 to C6 alkyl)C(O)OH, (C1 to C6 alkyl)C(O)NH2, (C1 to C6 alkyl)C(O)NHCH2CH2OH, (C1 to C6 alkyl)C(O)N(CH2CH2OH)2, C(O)(C1 to C6 alkyl)NH2, C(O)(C1 to C6 alkyl)OH, or C1 to C6 alkyl and n is 0 to 2. In one embodiment, R9 is CH2CH2OH. Hydrogen atoms on the same carbon atom of the heterocyclyl are optionally replaced with a 3-6 membered cycloalkyl or heterocyclyl to form a spirocycloalkyl or spiroheterocyclyl optionally substituted with one or more R20. R20 is C(O)O(C1 to C6 alkyl), C(O)OH, (C1 to C6 alkyl)C(O)OH, (C1 to C6 alkyl)C(O)NH2, (C1 to C6 alkyl)C(O)NHCH2CH2OH, or (C1 to C6 alkyl)C(O)N(CH2CH2OH)2. Alternatively, or in addition, hydrogen atoms on the same atom of the heterocyclyl (b) or cycloalkyl are optionally replaced with O to form an oxo substituent; or a pharmaceutically acceptable salt or ester thereof.
  • In some embodiments, the compound of Formula (I) is provided wherein R1 is NR4R5, C1 to C6 alkoxy, phenyl optionally substituted with C(O)O(C1 to C6 alkyl), C(O)OH, O(C1 to C3 perfluoroalkyl), C1 to C6 alkoxy, halogen, CH2-heterocyclyl, or CH2CN, 5-8 membered cycloalkyl, heteroaryl, or 3-10 membered monocyclic or bicyclic heterocyclyl optionally substituted with (C1 to C6 alkyl)C(O)OH, C1 to C6 alkyl, CN, C(O)OH, or (C1 to C6 alkyl)CN. Hydrogen atoms on the same carbon atom of the cycloalkyl or heterocyclyl are optionally replaced with an optionally substituted 3-6 membered cycloalkyl or heterocyclyl to form a spirocycloalkyl or spiroheterocyclyl. In addition or alternatively, hydrogen atoms on the same atom of the cycloalkyl or heterocyclyl are optionally replaced with O to form an oxo substituent. R2 is phenyl or pyrazole, wherein R2 is optionally substituted with one R19. R19 is NR4R5, (C1 to C6 alkyl)NR4R5, C1 to C6 alkyl, C(O)NR4R5, C3 to C8 cycloalkyl substituted with one or more R21, or heterocyclyl substituted with one or more R21. R21 is (C1 to C6 alkyl)CN, (C1 to C6 alkyl)C(O)OH, (C1 to C6 alkyl)C(O)NH2, (C1 to C6 alkyl)C(O)NHCH2CH2OH, or (C1 to C6 alkyl)C(O)N(CH2CH2OH)2. R4 and R5 are (a) independently selected from among H, C1 to C6 alkyl, C1 to C6 hydroxyalkyl, and (C1 to C6 alkyl)N(C1 to C6 alkyl)(C1 to C6 alkyl). R4 and R5 may also be (b) joined to form a 5-8 membered heterocyclyl optionally further containing one or two O, S(O)n, or NR9. R9 is H, OH, C1 to C6 hydroxyalkyl (C1 to C6 alkyl)C(O)OH, C(O)(C1 to C6 alkyl)NH2, C(O)(C1 to C6 alkyl)OH, (C1 to C6 alkyl)C(O)NH2, (C1 to C6 alkyl)C(O)NHCH2CH2OH, (C1 to C6 alkyl)C(O)N(CH2CH2OH)2, or C1 to C6 alkyl and n is 0 to 2. In one embodiment, R9 is CH2CH2OH. Hydrogen atoms on the same carbon atom of the heterocyclyl are optionally replaced with a 3-5 membered cycloalkyl optionally substituted with one or more R20 to form a spirocycloalkyl. R20 is C(O)O(C1 to C6 alkyl), C(O)OH, (C1 to C6 alkyl)C(O)OH, (C1 to C6 alkyl)C(O)NH2, (C1 to C6 alkyl)C(O)NHCH2CH2OH, or (C1 to C6 alkyl)C(O)N(CH2CH2OH)2. Alternatively, or in addition, hydrogen atoms on the same atom of the heterocyclyl (b) or cycloalkyl (b) are optionally replaced with O to form an oxo substituent; or a pharmaceutically acceptable salt or ester thereof.
  • Some compounds useful in the practice of the invention possess one or more chiral centers, and the present invention includes use of each separate enantiomer of such compounds as well as mixtures of the enantiomers. Where multiple chiral centers exist in compounds of the present invention, the invention includes uses of compound(s) with each possible combination of chiral centers within a compound, as well as all possible enantiomeric and diastereomeric mixtures thereof. All chiral, diastereomeric, and racemic forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials.
  • The following definitions are used in connection with the compounds useful in the present invention unless the context indicates otherwise. In general, the number of carbon atoms present in a given group is designated “Cx-Cy”, where x and y are the lower and upper limits, respectively. For example, a group designated as “C1-C6” contains from 1 to 6 carbon atoms. The carbon number as used in the definitions herein refers to carbon backbone and carbon branching, but does not include carbon atoms of the substituents, such as alkoxy substitutions and the like. Unless indicated otherwise, the nomenclature of substituents that are not explicitly defined herein are arrived at by naming from left to right the terminal portion of the functionality followed by the adjacent functionality toward the point of attachment. For example, the substituent “arylalkyloxycabonyl” refers to the group (C6-C14 aryl)-(C1-C6 alkyl)-O—C(O)—. Terms not defined herein have the meaning commonly attributed to them by those skilled in the art.
  • “Alkyl” refers to a hydrocarbon chain that may be a straight chain or branched chain, containing the indicated number of carbon atoms, for example, a C1-C12 alkyl group may have from 1 to 12 (inclusive) carbon atoms in it. Examples of C1-C6 alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, and isohexyl. Examples of C1-C8 alkyl groups include, but are not limited to, methyl, propyl, pentyl, hexyl, heptyl, 3-methylhex-1-yl, 2,3-dimethylpent-2-yl, 3-ethylpent-1-yl, octyl, 2-methylhept-2-yl, 2,3-dimethylhex-1-yl, and 2,3,3-trimethylpent-1-yl. An alkyl group can be unsubstituted or substituted with one or more of halogen, NH2, (alkyl)NH, (alkyl)(alkyl)N—, —N(alkyl)C(O)(alkyl), NHC(O)(alkyl), —NHC(O)H, —C(O)NH2, —C(O)NH(alkyl), —C(O)N(alkyl)(alkyl), CN, OH, alkoxy, alkyl, C(O)OH, —C(O)O(alkyl), —C(O)(alkyl), aryl, heteroaryl, heterocyclyl, cycloalkyl, haloalkyl, aminoalkyl-, —OC(O)(alkyl), carboxyamidoalkyl-, and NO2.
  • “Alkoxy” refers to the group R—O— where R is an alkyl group, as defined above. Exemplary C1-C6 alkoxy groups include but are not limited to methoxy, ethoxy, n-propoxy, 1-propoxy, n-butoxy and t-butoxy. An alkoxy group can be unsubstituted or substituted with one or more of halogen, OH, alkoxy, NH2, (alkyl)amino-, di(alkyl)amino-, (alkyl)C(O)N(C1-C3 alkyl)-, (alkyl)carboxyamido-, HC(O)NH—, H2NC(O)—, (alkyl)NHC(O)—, di(alkyl)NC(O)—, CN, C(O)OH, (alkoxy)carbonyl-, (alkyl)C(O)—, aryl, heteroaryl, cycloalkyl, haloalkyl, amino(C1-C6 alkyl)-, (alkyl)carboxyl-, carboxyamidoalkyl-, or NO2.
  • Aryl refers to an aromatic 6 to 14 membered hydrocarbon group. Examples of a C6-C14 aryl group include, but are not limited to, phenyl, α-naphthyl, β-naphthyl, biphenyl, anthryl, tetrahydronaphthyl, fluorenyl, indanyl, biphenylenyl, and acenanaphthyl. Examples of a C6-C10 aryl group include, but are not limited to, phenyl, α-naphthyl, β-naphthyl, biphenyl, and tetrahydronaphthyl. An aryl group can be unsubstituted or substituted with one or more of alkyl, halogen, haloalkyl, alkoxy, haloalkoxy, OH, hydroxyalkyl, —O-(hydroxyalkyl), —O-(alkyl)-C(O)OH, -(alkyl)-(alkoxy)-halogen, NH2, aminoalkyl-, dialkylamino-, C(O)OH, —C(O)O-(alkyl), —OC(O)(alkyl), —O-(alkyl)-N(alkyl)(alkyl),N-alkylamido-, —C(O)NH2, (alkyl)amido-, NO2, (aryl)alkyl, alkoxy, aryloxy, heteroaryloxy, (aryl)amino, (alkoxy)carbonyl-, (alkyl)amido-, (alkyl)amino, aminoalkyl-, alkylcarboxyl-, (alkyl)carboxyamido-, (aryl)alkyl-, (aryl)amino-, cycloalkenyl, di(alkyl)amino-, heteroaryl, (heteroaryl)alkyl-, heterocyclyl, —O-(heterocyclyl), heterocyclyl(alkyl)-, (hydroxyalkyl)NH—, (hydroxyalkyl)2N, —SO2(alkyl) or a spiro substituent.
  • The term “bicycle” or “bicyclic” as used herein refers to a molecule that features two fused rings, which rings are a cycloalkyl, heterocyclyl, or heteroaryl. In one embodiment, the rings are fused across a bond between two atoms. The bicyclic moiety formed therefrom shares a bond between the rings. In another embodiment, the bicyclic moiety is formed by the fusion of two rings across a sequence of atoms of the rings to form a bridgehead. Similarly, a “bridge” is an unbranched chain of one or more atoms connecting two bridgeheads in a polycyclic compound. In another embodiment, the bicyclic molecule is a “spiro” or “spirocyclic” moiety. The spirocyclic group is a carbocyclic or heterocyclic ring which bound through a single carbon atom of the spirocyclic moiety to a single carbon atom of a carbocyclic or heterocyclic moiety. In one embodiment, the spirocyclic group is a cycloalkyl and is bound to another cycloalkyl. In another embodiment, the spirocyclic group is a cycloalkyl and is bound to a heterocyclyl. In a further embodiment, the spirocyclic group is a heterocyclyl and is bound to another heterocyclyl. In still another embodiment, the spirocyclic group is a heterocyclyl and is bound to a cycloalkyl.
  • “(Aryl)alkyl” refers to an alkyl group, as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with an aryl group as defined above. (C6-C14 aryl)alkyl-moieties include benzyl, benzhydryl, 1-phenylethyl, 2-phenylethyl, 3-phenylpropyl, 2-phenylpropyl, 1-naphthylmethyl, 2-naphthylmethyl and the like. An (aryl)alkyl group can be unsubstituted or substituted with one or more of of halogen, CN, NH2, OH, (alkyl)amino-, di(alkyl)amino-, (alkyl)C(O)N(alkyl)-, (alkyl)carboxyamido-, HC(O)NH—, H2NC(O)—, (alkyl)NHC(O)—, di(alkyl)NC(O)—, CN, OH, alkoxy, alkyl, C(O)OH, (alkoxy)carbonyl-, (alkyl)C(O)—, aryl, heteroaryl, cycloalkyl, haloalkyl, amino(alkyl)-, (alkyl)carboxyl-, carboxyamidoalkyl-, or NO2.
  • “(Alkoxy)carbonyl-” refers to the group alkyl-O—C(O)—. Exemplary (C1-C6 alkoxy)carbonyl- groups include but are not limited to methoxy, ethoxy, n-propoxy, 1-propoxy, n-butoxy and t-butoxy. An (alkoxy)carbonyl group can be unsubstituted or substituted with one or more of halogen, OH, NH2, (alkyl)amino-, di(alkyl)amino-, (alkyl)C(O)N(alkyl)-, (alkyl)carboxyamido-, HC(O)NH—, H2NC(O)—, (alkyl)NHC(O)—, di(alkyl)NC(O)—, CN, alkoxy, C(O)OH, (alkoxy)carbonyl-, (alkyl)C(O)—, aryl, heteroaryl, cycloalkyl, haloalkyl, amino(alkyl)-, (alkyl)carboxyl-, carboxyamidoalkyl-, or NO2.
  • “(Alkyl)amido-” refers to a —C(O)NH— group in which the nitrogen atom of said group is attached to a C1-C6 alkyl group, as defined above. Representative examples of a (C1-C6 alkyl)amido- group include, but are not limited to, C(O)NHCH3, —C(O)NHCH2CH3, —C(O)NHCH2CH2CH3, C(O)NHCH2CH2CH2CH3, —C(O)NHCH2CH2CH2CH2CH3, —C(O)NHCH(CH3)2, C(O)NHCH2CH(CH3)2, —C(O)NHCH(CH3)CH2CH3, —C(O)NH—C(CH3)3 and C(O)NHCH2C(CH3)3.
  • “(Alkyl)amino-” refers to an —NH group, the nitrogen atom of said group being attached to a alkyl group, as defined above. Representative examples of an (C1-C6 alkyl)amino- group include, but are not limited to CH3NH—, CH3CH2NH—, CH3CH2CH2NH—, CH3CH2CH2CH2NH—, (CH3)2CHNH—, (CH3)2CHCH2NH—, CH3CH2CH(CH3)NH— and (CH3)3CNH—. An (alkyl)amino group can be unsubstituted or substituted on the alkyl moiety with one or more of halogen, NH2, (alkyl)amino-, di(alkyl)amino-, (alkyl)C(O)N(alkyl)-, (alkyl)carboxyamido-, HC(O)NH—, H2NC(O)—, (alkyl)NHC(O)—, di(alkyl)NC(O)—, CN, OH, alkoxy, alkyl, C(O)OH, (alkoxy)carbonyl-, (alkyl)C(O)—, aryl, heteroaryl, cycloalkyl, haloalkyl, amino(alkyl)-, (alkyl)carboxyl-, carboxyamidoalkyl-, or NO2.
  • “Aminoalkyl-” refers to an alkyl group, as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with —NH2; one or both H of the NH2 may be replaced by a substituent.
  • “Alkylcarboxyl-” refers to an alkyl group, defined above that is attached to the parent structure through the oxygen atom of a carboxyl (C(O)—O—) functionality. Examples of (C1-C6 alkyl)carboxyl- include acetoxy, propionoxy, propylcarboxyl, and isopentylcarboxyl.
  • “(Alkyl)carboxyamido-” refers to a —NHC(O)— group in which the carbonyl carbon atom of said group is attached to a C1-C6 alkyl group, as defined above. Representative examples of a (C1-C6 alkyl)carboxyamido- group include, but are not limited to, —NHC(O)CH3, —NHC(O)CH2CH3, —NHC(O)CH2CH2CH3, NHC(O)CH2CH2CH2CH3, —NHC(O)CH2CH2CH2CH2CH3, —NHC(O)CH(CH3)2, NHC(O)CH2CH(CH3)2, —NHC(O)CH(CH3)CH2CH3, —NHC(O)—C(CH3)3 and NHC(O)CH2C(CH3)3.
  • “(Aryl)amino” refers to a radical of formula (aryl)-NH—, wherein aryl is as defined above. “(Aryl)oxy” refers to the group Ar—O— where Ar is an aryl group, as defined above.
  • “Cycloalkyl” refers to a non-aromatic, saturated, partially saturated, monocyclic, bicyclic or polycyclic hydrocarbon 3 to 12 membered ring system. Representative examples of a C3-C12 cycloalkyl include, but are not limited to, cyclopropyl, cyclopentyl, cycloheptyl, cyclooctyl, decahydronaphthalen-1-yl, octahydro-1H-inden-2-yl, decahydro-1H-benzo[7]annulen-2-yl, and dodecahydros-indacen-4-yl. Representative examples of a C3-C10 cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, decahydronaphthalen-1-yl, and octahydro-1H-inden-2-yl. Representative examples of a C3-C8 cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and octahydropentalen-2-yl. A cycloalkyl can be unsubstituted or substituted with one or more of halogen, NH2, (alkyl)NH, (alkyl)(alkyl)N—, —N(alkyl)C(O)(alkyl), —NHC(O)(alkyl), —NHC(O)H, —C(O)NH2, —C(O)NH(alkyl), —C(O)N(alkyl)(alkyl), CN, OH, alkoxy, alkyl, C(O)OH, —C(O)O(alkyl), —C(O) alkyl), aryl, heteroaryl, cycloalkyl, haloalkyl, aminoalkyl-, —OC(O)(alkyl), carboxyamidoalkyl-, and NO2. Additionally, each of any two hydrogen atoms on the same carbon atom of the carbocyclic ring can be replaced by an oxygen atom to form an oxo (═O) substituent.
  • “Halo” or “halogen” refers to —F, —Cl, —Br and —I.
  • “C1-C6 haloalkyl” refers to a C1-C6 alkyl group, as defined above, wherein one or more of the C1-C6 alkyl group's hydrogen atoms has been replaced with F, Cl, Br, or I. Each substitution can be independently selected from F, Cl, Br, or I. Representative examples of an C1-C6 haloalkyl- group include, but are not limited to, —CH2F, —CCl3, —CF3, CH2CF3, —CH2Cl, —CH2CH2Br, —CH2CH2I, —CH2CH2CH2F, —CH2CH2CH2Cl, —CH2CH2CH2CH2Br, —CH2CH2CH2CH2I, CH2CH2CH2CH2CH2Br, —CH2CH2CH2CH2CH2I, —CH2CH(Br)CH3, —CH2CH(Cl)CH2CH3, —CH(F)CH2CH3 and —C(CH3)2(CH2Cl).
  • “Heteroaryl” refers to a monocyclic, bicyclic, or polycyclic aromatic ring system containing at least one ring atom selected from the heteroatoms oxygen, sulfur and nitrogen. Examples of C1-C9 heteroaryl groups include furan, thiophene, indole, azaindole, oxazole, thiazole, isoxazole, isothiazole, imidazole, N-methylimidazole, pyridine, pyrimidine, pyrazine, pyrrole, N-methylpyrrole, pyrazole, N-methylpyrazole, 1,3,4-oxadiazole, 1,2,4-triazole, 1-methyl-1,2,4-triazole, 1H-tetrazole, 1-methyltetrazole, benzoxazole, benzothiazole, benzofuran, benzisoxazole, benzimidazole, N-methylbenzimidazole, azabenzimidazole, indazole, quinazoline, quinoline, and isoquinoline. Bicyclic C1-C9 hetroaryl groups include those where a phenyl, pyridine, pyrimidine or pyridazine ring is fused to a 5 or 6-membered monocyclic heteroaryl ring having one or two nitrogen atoms in the ring, one nitrogen atom together with either one oxygen or one sulfur atom in the ring, or one O or S ring atom. Examples of monocyclic C1-C4 heteroaryl groups include 2H-tetrazole, 3H-1,2,4-triazole, furan, thiophene, oxazole, thiazole, isoxazole, isothiazole, imidazole, and pyrrole. A heteroaryl group can be unsubstituted or substituted with one or more of C1-C6 alkyl, halogen, haloalkyl, OH, CN, hydroxyalkyl, NH2, aminoalkyl-, dialkylamino-, C(O)OH, —C(O)O-(alkyl), —OC(O)(alkyl), N-alkylamido-, —C(O)NH2, (alkyl)amido-, —NO2, (aryl)alkyl, alkoxy, aryloxy, heteroaryloxy, (aryl)amino, (alkoxy)carbonyl-, (alkyl)amido-, (alkyl)amino, aminoalkyl-, alkylcarboxyl-, (alkyl)carboxyamido-, (aryl)alkyl-, (aryl)amino-, cycloalkenyl, di(alkyl)amino-, heteroaryl, (heteroaryl)alkyl-, heterocyclyl, hetyerocyclyl(alkyl)-, (hydroxyalkyl)NH—, (hydroxyalkyl)2N or a spiro substituent.
  • “Heterocycle” or “heterocyclyl” refers to monocyclic, bicyclic, polycyclic, or bridged head molecules in which at least one ring atom is a heteroatom. A heterocycle may be saturated or partially saturated. Exemplary C1-C9 heterocyclyl groups include but are not limited to aziridine, oxirane, oxirene, thiirane, pyrroline, pyrrolidine, dihydrofuran, tetrahydrofuran, dihydrothiophene, tetrahydrothiophene, dithiolane, piperidine, 1,2,3,6-tetrahydropyridine-1-yl, tetrahydropyran, pyran, thiane, thiine, piperazine, azepane, diazepane, oxazine, 5,6-dihydro-4H-1,3-oxazin-2-yl, 2,5-diazabicyclo[2.2.1]heptane, 2,5-diazabicyclo[2.2.2]octane, 3,6-diazabicyclo[3.1.1]heptane, 3,8-diazabicyclo[3.2.1]octane, 6-oxa-3,8-diazabicyclo[3.2.1]octane, 7-oxa-2,5-diazabicyclo[2.2.2]octane, 2,7-dioxa-5-azabicyclo[2.2.2]octane, 2-oxa-5-azabicyclo[2.2.1]heptane-5-yl, 2-oxa-5-azabicyclo[2.2.2]octane, 3,6-dioxa-8-azabicyclo[3.2.1]octane, 3-oxa-6-azabicyclo[3.1.1]heptane, 3-oxa-8-azabicyclo[3.2.1]octan-8-yl, 5,7-dioxa-2-azabicyclo[2.2.2]octane, 6,8-dioxa-3-azabicyclo[3.2.1]octane, 6-oxa-3-azabicyclo[3.1.1]heptane, 8-oxa-3-azabicyclo[3.2.1]octan-3-yl, 2-methyl-2,5-diazabicyclo[2.2.1]heptane-5-yl, 1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl, 3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl-, 7-methyl-3-oxa-7,9-diazabicyclo[3.3.1]nonan-9-yl, 9-oxa-3-azabicyclo[3.3.1]nonan-3-yl, 3-oxa-9-azabicyclo[3.3.1]nonan-9-yl, 3,7-dioxa-9-azabicyclo[3.3.1]nonan-9-yl, 4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl, thiazine, dithiane, and dioxane. The contemplated heterocycle rings or ring systems have a minimum of 3 members. Therefore, for example, C1 heterocyclyl radicals would include but are not limited to oxaziranyl, diaziridinyl, and diazirinyl, C2 heterocyclyl radicals include but are not limited to aziridinyl, oxiranyl, and diazetidinyl, C9 heterocyclyl radicals include but are not limited to azecanyl, tetrahydroquinolinyl, and perhydroisoquinolinyl. A heterocyclyl group can be unsubstituted or substituted with one or more of alkyl, halogen, alkoxy, haloalkyl, OH, hydroxyalkyl, —C(O)-(hydroxyalkyl), NH2, aminoalkyl-, dialkylamino-, C(O)OH, —C(O)O-(alkyl), —OC(O)(alkyl), N-alkylamido-, —C(O)NH2, (alkyl)amido-, —C(O)-(alkyl)-CN, (alkyl)-CN, or NO2.
  • “Heterocyclyl(alkyl)-” refers to an alkyl group, as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with a heterocycle group as defined above. Heterocyclyl(C1-C6 alkyl)- moieties include 1-piperazinylethyl, 4-morpholinylpropyl, 6-piperazinylhexyl, and the like. A heterocyclyl(alkyl) group can be unsubstituted or substituted with one or more of halogen, NH2, (alkyl)amino-, di(alkyl)amino-, (alkyl)C(O)N(alkyl)-, (alkyl)carboxyamido-, HC(O)NH—, H2NC(O)—, (alkyl)NHC(O)—, di(alkyl)NC(O)—, CN, OH, alkoxy, alkyl, C(O)OH, (alkoxy)carbonyl-, (alkyl)C(O)—, 4- to 7-membered monocyclic heterocycle, aryl, heteroaryl, or cycloalkyl.
  • “Heteroaryl(alkyl)” refers to a heteroaryl which is attached to an alkyl group and the heteroaryl is defined above.
  • “Hydroxyalkyl” refers to a alkyl group, as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with OH groups. Examples of C1-C6 hydroxyalkyl moieties include, for example, —CH2OH, CH2CH2OH, —CH2CH2CH2OH, —CH2CH(OH)CH2OH, —CH2CH(OH)CH3, —CH(CH3)CH2OH and higher homologs.
  • “Perfluoroalkyl-” refers to alkyl group, defined above, having two or more fluorine atoms. Examples of a C1-C6 perfluoroalkyl- group include CF3, CH2CF3, CF2CF3 and CH(CF3)2.
  • Representative “pharmaceutically acceptable salts” include, e.g., water-soluble and water-insoluble salts, such as the acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, bromide, butyrate, calcium, chloride, choline, citrate, edisylate (camphorsulfonate), fumarate, gluconate, glucuronate, glutamate, hydrobromide, hydrochloride, lauryl sulfate, malate, maleate, mandelate, mesylate, palmitate, pantothenate, phosphate, potassium, propionate, p-toluenesulfonate, salicylate, sodium, stearate, succinate, and sulfate salts. Representative pharmaceutically acceptable esters include acetyl, propionyl, benzoyl, nicotinoyl and phenylacetyl ester derivatives of compounds of Formula (I) that have a hydroxyl group.
  • Examples of specific compounds falling within Formula (I) that may be useful in the methods of the present invention are set forth in Table I, below.
  • TABLE 1
    Structure IUPAC Name
    Figure US20190070182A1-20190307-C00036
         		4-(4-morpholinophenylamino)-2- phenylpyrimido[4,5-d]pyridazin-5(6H)- one
    Figure US20190070182A1-20190307-C00037
         		methyl 4-(5-oxo-4-(4-(piperazin-1- ylmethyl)phenylamino)-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)benzoate hydrochloride
    Figure US20190070182A1-20190307-C00038
         		2-morpholino-4-(4-(piperazin-1- ylmethyl)phenylamino)pyrimido[4,5- d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00039
         		4-(4-(morpholinomethyl)phenylamino)-2- phenylpyrimido[4,5-d]pyridazin-5(6H)- one
    Figure US20190070182A1-20190307-C00040
         		4-(4-(4-ethylpiperazin-1-yl)phenylamino)- 2-phenylpyrimido[4,5-d]pyridazin-5(6H)- one
    Figure US20190070182A1-20190307-C00041
         		4-(4-((4-ethylpiperazin-1- yl)methyl)phenylamino)-2- phenylpyrimido[4,5-d]pyridazin-5(6H)- one
    Figure US20190070182A1-20190307-C00042
         		2-phenyl-4-(4-(piperazin-1- ylmethyl)phenylamino)pyrimido[4,5- d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00043
         		2-phenyl-4-(4-(piperazin-1- yl)phenylamino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00044
         		4-(4-(morpholine-4- carbonyl)phenylamino)-2- phenylpyrimido[4,5-d]pyridazin-5(6H)- one
    Figure US20190070182A1-20190307-C00045
         		4-(4-(bis(2- hydroxyethyl)amino)phenylamino)-2- phenylpyrimido[4,5-d]pyridazin-5(6H)- one
    Figure US20190070182A1-20190307-C00046
         		4-(4-(4-(2-aminoacetyl)piperazin-1- yl)phenylamino)-2-phenylpyrimido[4,5- d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00047
         		2-(4-(4-(5-oxo-2-phenyl-5,6- dihydropyrimido[4,5-d]pyridazin-4- ylamino)phenyl)piperazin-1-yl)acetic acid
    Figure US20190070182A1-20190307-C00048
         		1-(4-(5-oxo-2-phenyl-5,6- dihydropyrimido[4,5-d]pyridazin-4- ylamino)phenyl)piperidine-4-carboxylic acid
    Figure US20190070182A1-20190307-C00049
         		4-(4-(4-(2-aminoacetyl)piperazin-1- yl)phenylamino)-2-phenylpyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00050
         		N-(2-(dimethylamino)ethyl)-N-methyl-4- (5-oxo-2-phenyl-5,6- dihydropyrimido[4,5-d]pyridazin-4- ylamino)benzamide
    Figure US20190070182A1-20190307-C00051
         		4-(4-(2-oxo-1,7-diazaspiro[3.5]nonan-7- yl)phenylamino)-2-phenylpyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00052
         		4-(4-(2-oxa-7-azaspiro[3.5]nonan-7- yl)phenylamino)-2-phenylpyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00053
         		4-(4-morpholinophenylamino)-2-(6- azaspiro[2.5]octan-6-yl)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00054
         		6-(4-(5-oxo-2-phenyl-5,6- dihydropyrimido[4,5-d]pyridazin-4- ylamino)phenyl)-6-azaspiro[2.5]octane-1- carboxylic acid
    Figure US20190070182A1-20190307-C00055
         		ethyl 6-(4-(5-oxo-2-phenyl-5,6- dihydropyrimido[4,5-d]pyridazin-4- ylamino)phenyl)-6-azaspiro[2.5]octane-1- carboxylate
    Figure US20190070182A1-20190307-C00056
         		6-(4-(5-oxo-2-phenyl-5,6- dihydropyrimido[4,5-d]pyridazin-4- ylamino)benzyl)-6-azaspiro[2.5]octane-1- carboxylic acid
    Figure US20190070182A1-20190307-C00057
         		sodium 6-(4-(5-oxo-2-phenyl-5,6- dihydropyrimido[4,5-d]pyridazin-4- ylamino)phenyl)-6-azaspiro[2.5]octane-1- carboxylate
    Figure US20190070182A1-20190307-C00058
         		4-(4-(2-oxa-7-azaspiro[3.5]nonan-7- ylmethyl)phenylamino)-2- phenylpyrimido[4,5-d]pyridazin-5(6H)- one
    Figure US20190070182A1-20190307-C00059
         		4-(4-(piperazin-1-ylmethyl)phenylamino)- 2-(thiophen-3-yl)pyrimido[4,5- d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00060
         		6-(5-oxo-4-(4-(piperazin-1- ylmethyl)phenylamino)-5,6- dihydropyrimido[4,5-d]pyridazin-2-yl)-6- azaspiro[2.5]octane-1-carboxylic acid hydrochloride
    Figure US20190070182A1-20190307-C00061
         		4-(4-(4-ethylpiperazin-1-yl)phenylamino)- 2-morpholinopyrimido[4,5-d]pyridazin- 5(6H)-one
    Figure US20190070182A1-20190307-C00062
         		4-(5-oxo-4-(4-(piperazin-1- ylmethyl)phenylamino)-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)benzoic acid hydrochloride
    Figure US20190070182A1-20190307-C00063
         		4-(4-(4-ethylpiperazin-1-yl)phenylamino)- 2-(4- (trifluoromethoxy)phenyl)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00064
         		methyl 4-(4-(4-morpholinophenylamino)- 5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-2-yl)benzoate
    Figure US20190070182A1-20190307-C00065
         		4-(4-(piperazin-1-ylmethyl)phenylamino)- 2-(piperidin-1-yl)pyrimido[4,5- d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00066
         		2-(3-methoxyphenyl)-4-(4-(piperazin-1- ylmethyl)phenylamino)pyrimido[4,5- d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00067
         		2-(piperazin-1-yl)-4-(4-(piperazin-1- ylmethyl)phenylamino)pyrimido[4,5- d]pyridazin-5(6H)-one dihydrochloride
    Figure US20190070182A1-20190307-C00068
         		2-(benzo[d][1,3]dioxol-5-yl)-4-(4- (piperazin-1- ylmethyl)phenylamino)pyrimido[4,5- d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00069
         		2-(1-(4-(5-oxo-2-phenyl-5,6- dihydropyrimido[4,5-d]pyridazin-4- ylamino)phenyl)piperidin-4-yl)acetic acid
    Figure US20190070182A1-20190307-C00070
         		1-(4-(5-oxo-2-phenyl-5,6- dihydropyrimido[4,5-d]pyridazin-4- ylamino)benzyl)piperidine-4-carboxylic acid
    Figure US20190070182A1-20190307-C00071
         		2-(2-methoxyphenyl)-4-(4-(piperazin-1- ylmethyl)phenylamino)pyrimido[4,5- d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00072
         		4-(4-(4-ethylpiperazin-1-yl)phenylamino)- 2-(thiophen-3-yl)pyrimido[4,5- d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00073
         		9-(5-oxo-4-(4-(piperazin-1- ylmethyl)phenylamino)-5,6- dihydropyrimido[4,5-d]pyridazin-2-yl)- 3,9-diazaspiro[5.5]undecane-2,4-dione hydrochloride
    Figure US20190070182A1-20190307-C00074
         		6-(4-(5-oxo-2-(thiophen-3-yl)-5,6- dihydropyrimido[4,5-d]pyridazin-4- ylamino)phenyl)-6-azaspiro[2.5]octane-1- carboxylic acid
    Figure US20190070182A1-20190307-C00075
         		2-(4-chlorophenyl)-4-(4-(piperazin-1- ylmethyl)phenylamino)pyrimido[4,5- d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00076
         		2-(4-methoxyphenyl)-4-(4-(piperazin-1- ylmethyl)phenylamino)pyrimido[4,5- d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00077
         		6-(4-((2-morpholino-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)-6-azaspiro[2.5]octane- 1-carboxylic acid
    Figure US20190070182A1-20190307-C00078
         		2-(1-(5-oxo-4-((4-(piperazin-1- ylmethyl)phenyl)amino)-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetic acid hydrochloride
    Figure US20190070182A1-20190307-C00079
         		2-(1-oxidothiomorpholino)-4-((4- (piperazin-1- ylmethyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00080
         		2-(4-methylpiperazin-1-yl)-4-((4- (piperazin-1- ylmethyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00081
         		6-(4-((2-(4-methoxyphenyl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)-6-azaspiro[2.5]octane- 1-carboxylic acid
    Figure US20190070182A1-20190307-C00082
         		6-(4-((2-(3-methoxyphenyl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)-6-azaspiro[2.5]octane- 1-carboxylic acid
    Figure US20190070182A1-20190307-C00083
         		4-((4-(piperazin-1- ylmethyl)phenyl)amino)-2-(pyrrolidin-1- yl)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00084
         		2-(dimethylamino)-4-((4-(piperazin-1- ylmethyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00085
         		2-ethoxy-4-((4-(piperazin-1- ylmethyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00086
         		1-(5-oxo-4-((4-(piperazin-1- ylmethyl)phenyl)amino)-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidine-4-carboxylic acid hydrochloride
    Figure US20190070182A1-20190307-C00087
         		2-(azepan-1-yl)-4-((4-(piperazin-1- ylmethyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00088
         		6-(4-((2-(2-methoxyphenyl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)-6-azaspiro[2.5]octane- 1-carboxylic acid
    Figure US20190070182A1-20190307-C00089
         		2-(diisopropylamino)-4-((4-(piperazin-1- ylmethyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00090
         		2-(4-(morpholinomethyl)phenyl)-4-((4- (piperazin-1- ylmethyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00091
         		1-(5-oxo-4-((4-(piperazin-1- ylmethyl)phenyl)amino)-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidine-4-carbonitrile hydrochloride
    Figure US20190070182A1-20190307-C00092
         		2-(4-ethylpiperazin-1-yl)-4-((4-(piperazin- 1-ylmethyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00093
         		4-((1-(2-morpholinoethyl)-1H-pyrazol-4- yl)amino)-2-phenylpyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00094
         		2-(1,4-diazepan-1-yl)-4-((4-(piperazin-1- ylmethyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one dihydrochloride
    Figure US20190070182A1-20190307-C00095
         		2-(azepan-1-yl)-4-((4- morpholinophenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00096
         		2-methoxy-4-((4-(piperazin-1- ylmethyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00097
         		6-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)-6-azaspiro[2.5]octane- 1-carboxylic acid
    Figure US20190070182A1-20190307-C00098
         		2-phenyl-4-((1-(2-(piperazin-1-yl)ethyl)- 1H-pyrazol-4-yl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00099
         		4-((1-(2-(4-methylpiperazin-1-yl)ethyl)- 1H-pyrazol-4-yl)amino)-2- phenylpyrimido[4,5-d]pyridazin-5(6H)- one
    Figure US20190070182A1-20190307-C00100
         		4-((1-(2-(4-ethylpiperazin-1-yl)ethyl)-1H- pyrazol-4-yl)amino)-2- phenylpyrimido[4,5-d]pyridazin-5(6H)- one
    Figure US20190070182A1-20190307-C00101
         		6-(4-((2-(4-(cyanomethyl)piperidin-1-yl)- 5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-4-yl)amino)phenyl)-6- azaspiro[2.5]octane-1-carboxylic acid
    Figure US20190070182A1-20190307-C00102
         		2-(azepan-1-yl)-4-((3,4,5- trimethoxyphenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00103
         		2-(azepan-1-yl)-4-((4-(morpholine-4- carbonyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00104
         		2-(1-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperidin-4-yl)acetic acid
    Figure US20190070182A1-20190307-C00105
         		2-(1-(4-((2-(4-(cyanomethyl)piperazin-1- yl)-5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-4-yl)amino)phenyl)piperidin- 4-yl)acetic acid
    Figure US20190070182A1-20190307-C00106
         		2-(1-(4-((2-(4-(cyanomethyl)piperidin-1- yl)-5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-4-yl)amino)phenyl)piperidin- 4-yl)acetic acid
    Figure US20190070182A1-20190307-C00107
         		6-(4-((2-(1,4-diazepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)-6-azaspiro[2.5]octane- 1-carboxylic acid hydrochloride
    Figure US20190070182A1-20190307-C00108
         		6-(4-((2-(4-(cyanomethyl)piperazin-1-yl)- 5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-4-yl)amino)phenyl)-6- azaspiro[2.5]octane-1-carboxylic acid
    Figure US20190070182A1-20190307-C00109
         		6-(4-((2-(4-cyanopiperidin-1-yl)-5-oxo- 5,6-dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)-6-azaspiro[2.5]octane- 1-carboxylic acid
    Figure US20190070182A1-20190307-C00110
         		2-(1-(4-((2-(4-cyanopiperidin-1-yl)-5- oxo-5,6-dihydropyrimido[4,5-d]pyridazin- 4-yl)amino)phenyl)piperidin-4-yl)acetic acid
    Figure US20190070182A1-20190307-C00111
         		1-(4-((2-(4-cyanopiperidin-1-yl)-5-oxo- 5,6-dihydropyrimido[4,5-d]pyridazin-4- yl)amino)benzyl)piperidine-4-carboxylic acid
    Figure US20190070182A1-20190307-C00112
         		2-(1-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)benzyl)piperidin-4-yl)acetic acid
    Figure US20190070182A1-20190307-C00113
         		1-(4-((2-(4-(cyanomethyl)piperidin-1-yl)- 5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-4- yl)amino)benzyl)piperidine-4-carboxylic acid
    Figure US20190070182A1-20190307-C00114
         		6-(4-((2-cyclohexyl-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)-6-azaspiro[2.5]octane- 1-carboxylic acid
    Figure US20190070182A1-20190307-C00115
         		2-(1-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperidin-4- yl)acetonitrile
    Figure US20190070182A1-20190307-C00116
         		6-(4-((2-cycloheptyl-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)-6-azaspiro[2.5]octane- 1-carboxylic acid
    Figure US20190070182A1-20190307-C00117
         		2-(1-(4-((5-oxo-2-phenyl-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperidin-4- yl)acetonitrile
    Figure US20190070182A1-20190307-C00118
         		4-((4-((4-(2-hydroxy-2- methylpropanoyl)piperazin-1- yl)methyl)phenyl)amino)-2- phenylpyrimido[4,5-d]pyridazin-5(6H)- one
    Figure US20190070182A1-20190307-C00119
         		2-(azepan-1-yl)-4-((4-((4-(2-hydroxy-2- methylpropanoyl)piperazin-1- yl)methyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00120
         		2-(azepan-1-yl)-4-((4-((4- methylpiperazin-1- yl)methyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00121
         		2-(4-(4-((5-oxo-2-phenyl-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperidin-1-yl)acetic acid
    Figure US20190070182A1-20190307-C00122
         		2-(4-(4-((5-oxo-2-phenyl-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)cyclohexyl)acetic acid
    Figure US20190070182A1-20190307-C00123
         		2-(1-(4-((2-(azocan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperidin-4-yl)acetic acid
    Figure US20190070182A1-20190307-C00124
         		2-(azepan-1-yl)-4-((4-(2-(piperazin-1- yl)ethoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00125
         		2-(1-(4-((2-cycloheptyl-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperidin-4-yl)acetic acid
    Figure US20190070182A1-20190307-C00126
         		2-(4-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)cyclohexyl)acetic acid
    Figure US20190070182A1-20190307-C00127
         		4-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenoxy)butanoic acid
    Figure US20190070182A1-20190307-C00128
         		2-(azepan-1-yl)-4-((4-(2-morpholino- ethoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00129
         		4-((4-(2- morpholinoethoxy)phenyl)amino)-2- phenylpyrimido[4,5-d]pyridazin-5(6H)- one
    Figure US20190070182A1-20190307-C00130
         		2-(azepan-1-yl)-4-((4-(2-(4- methylpiperazin-1- yl)ethoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00131
         		2-(1-(2-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenoxy)ethyl)piperidin-4- yl)acetic acid
    Figure US20190070182A1-20190307-C00132
         		2-(1-(5-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)pyridin-2-yl)piperidin-4- yl)acetonitrile
    Figure US20190070182A1-20190307-C00133
         		1-(2-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenoxy)ethyl)piperidine-4- carboxylic acid
    Figure US20190070182A1-20190307-C00134
         		2-(1-(5-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)pyridin-2-yl)piperidin-4- yl)acetamide
    Figure US20190070182A1-20190307-C00135
         		2-(1-(4-((2-(4-(2-cyanopropan-2- yl)piperidin-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperidin-4-yl)acetic acid
    Figure US20190070182A1-20190307-C00136
         		2-(1-(5-((5-oxo-2-phenyl-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)pyridin-2-yl)piperidin-4- yl)acetonitrile
    Figure US20190070182A1-20190307-C00137
         		2-(1-(5-((5-oxo-2-phenyl-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)pyridin-2-yl)piperidin-4- yl)acetamide
    Figure US20190070182A1-20190307-C00138
         		2-(1-(5-((2-(4-(cyanomethyl)piperidin-1- yl)-5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-4-yl)amino)pyridin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00139
         		2-(azepan-1-yl)-4-((4-(piperazine-1- carbonyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00140
         		2-(1-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperidin-4-yl)acetamide
    Figure US20190070182A1-20190307-C00141
         		2-(4-(2-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenoxy)ethyl)piperazin-1- yl)acetic acid
    Figure US20190070182A1-20190307-C00142
         		2-(azepan-1-yl)-4-((4-(2-(piperazin-1- yl)ethoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00143
         		2-(1-(5-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)pyridin-2-yl)piperidin-4- yl)acetic acid
    Figure US20190070182A1-20190307-C00144
         		2-(1-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperidin-4-yl)-N-(2- hydroxyethyl)acetamide
    Figure US20190070182A1-20190307-C00145
         		2-(azepan-1-yl)-4-((4-(((2S,5S)-5- (hydroxymethyl)-1,4-dioxan-2- yl)methoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00146
         		2-(4-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperazin-1-yl)-2- methylpropanenitrile
    Figure US20190070182A1-20190307-C00147
         		2-(4-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperazin-1-yl)-2- methylpropanamide
    Figure US20190070182A1-20190307-C00148
         		2-(1-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperidin-4- yl)acetonitrile
    Figure US20190070182A1-20190307-C00149
         		2-(1-(5-((2-(4-(cyanomethyl)piperidin-1- yl)-5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-4-yl)amino)pyridin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00150
         		2-(azepan-1-yl)-4-((4-(2-(4-(2-hydroxy-2- methylpropanoyl)piperazin-1- yl)ethoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00151
         		2-(1-(5-((2-(4-(cyanomethyl)piperidin-1- yl)-5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-4-yl)amino)pyridin-2- yl)piperidin-4-yl)acetic acid
    Figure US20190070182A1-20190307-C00152
         		2-(1-(4-((2-(3,5-dimethylpiperidin-1-yl)- 5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-4-yl)amino)phenyl)piperidin- 4-yl)acetic acid
    Figure US20190070182A1-20190307-C00153
         		2-(1-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperidin-4-yl)-N,N- bis(2-hydroxyethyl)acetamide
    Figure US20190070182A1-20190307-C00154
         		2-methyl-2-(1-(4-((5-oxo-2-phenyl-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperidin-4- yl)propanenitrile
    Figure US20190070182A1-20190307-C00155
         		2-(4-(2-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenoxy)ethyl)piperazin-1-yl)- 2-methylpropanenitrile
    Figure US20190070182A1-20190307-C00156
         		2-(1-(4-((2-(2,6-dimethylmorpholino)-5- oxo-5,6-dihydropyrimido[4,5-d]pyridazin- 4-yl)amino)phenyl)piperidin-4-yl)acetic acid
    Figure US20190070182A1-20190307-C00157
         		4-((4-(((2S,5S)-5-(hydroxymethyl)-1,4- dioxan-2-yl)methoxy)phenyl)amino)-2- phenylpyrimido[4,5-d]pyridazin-5(6H)- one
    Figure US20190070182A1-20190307-C00158
         		2-((1S,4S)-4-(4-((2-(azepan-1-yl)-5-oxo- 5,6-dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)cyclohexyl)acetic acid
    Figure US20190070182A1-20190307-C00159
         		(2R,5S)-5-((4-((2-(azepan-1-yl)-5-oxo- 5,6-dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenoxy)methyl)-1,4-dioxane- 2-carboxylic acid
    Figure US20190070182A1-20190307-C00160
         		2-(4-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperazin-1-yl)acetic acid
    Figure US20190070182A1-20190307-C00161
         		2-(1-(3-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenoxy)propyl)piperidin-4- yl)acetic acid
    Figure US20190070182A1-20190307-C00162
         		6-(4-((2-(cyclohexylamino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)spiro[2.5]octane-1- carboxylic acid
    Figure US20190070182A1-20190307-C00163
         		6-(4-((5-oxo-2-(piperidin-1-yl)-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)spiro[2.5]octane-1- carboxylic acid
    Figure US20190070182A1-20190307-C00164
         		2-((1R,4R)-4-(4-((2-(azepan-1-yl)-5-oxo- 5,6-dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)cyclohexyl)acetic acid
    Figure US20190070182A1-20190307-C00165
         		3-(1-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperidin-4-yl)propanoic acid
    Figure US20190070182A1-20190307-C00166
         		2-(1-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperidin-4- yl)cyclopropanecarboxylic acid
    Figure US20190070182A1-20190307-C00167
         		3-(1-(4-((5-oxo-2-phenyl-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperidin-4-yl)propanoic acid
    Figure US20190070182A1-20190307-C00168
         		6-(4-((2-(4-fluorophenyl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)-6-azaspiro[2.5]octane- 1-carboxylic acid
    Figure US20190070182A1-20190307-C00169
         		6-(5-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)pyridin-2-yl)-6- azaspiro[2.5]octane-1-carboxylic acid
    Figure US20190070182A1-20190307-C00170
         		6-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)-2-fluorophenyl)-6- azaspiro[2.5]octane-1-carboxylic acid
    Figure US20190070182A1-20190307-C00171
         		2-(azepan-1-yl)-4-((4-(3-(piperazin-1- yl)propoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00172
         		6-(5-((5-oxo-2-phenyl-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)pyridin-2-yl)-6- azaspiro[2.5]octane-1-carboxylic acid
    Figure US20190070182A1-20190307-C00173
         		6-(4-((5-oxo-2-(pyridin-4-yl)-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)-6-azaspiro[2.5]octane- 1-carboxylic acid
    Figure US20190070182A1-20190307-C00174
         		2-(azepan-1-yl)-4-((4-(4-(2- hydroxypropan-2-yl)piperidin-1- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00175
         		2-(4-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperazin-1-yl)-2- methylpropanoic acid
    Figure US20190070182A1-20190307-C00176
         		6-(4-((2-(azocan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)-6-azaspiro[2.5]octane- 1-carboxylic acid
    Figure US20190070182A1-20190307-C00177
         		2-(1-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperidin-4-yl)-2- methylpropanoic acid
    Figure US20190070182A1-20190307-C00178
         		2-methyl-2-(1-(4-((5-oxo-2-phenyl-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperidin-4-yl)propanoic acid
    Figure US20190070182A1-20190307-C00179
         		2-(4-(5-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)pyridin-2-yl)piperazin-1- yl)acetic acid
    Figure US20190070182A1-20190307-C00180
         		2-(4-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)-1,4-diazepan-1- yl)acetic acid
    Figure US20190070182A1-20190307-C00181
         		2-(1-(4-((4-(4-(2-hydroxypropan-2- yl)piperidin-1-yl)phenyl)amino)-5-oxo- 5,6-dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00182
         		3-(1-(4-((2-(4-(cyanomethyl)piperidin-1- yl)-5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-4-yl)amino)phenyl)piperidin- 4-yl)propanoic acid
    Figure US20190070182A1-20190307-C00183
         		6-(5-((2-(4-(cyanomethyl)piperidin-1-yl)- 5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-4-yl)amino)pyridin-2-yl)-6- azaspiro[2.5]octane-1-carboxylic acid
    Figure US20190070182A1-20190307-C00184
         		1-(5-oxo-4-((4-(2-(piperazin-1- yl)ethoxy)phenyl)amino)-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidine-4-carbonitrile
    Figure US20190070182A1-20190307-C00185
         		2-(1-(5-oxo-4-((4-(2-(piperazin-1- yl)ethoxy)phenyl)amino)-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00186
         		2-(azepan-1-yl)-4-((4-(2-(4- ethylpiperazin-1- yl)ethoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00187
         		2-phenyl-4-((4-(2-(piperazin-1- yl)ethoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00188
         		4-((4-(2-(piperazin-1- yl)ethoxy)phenyl)amino)-2-(piperidin-1- yl)pyrimido[4,5-d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00189
         		2-(4-(4-((5-oxo-2-(piperidin-1-yl)-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)-1,4-diazepan-1- yl)acetic acid
    Figure US20190070182A1-20190307-C00190
         		6-(4-((2-(4-methylpiperidin-1-yl)-5-oxo- 5,6-dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)-6-azaspiro[2.5]octane- 1-carboxylic acid
    Figure US20190070182A1-20190307-C00191
         		2-(4-methylpiperidin-1-yl)-4-((4-(2- (piperazin-1- yl)ethoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00192
         		2-(azepan-1-yl)-4-((4-(2-(3-oxopiperazin- 1-yl)ethoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00193
         		6-(2-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenoxy)ethyl)-6- azaspiro[2.5]octane-1-carboxylic acid
    Figure US20190070182A1-20190307-C00194
         		2-(azepan-1-yl)-4-((4-(2- (diethylamino)ethoxy)phenyl)amino) pyrimido[4,5-d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00195
         		2-(cyclohexyl(methyl)amino)-4-((4-(2- (piperazin-1- yl)ethoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00196
         		2-(1-(4-((2-(cyclohexyl(methyl)amino)-5- oxo-5,6-dihydropyrimido[4,5-d]pyridazin- 4-yl)amino)phenyl)piperidin-4-yl)acetic acid
    Figure US20190070182A1-20190307-C00197
         		2-(4-(4-((2-(4-(cyanomethyl)piperidin-1- yl)-5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-4-yl)amino)phenyl)piperazin- 1-yl)acetic acid
    Figure US20190070182A1-20190307-C00198
         		2-(1-(4-((2-(3-methoxyphenyl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperidin-4- yl)acetonitrile
    Figure US20190070182A1-20190307-C00199
         		4-((4-(2-(1,4-diazepan-1- yl)ethoxy)phenyl)amino)-2-(azepan-1- yl)pyrimido[4,5-d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00200
         		2-(azepan-1-yl)-4-((4-(3-oxopiperazin-1- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00201
         		2-(3-methoxyphenyl)-4-((4-(2-(piperazin- 1-yl)ethoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00202
         		2-(azepan-1-yl)-4-((4-(2-(dimethyl- amino)ethoxy)phenyl)amino) pyrimido[4,5-d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00203
         		2-(azepan-1-yl)-4-((4-(2-(piperidin-4- yl)ethoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00204
         		2-(1-(5-oxo-4-((4-(2-(piperidin-4- yl)ethoxy)phenyl)amino)-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00205
         		6-(4-((2-(cyclohexyl(methyl)amino)-5- oxo-5,6-dihydropyrimido[4,5-d]pyridazin- 4-yl)amino)phenyl)-6- azaspiro[2.5]octane-1-carboxylic acid
    Figure US20190070182A1-20190307-C00206
         		4-((4-(2-(1,4-diazepan-1- yl)ethoxy)phenyl)amino)-2-(piperidin-1- yl)pyrimido[4,5-d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00207
         		2-(azepan-1-yl)-4-((4-(2-(4- hydroxypiperidin-1- yl)ethoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00208
         		2-(azepan-1-yl)-4-((4-(3-(piperazin-1- yl)propyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00209
         		2-(1-(5-oxo-4-((4-(3-(piperazin-1- yl)propyl)phenyl)amino)-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00210
         		2-(azepan-1-yl)-4-((4-(4-ethyl-3- oxopiperazin-1- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00211
         		2-morpholino-4-((4-(2-(piperazin-1- yl)ethoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00212
         		2-(2,6-dimethylmorpholino)-4-((4-(2- (piperazin-1- yl)ethoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00213
         		2-(1-(4-((4-(4-ethyl-3-oxopiperazin-1- yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00214
         		2-(azepan-1-yl)-4-((4-(3-(4- hydroxypiperidin-1- yl)propyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00215
         		2-(azepan-1-yl)-4-((4-(4-ethylpiperazin-1- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00216
         		4-((6-(2-(piperazin-1-yl)ethoxy)pyridin-3- yl)amino)-2-(piperidin-1-yl)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00217
         		2-(azepan-1-yl)-4-((6-(2-(piperazin-1- yl)ethoxy)pyridin-3- yl)amino)pyrimido[4,5-d]pyridazin- 5(6H)-one
    Figure US20190070182A1-20190307-C00218
         		4-((4-(2-(4-hydroxypiperidin-1- yl)ethoxy)phenyl)amino)-2-(piperidin-1- yl)pyrimido[4,5-d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00219
         		2-(azepan-1-yl)-4-((4-(2-(4-hydroxy-4- methylpiperidin-1- yl)ethoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00220
         		2-(1-(4-((4-(2-(4-hydroxy-4- methylpiperidin-1- yl)ethoxy)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00221
         		2-(azepan-1-yl)-4-((4-(4- hydroxypiperidin-1- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00222
         		2-(1-(4-((4-(4-ethylpiperazin-1- yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00223
         		2-(azepan-1-yl)-4-((4-(2- (diisopropylamino)ethoxy)phenyl)amino) pyrimido[4,5-d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00224
         		2-(1-(4-((4-(4-hydroxypiperidin-1- yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00225
         		2-(azepan-1-yl)-4-((4-(4-(2- hydroxyethyl)piperazin-1- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00226
         		2-(1-(4-((4-(4-(2-hydroxyethyl)piperazin- 1-yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00227
         		2-(azepan-1-yl)-4-((4-(piperazin-1- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00228
         		2-(1-(5-oxo-4-((4-(piperazin-1- yl)phenyl)amino)-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00229
         		2-(azepan-1-yl)-4-((4-(4-(3- hydroxypropyl)piperidin-1- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00230
         		2-(azepan-1-yl)-4-((4-(4-(2- hydroxyethyl)piperidin-1- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00231
         		2-(1-(4-((4-(4-(2-hydroxyethyl)piperidin- 1-yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00232
         		2-(1-(4-((4-(2-(4-ethylpiperazin-1- yl)ethyl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00233
         		2-(azepan-1-yl)-4-((4-(2-(piperazin-1- yl)ethyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00234
         		4-((4-(2-aminoethoxy)phenyl)amino)-2- (azepan-1-yl)pyrimido[4,5-d]pyridazin- 5(6H)-one
    Figure US20190070182A1-20190307-C00235
         		2-(1-(4-((4-(2- aminoethoxy)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00236
         		2-(azepan-1-yl)-4-((4-(2-(4- hydroxypiperidin-1- yl)ethyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00237
         		2-(azepan-1-yl)-4-((4-(4- (hydroxymethyl)piperidin-1- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00238
         		2-(azepan-1-yl)-4-((4-(2-(4- (hydroxymethyl)piperidin-1- yl)ethoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00239
         		2-(1-(2-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)piperidin-1-yl)ethyl)piperidin-4- yl)acetonitrile
    Figure US20190070182A1-20190307-C00240
         		2-(1-(4-((4-(4-(3- hydroxypropyl)piperidin-1- yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00241
         		2-(4-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperazin-1- yl)acetonitrile
    Figure US20190070182A1-20190307-C00242
         		2-(1-(4-((4-(4-(cyanomethyl)piperazin-1- yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00243
         		3-(4-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperazin-1-yl)propanoic acid
    Figure US20190070182A1-20190307-C00244
         		2-(azepan-1-yl)-4-((4-(2-(4- ethylpiperazin-1- yl)ethyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00245
         		2-(azepan-1-yl)-4-((4-(2-(4-hydroxy-4- methylpiperidin-1- yl)ethyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00246
         		2-(azepan-1-yl)-4-((4-(2-(4-(2- hydroxyethyl)piperazin-1- yl)ethyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00247
         		2-(1-(4-((4-(2-(4-(2- hydroxyethyl)piperazin-1- yl)ethyl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00248
         		2-(4-(4-((2-(4-(cyanomethyl)piperidin-1- yl)-5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-4-yl)amino)phenyl)piperazin- 1-yl)-2-methylpropanoic acid
    Figure US20190070182A1-20190307-C00249
         		2-(azepan-1-yl)-4-((4-(4-(2-hydroxy-2- methylpropanoyl)piperazin-1- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00250
         		3-(4-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperazin-1-yl)-3- oxopropanenitrile
    Figure US20190070182A1-20190307-C00251
         		2-(1-(4-((4-(4-(hydroxymethyl)piperidin- 1-yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00252
         		2-(azepan-1-yl)-4-((6-(4- hydroxypiperidin-1-yl)pyridin-3- yl)amino)pyrimido[4,5-d]pyridazin- 5(6H)-one
    Figure US20190070182A1-20190307-C00253
         		2-(1-(4-((4-(2-(4- (hydroxymethyl)piperidin-1- yl)ethoxy)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00254
         		(phosphonooxy)methyl 6-(4-((2-(azepan- 1-yl)-5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-4-yl)amino)phenyl)-6- azaspiro[2.5]octane-1-carboxylate
    Figure US20190070182A1-20190307-C00255
         		3-(4-(4-((2-(4-(cyanomethyl)piperidin-1- yl)-5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-4-yl)amino)phenyl)piperazin- 1-yl)propanoic acid
    Figure US20190070182A1-20190307-C00256
         		2-(azepan-1-yl)-4-((6-(piperazin-1- yl)pyridin-3-yl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00257
         		2-(azepan-1-yl)-4-((4-(2-(2- hydroxyethyl)-2H-tetrazol-5- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00258
         		2-(1-(4-((4-(4-(2-hydroxy-2- methylpropanoyl)piperazin-1- yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00259
         		2-(1-(4-((4-(2- (diethylamino)ethoxy)phenyl)amino)-5- oxo-5,6-dihydropyrimido[4,5-d]pyridazin- 2-yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00260
         		2-(azepan-1-yl)-4-((4-(2-ethyl-2H- tetrazol-5-yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00261
         		2-(1-(4-((4-(2-ethyl-2H-tetrazol-5- yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00262
         		4-((4-(2H-tetrazol-5-yl)phenyl)amino)-2- (azepan-1-yl)pyrimido[4,5-d]pyridazin- 5(6H)-one
    Figure US20190070182A1-20190307-C00263
         		2-(1-(4-((6-(4-ethylpiperazin-1-yl)pyridin- 3-yl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00264
         		2-(azepan-1-yl)-4-((6-(4-ethylpiperazin-1- yl)pyridin-3-yl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00265
         		2-(4-(5-oxo-4-((4-(2-(piperazin-1- yl)ethoxy)phenyl)amino)-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperazin-1-yl)acetonitrile
    Figure US20190070182A1-20190307-C00266
         		2-(1-(5-oxo-4-((6-(piperazin-1-yl)pyridin- 3-yl)amino)-5,6-dihydropyrimido[4,5- d]pyridazin-2-yl)piperidin-4- yl)acetonitrile
    Figure US20190070182A1-20190307-C00267
         		2-(1-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperidin-3-yl)acetic acid
    Figure US20190070182A1-20190307-C00268
         		2-(1-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)piperidin-3-yl)acetic acid
    Figure US20190070182A1-20190307-C00269
         		3-(4-(5-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)pyridin-2-yl)piperazin-1-yl)-3- oxopropanenitrile
    Figure US20190070182A1-20190307-C00270
         		2-(5-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)-2H-tetrazol-2-yl)acetic acid
    Figure US20190070182A1-20190307-C00271
         		2-(azepan-1-yl)-4-((6-(4-(2- hydroxyethyl)piperidin-1-yl)pyridin-3- yl)amino)pyrimido[4,5-d]pyridazin- 5(6H)-one
    Figure US20190070182A1-20190307-C00272
         		3-(4-(5-((2-(4-(cyanomethyl)piperidin-1- yl)-5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-4-yl)amino)pyridin-2- yl)piperazin-1-yl)-3-oxopropanenitrile
    Figure US20190070182A1-20190307-C00273
         		2-(azepan-1-yl)-4-((6-(4-(2-hydroxy-2- methylpropanoyl)piperazin-1-yl)pyridin- 3-yl)amino)pyrimido[4,5-d]pyridazin- 5(6H)-one
    Figure US20190070182A1-20190307-C00274
         		2-(azepan-1-yl)-4-((4-(2-(4-(2- hydroxyethyl)piperazin-1- yl)ethoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00275
         		3-(4-(4-((2-(4-(cyanomethyl)piperidin-1- yl)-5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-4-yl)amino)phenyl)piperazin- 1-yl)-3-oxopropanenitrile
    Figure US20190070182A1-20190307-C00276
         		2-(5-(4-((2-(4-(cyanomethyl)piperidin-1- yl)-5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-4-yl)amino)phenyl)-2H- tetrazol-2-yl)acetic acid
    Figure US20190070182A1-20190307-C00277
         		2-(azepan-1-yl)-4-((6-(4-methylpiperazin- 1-yl)pyridin-3-yl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00278
         		2-(1-(4-((6-(4-methylpiperazin-1- yl)pyridin-3-yl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00279
         		4-((4-(4-((2H-tetrazol-5- yl)methyl)piperidin-1-yl)phenyl)amino)- 2-(azepan-1-yl)pyrimido[4,5-d]pyridazin- 5(6H)-one
    Figure US20190070182A1-20190307-C00280
         		2-(1-(4-((4-(2H-tetrazol-5- yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00281
         		2-(1-(4-((4-(4-((2H-tetrazol-5- yl)methyl)piperidin-1-yl)phenyl)amino)- 5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-2-yl)piperidin-4- yl)acetonitrile
    Figure US20190070182A1-20190307-C00282
         		2-(azepan-1-yl)-4-((4-(4-methylpiperazin- 1-yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00283
         		2-(1-(4-((4-(4-methylpiperazin-1- yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00284
         		2-(1-(5-((2-(4-(cyanomethyl)piperidin-1- yl)-5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-4-yl)amino)pyridin-2- yl)piperidin-3-yl)acetic acid
    Figure US20190070182A1-20190307-C00285
         		2-(1-(4-((2-(4-(cyanomethyl)piperidin-1- yl)-5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-4-yl)amino)phenyl)piperidin- 3-yl)acetic acid
    Figure US20190070182A1-20190307-C00286
         		2-(1-(4-((6-(4-(2-hydroxy-2- methylpropanoyl)piperazin-1-yl)pyridin- 3-yl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00287
         		4-((6-(4-((2H-tetrazol-5- yl)methyl)piperidin-1-yl)pyridin-3- yl)amino)-2-(azepan-1-yl)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00288
         		2-(1-(4-((6-(4-((2H-tetrazol-5- yl)methyl)piperidin-1-yl)pyridin-3- yl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00289
         		2-(4-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenoxy)piperidin-1-yl)acetic acid
    Figure US20190070182A1-20190307-C00290
         		2-(azepan-1-yl)-4-((4-(4-(2- methoxyethyl)piperazin-1- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00291
         		2-(1-(4-((4-(4-(2-methoxyethyl)piperazin- 1-yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00292
         		2-(1-(4-((4-(4-(2-aminoethyl)piperazin-1- yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00293
         		2-(azepan-1-yl)-4-((4-(1- (hydroxymethyl)-6-azaspiro[2.5]octan-6- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00294
         		2-(1-(4-((4-(1-(hydroxymethyl)-6- azaspiro[2.5]octan-6-yl)phenyl)amino)-5- oxo-5,6-dihydropyrimido[4,5-d]pyridazin- 2-yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00295
         		2-(azepan-1-yl)-4-((4-(4-(3- hydroxypropyl)piperazin-1- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00296
         		2-(1-(4-((4-(4-(3- hydroxypropyl)piperazin-1- yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00297
         		2-(4-(4-((2-(4-(cyanomethyl)piperidin-1- yl)-5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-4- yl)amino)phenoxy)piperidin-1-yl)acetic acid
    Figure US20190070182A1-20190307-C00298
         		2-(azepan-1-yl)-4-((4-(4-(2- hydroxyethyl)-1,4-diazepan-1- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00299
         		2-(1-(4-((4-(4-(2-hydroxyethyl)-1,4- diazepan-1-yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00300
         		2-(azepan-1-yl)-4-((4-(4-(1-hydroxy-2- methylpropan-2-yl)piperazin-1- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00301
         		2-(1-(4-((4-(4-(1-hydroxy-2- methylpropan-2-yl)piperazin-1- yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00302
         		2-(azepan-1-yl)-4-((4-(4-(2- (dimethylamino)ethyl)piperazin-1- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00303
         		2-(1-(4-((4-(4-(2- (dimethylamino)ethyl)piperazin-1- yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00304
         		2-(azepan-1-yl)-4-((4-(2-(4- ethylpiperazin-1-yl)-2- oxoethoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00305
         		2-(1-(4-((4-(2-(4-ethylpiperazin-1-yl)-2- oxoethoxy)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00306
         		2-(1-(4-((4-(2-(4-methylpiperazin-1-yl)- 2-oxoethoxy)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00307
         		2-(azepan-1-yl)-4-((4-(3-(2- hydroxyethyl)piperidin-1- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00308
         		2-(azepan-1-yl)-4-((4-(4-(2,3- dihydroxypropyl)piperazin-1- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00309
         		2-(1-(4-((4-(4-(2,3- dihydroxypropyl)piperazin-1- yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00310
         		2-(azepan-1-yl)-4-((4-(4-(2- fluoroethyl)piperazin-1- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00311
         		2-(1-(4-((4-(4-(2-fluoroethyl)piperazin-1- yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00312
         		2-(azepan-1-yl)-4-((6-(3- hydroxypiperidin-1-yl)pyridin-3- yl)amino)pyrimido[4,5-d]pyridazin- 5(6H)-one
    Figure US20190070182A1-20190307-C00313
         		2-(1-(4-((6-(3-hydroxypiperidin-1- yl)pyridin-3-yl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00314
         		2-(azepan-1-yl)-4-((4-(4,4- difluoropiperidin-1- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00315
         		2-(1-(4-((4-(4,4-difluoropiperidin-1- yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00316
         		2-(azepan-1-yl)-4-((4-(3- hydroxypiperidin-1- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00317
         		2-(1-(4-((4-(3-hydroxypiperidin-1- yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00318
         		2-(azepan-1-yl)-4-((4-(2-(4- methylpiperazin-1-yl)-2- oxoethoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00319
         		2-(1-(4-((4-(3-(hydroxymethyl)piperidin- 1-yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00320
         		2-(azepan-1-yl)-4-((4-(3- (hydroxymethyl)piperidin-1- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00321
         		2-(1-(4-((4-(3-(2-hydroxyethyl)piperidin- 1-yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00322
         		2-(1-(4-((4-(4-methoxypiperidin-1- yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00323
         		2-(azepan-1-yl)-4-((4-(4- methoxypiperidin-1- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00324
         		2-(azepan-1-yl)-4-((4-(4-fluoropiperidin- 1-yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00325
         		2-(1-(4-((4-(4-fluoropiperidin-1- yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00326
         		2-(1-(4-((4-((1-(2-hydroxyethyl)piperidin- 4-yl)oxy)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00327
         		2-(azepan-1-yl)-4-((4-(piperidin-4- yloxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one hydrochloride
    Figure US20190070182A1-20190307-C00328
         		2-(1-(4-((4-(2- hydroxyethoxy)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00329
         		2-(azepan-1-yl)-4-((4-(2-hydroxy- ethoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00330
         		2-(1-(4-((4-(3- hydroxypropoxy)phenyl)amino)-5-oxo- 5,6-dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00331
         		2-(azepan-1-yl)-4-((4-(3- hydroxypropoxy)phenyl)amino) pyrimido[4,5-d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00332
         		2-(1-(4-((4-(4-(1-hydroxy-2- methylpropan-2-yl)-1,4-diazepan-1- yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00333
         		2-(azepan-1-yl)-4-((4-(4-(2- fluoroethyl)piperidin-1- yl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00334
         		2-(1-(4-((4-(4-(2-fluoroethyl)piperidin-1- yl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00335
         		2-(1-(4-((3,5-dimethoxyphenyl)amino)-5- oxo-5,6-dihydropyrimido[4,5-d]pyridazin- 2-yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00336
         		2-(1-(5-oxo-4-((4- (trifluoromethoxy)phenyl)amino)-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00337
         		2-(azepan-1-yl)-4-((3,5- dimethoxyphenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00338
         		2-(azepan-1-yl)-4-((4-(trifluoro- methoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00339
         		3-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenyl)propanoic acid
    Figure US20190070182A1-20190307-C00340
         		3-(4-((2-(4-(cyanomethyl)piperidin-1-yl)- 5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-4-yl)amino)phenyl)propanoic acid
    Figure US20190070182A1-20190307-C00341
         		2-(azepan-1-yl)-4-((4-(bis(2-hydroxy- ethyl)amino)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00342
         		2-(1-(4-((4-(bis(2- hydroxyethyl)amino)phenyl)amino)-5- oxo-5,6-dihydropyrimido[4,5-d]pyridazin- 2-yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00343
         		2-(azepan-1-yl)-4-((4-(3-hydroxy- propyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00344
         		2-(1-(4-((4-(3- hydroxypropyl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00345
         		2-(azepan-1-yl)-4-((3-(hydroxy- methyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00346
         		2-(1-(4-((3- (hydroxymethyl)phenyl)amino)-5-oxo- 5,6-dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00347
         		2-(1-(4-((4-fluorophenyl)amino)-5-oxo- 5,6-dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00348
         		2-(azepan-1-yl)-4-((4- fluorophenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00349
         		2-(azepan-1-yl)-4-((4-((1-hydroxy-2- methylpropan-2- yl)oxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00350
         		2-(1-(4-((4-((1-hydroxy-2-methylpropan- 2-yl)oxy)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00351
         		2-(4-((2-(azepan-1-yl)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-4- yl)amino)phenoxy)-2-methylpropanoic acid
    Figure US20190070182A1-20190307-C00352
         		2-(4-((2-(4-(cyanomethyl)piperidin-1-yl)- 5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-4-yl)amino)phenoxy)-2- methylpropanoic acid
    Figure US20190070182A1-20190307-C00353
         		2-(azepan-1-yl)-4-((3,4- dimethoxyphenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00354
         		2-(1-(4-((3,4-dimethoxyphenyl)amino)-5- oxo-5,6-dihydropyrimido[4,5-d]pyridazin- 2-yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00355
         		2-(azepan-1-yl)-4-((3- methoxyphenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00356
         		2-(1-(4-((3-methoxyphenyl)amino)-5-oxo- 5,6-dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00357
         		2-(azepan-1-yl)-4-((4-(2-hydroxy- ethyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00358
         		2-(1-(4-((4-(2- hydroxyethyl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00359
         		2-(azepan-1-yl)-4-((4-(2-methoxy- ethoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00360
         		2-(1-(4-((4-(2-methoxy- ethoxy)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00361
         		2-(1-(5-oxo-4-((3,4,5- trimethoxyphenyl)amino)-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00362
         		2-(azepan-1-yl)-4-(benzo[d][1,3]dioxol-5- ylamino)pyrimido[4,5-d]pyridazin-5(6H)- one
    Figure US20190070182A1-20190307-C00363
         		2-(1-(4-(benzo[d][1,3]dioxol-5-ylamino)- 5-oxo-5,6-dihydropyrimido[4,5- d]pyridazin-2-yl)piperidin-4- yl)acetonitrile
    Figure US20190070182A1-20190307-C00364
         		2-(azepan-1-yl)-4-((4-((1-(2- hydroxyethyl)piperidin-4- yl)oxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00365
         		sodium (2-(4-(cyanomethyl)piperidin-1- yl)-4-((4-(4-hydroxypiperidin-1- yl)phenyl)amino)-5-oxopyrimido[4,5- d]pyridazin-6(5H)-yl)methyl phosphate
    Figure US20190070182A1-20190307-C00366
         		2-(azepan-1-yl)-4-((4-(hydroxy- methyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00367
         		2-(1-(4-((4- (hydroxymethyl)phenyl)amino)-5-oxo- 5,6-dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00368
         		2-(1-(4-((4- (methylsulfonyl)phenyl)amino)-5-oxo- 5,6-dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00369
         		2-(azepan-1-yl)-4-((4-(methyl- sulfonyl)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one
    Figure US20190070182A1-20190307-C00370
         		2-(1-(4-((1H-benzo[d][1,2,3]triazol-5- yl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00371
         		2-(1-(5-oxo-4-((2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00372
         		2-(1-(4-((4-(3- fluoropropyl)phenyl)amino)-5-oxo-5,6- dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00373
         		2-(1-(4-((4- (difluoromethoxy)phenyl)amino)-5-oxo- 5,6-dihydropyrimido[4,5-d]pyridazin-2- yl)piperidin-4-yl)acetonitrile
    Figure US20190070182A1-20190307-C00374
         		4-((1H-benzo[d][1,2,3]triazol-5- yl)amino)-2-(azepan-1-yl)pyrimido[4,5- d]pyridazin-5(6H)-one

    Methods of preparing compounds of Formula (I), as well as methods of preparing specific compounds set forth in Table 1, are disclosed in U.S. Pat. No. 8,729,079 B2.
  • To practice the inventive methods, the compound of formula (I) may be appropriately formulated into a desired dosage form, alone (neat) or optionally with other pharmaceutically inert or inactive ingredients. It may be used alone or in a composition suitable for in vitro applications. In one embodiment, the pharmaceutically inert or inactive ingredient includes one or more pharmaceutically acceptable carriers or excipients. The present invention also contemplates combining the compound of Formula (I) with one or more therapeutic agents, e.g., anti-cancer agents (e.g., in the same dosage form or in the same treatment regimen). In a further embodiment, a compound of Formula (I) may be combined with one or more inert/inactive ingredients and one or more therapeutic agents.
  • The pharmaceutical compositions of the invention contain an amount of a compound of Formula (I) that is effective for treating cancer in a subject, or inhibiting growth and proliferation of cancer cells (in vivo or in vitro) or inhibiting tumor growth (which may be referred to collectively as an “anti-cancer effect”). Specifically, the dosage of the compound of Formula (I) to achieve a therapeutic effect (as described herein) may depend on factors such as the formulation, pharmacological potency of the drug, age, weight and sex of the patient, condition being treated, severity of the patient's symptoms, specific compound of Formula (I), and route of delivery. Dosages may be adjusted depending, for example, on the response pattern of the patient. It is also contemplated that the treatment and dosage of the compound of Formula (I) may be administered in unit dosage form and that one skilled in the art would adjust the unit dosage form accordingly to reflect the relative level of activity. The decision as to the particular dosage to be employed (and the number of times to be administered per day) is within the discretion of the ordinarily-skilled physician, and may be varied by titration of the dosage to the particular circumstances to produce the desired therapeutic effect. The effective amount of the compound of formula (I) to achieve an anti-cancer effect in a patient may range from about 1 to about 1000 mg daily dose, and in some embodiments from about 5 to about 500 mg daily dose, and in some other embodiments, from about 10 to about 100 mg daily dose.
  • The therapeutically effective amounts may be provided on regular schedule, i.e., on a less than daily, daily, weekly, monthly, or yearly basis or on an irregular schedule with varying administration days, weeks, months, etc. Alternatively, the therapeutically effective amount to be administered may vary. In one embodiment, the therapeutically effective amount for the first dose may be higher than the therapeutically effective amount for one or more of the subsequent doses. In another embodiment, the therapeutically effective amount for the first dose may be lower than the therapeutically effective amount for one or more of the subsequent doses. Equivalent dosages may be administered over various time periods including, for example, about every 2 hours, about every 6 hours, about every 8 hours, about every 12 hours, about every 24 hours, about every 36 hours, about every 48 hours, about every 72 hours, about every week, about every 2 weeks, about every 3 weeks, about every month, about every 2 months, about every 3 months and about every 6 months. The number and frequency of dosages corresponding to a completed course of anti-cancer therapy will be determined according to the judgment of a health-care practitioner. The therapeutically effective amounts described herein refer to total amounts administered for a given time period such that if more than one compound of Formula (I) is administered, the therapeutically effective amounts correspond to the total amount administered.
  • The compound of Formula (I) may be administered by any medically acceptable route, taking into consideration the specific cancerous condition for which it has been selected. The compounds of Formula (I) may be delivered orally, by injection (including intravascularly, e.g., intravenously or intra-arterially), inhalation (intranasally and intratracheally), ocularly, transdermally (via simple passive diffusion formulations or via facilitated delivery using, for example, iontophoresis, microporation with microneedles, radio-frequency ablation or the like), intravascularly, subcutaneously, intramuscularly, sublingually, intracranially, epidurally, rectally, and vaginally, among other routes. In some embodiments, the compound of Formula (I) may be administered by injection, orally or topically.
  • The compound of Formula (I) may be administered alone, i.e., neat. It may also be administered as a formulation that also contains a pharmaceutically acceptable carrier and/or excipient (collectively referred to as a “carrier”. The amount of the pharmaceutical carrier is determined by factors that may include the solubility and chemical nature of the compound of Formula (I), chosen route of administration, and standard pharmacological practice. The carriers may be in dry (solid) or liquid form. Liquid pharmaceutical compositions are typically sterile solutions or suspensions. When liquid carriers are utilized for parenteral administration, they are desirably sterile liquids. Liquid carriers are typically utilized in preparing solutions, suspensions, emulsions, syrups and elixirs. A variety of suitable liquid carriers is known and may be readily selected by one of skill in the art. Such carriers may include, e.g., dimethylsulfoxide (DMSO), saline, buffered saline, cyclodextrin, hydroxypropylcyclodextrin (HPβCD), n-dodecyl-β-D-maltoside (DDM) and mixtures thereof. In one embodiment, the compound of Formula (I) is dissolved a liquid carrier. In another embodiment, the compound of Formula (I) is suspended in a liquid carrier. One of skill in the art of formulations would be able to select a suitable liquid carrier, depending on the route of administration. The compound of Formula (I) may alternatively be formulated in a solid carrier of which a variety of solid carriers and excipients are known to those of skill in the art. In one embodiment, the composition may be compacted into a unit dose form, i.e., tablet or caplet. In another embodiment, the composition may be added to unit dose form, i.e., a capsule. In a further embodiment, the composition may be formulated for administration as a powder. The solid carrier may perform a variety of functions, i.e., may perform the functions of two or more of the excipients described below. For example, a solid carrier may also act as a flavoring agent, diluent, lubricant, solubilizer, suspending agent, filler, glidant, compression aid, binder, disintegrant, or encapsulating material.
  • Further examples of carriers include adjuvants, antioxidants, binders, buffers, coatings, coloring agents, compression aids, emulsifiers (e g., polyoxyethylene fatty acid esters), emollients, encapsulating materials, fillers, granulating agents, metal chelators, osmo-regulators, pH adjustors (e.g., sodium hydroxide), preservatives, sorbents, stabilizing agents, suspending agents, syrups, penetration enhancers (e.g., hydroxypolyethoxydodecane, DMSO, DMAC, DDM, etc.) and thickening agents (e.g., carboxypolymethylene or hydroxypropylmethylcellulose) and other viscosity regulators. See, for example, the excipients described in the “Handbook of Pharmaceutical Excipients”, 5th Edition, Eds.: Rowe, Sheskey, and Owen, APhA Publications (Washington, D.C.), Dec. 14, 2005.
  • The compound of formula (I) may be formulated to achieve a modified-release. “Modified-release” as used herein refers to delivery of a compound of Formula (I) which is controlled, for example over a period of time, e.g., at least about 8 hours (e.g., extended delivery) to at least about 12 hours (e.g., sustained delivery). Otherwise, the formulations of the present invention may permit immediate release (e.g., therapeutic levels achieved in under about 1 hour, or in less than about 2 hours).
  • The inventive methods may entail administering to a subject or contacting cancer cells or a tumor in need thereof a therapeutically effective amount of a compound of formula (I). As used herein, the term “cancer” refers to or describes the physiological condition in subjects in which a population of cells is characterized by unregulated cell growth. As used herein, the term “subject” refers to any animal (e.g., a mammal), including, for example, humans, non-human primates (e.g., monkeys, chimpanzees, baboons and gorillas), domestic animals (e.g., dogs and cats), rodents (e.g., mice, rats and guinea pigs), livestock (e.g., cows and swine), equines and the like, which is to be the recipient of a particular treatment or protocol described herein. Typically, the terms “subject” and “patient” are used interchangeably herein in reference to a subject that is a human subject. In one embodiment, the mammal to be treated is human. In some embodiments, the cancer patient (e.g., human cancer patient) has not been diagnosed with inflammation associated with or as a side effect of the cancer.
  • As used herein, the terms “treat” and “treatment” refer to therapeutic treatment, including prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological change associated with cancer. Beneficial or desired clinical results of the treating may include inhibition of growth and proliferation of cancer cells or inhibition of tumor growth. Such results may also include diminishment of the extent of a disease or condition, stabilization of a disease or condition (i.e., where the disease or condition does not worsen), delay or slowing of the progression of a disease or condition, amelioration or palliation of the disease or condition, and remission (whether partial or total) of the disease or condition, whether detectable or undetectable. Such results may further include prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the disease or condition as well as those prone to having the disease or condition or those in which the disease or condition is to be prevented. By “contacting”, it is meant administering to a cancer subject or otherwise bringing a compound of formula (I) into contact with a tumor or a cancer cell (e.g., which cancer cell may be in vivo or in vitro) such that it can exert its intended effect.
  • Any of the methods provided herein may be used to treat cancer, cancer cells or tumors at any stage of development. Such stages include an advanced stage, a locally advanced stage, early stage cancer, progressive cancer, cancer in remission, relapsed cancer, and cancer that has proven refractory to other treatment (such as FDA-approved treatment). Accordingly, therapy may be “first-line”, i.e., as an initial treatment in patients who have undergone no prior anti-cancer treatment regimens, either alone or in combination with other treatments; or “second-line”, as a treatment in patients who have undergone a prior anti-cancer treatment regimen, either alone or in combination with other treatments; or as “third-line”, “fourth-line”, etc. treatments, either alone or in combination with other treatments. Therapy may also be given to patients who have had previous treatments which have been partially successful but are intolerant to the particular treatment. Therapy may also be given as an adjuvant treatment, i.e., to prevent reoccurrence of cancer in patients with no currently detectable disease or after surgical removal of tumor.
  • Cancers, cancer cells and tumors treatable in accordance with the methods of the present invention may include, by way of example, primary tumors and secondary or metastatic tumors (including those metastasized from lung, breast, or prostate), as well as recurrent or refractory tumors. Recurrent tumors encompass tumors that appear to be inhibited by treatment with such agents, but recur up to five years, sometimes up to ten years or longer after treatment is discontinued. Refractory tumors are tumors that have failed to respond or are resistant to treatment with one or more conventional therapies for the particular tumor type. Refractory tumors include those that are hormone-refractory (e.g., androgen-independent prostate cancer; or hormone-refractory breast cancer, such as breast cancer that is refractory to tamoxifen); those that are refractory to treatment with one or more chemotherapeutic agents; those that are refractory to radiation; and those that are refractory to combinations of chemotherapy and radiation, chemotherapy and hormone therapy, or hormone therapy and radiation. By way of specific example, in some embodiments, the inventive methods, e.g., using ASN002, are directed to treating hematological cancer patients (e.g., leukemia and lymphoma patients) who are refractory to treatment with FDA-approved ibrutinib.
  • Representative types of cancers, cancer cells and tumors treatable in accordance with the methods of the present invention include carcinomas, sarcomas, benign and malignant tumors, and malignancies. Adult tumors/cancers and pediatric tumors/cancers are included. The cancers may be vascularized, or not yet substantially vascularized, or non-vascularized tumors. Thus, the cancers may be characterized by non-solid tumors, e.g., hematopoietic cancers such as leukemias and lymphomas (Hodgkins and non-Hodgkins) or solid tumors.
  • Representative examples of cancers characterized by solid tumors which may be treated in accordance with the methods of the present invention include breast (including HER2+ and metastatic), colorectal, colon, renal, rectal, pancreatic, prostate, stomach, gastrointestinal, gastric, stomach, esophageal, bile duct, lung (including small cell and non-small cell lung tumors, adenocarcinoma of the lung and squamous carcinoma of the lung), liver, lymphoma, epidermoid tumors, squamous tumors such as head and neck tumors, epithelial squamous cell cancer, thyroid, cervical, ovarian, neuroendocrine tumors of the digestive system, neuroendocrine tumors, pheochromacytomas, cancer of the peritoneum, hepatocellular cancer, hepatoblastoma, HPCR, glioblastoma, bladder cancer, hepatoma, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, bone cancer, soft tissue sarcoma (including embryonal and alveolar rhabdomyosarcoma, GIST, alveolar soft part sarcoma and clear cell sarcoma), cholangiocarcinoma, bile cancer, gallbladder carcinoma, myeloma, vulval cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, retinal, androgen-dependent tumors, androgen-independent tumors, Kaposi's sarcoma, synovial sarcoma, vasoactive intestinal peptide secreting tumor, CNS neoplasms, neuroblastomas, capillary hemangioblastomas, meningiomas, and cerebral metastases, melanoma, rhabdomyosarcoma, glioblastoma, including glioblastoma multiforme, EMB, RMS, ALV, medulloblastoma, ependymoma, Wilm's cancer, Ewing's cancer, osteosarcoma, PNT, rhabdoid, rhabdomyosarcoma, retinoblastoma, adrenal cortical cancer, adrenal cancer, and leiomyosarcoma.
  • Representative examples of hematologic malignancies amenable to treatment in accordance with the present invention include lymphomas, multiple myelomas, and leukemias.
  • In some embodiments, the hematologic malignancy is leukemia or lymphoma. Leukemias treatable in accordance with the present invention include lymphocytic leukemias and chronic myeloid (myelogenous) leukemias. Specific examples include acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML) (e.g., HEL), chronic lymphocytic leukemia (CLL), and chronic myelogenous leukemia (CML). Other examples include T-cell acute lymphoblastic leukemia (T-ALL) and B-cell acute lymphoblastic leukemia (B-ALL).
  • In some embodiments, the hematologic malignancy is lymphoma (e.g., malignant neoplasms of lymphoid and reticuloendothelial tissues). Examples of lymphomas treatable in accordance with the present invention include Burkitt's lymphoma, Hodgkins' lymphoma, non-Hodgkins' lymphomas, lymphocytic lymphomas such as small lymphocytic lymphoma (SLL), myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), indolent non-Hodgkin's lymphoma (iNHL), refractory iNHL, mantle cell lymphoma (MCL), follicular lymphoma (FL), Waldestrom's macroglobulinemia (WM), T-cell lymphoma, B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), lymphoplasmacytic lymphoma (LPL), and marginal zone lymphoma (MZL).
  • The compound of formula (I) may be administered alone (monotherapy), in the form of a conjugate (e.g., chemically bonded to another moiety that targets cancer cells) or in combination with one or more therapeutically effective active agents (e.g., anti-cancer agents) or treatments (combination therapy). The other therapeutically effective agent, which is different from the compound of formula (I), may be incorporated into the same composition as the compound of formula (I), or may be administered as a separate composition. The other therapeutically effective agent or treatment may be administered prior to, during and/or after the administration of the compound of formula (I). The other therapeutically effective agent may be administered to augment the therapeutic effect of the compound of formula (I), or to diminish the negative side effects of the compound of formula (I).
  • Other anti-cancer therapeutically effective agents/treatments include surgery, radiation chemotherapeutic agents, cytokines, chemokines and biological agents such as antibodies and enzymes.
  • When the anti-neoplastic agent is radiation, the source of the radiation can be either external (external beam radiation therapy—EBRT) or internal (brachytherapy—BT) to the patient being treated. The dose of anti-neoplastic agent administered depends on numerous factors, including, for example, the type of agent, the type and severity of tumor being treated and the route of administration of the agent. It should be emphasized, however, that the present invention is not limited to any particular dose. Radiation may also be used in conjunction with other antineoplastic agents.
  • Examples of chemotherapeutic agents (which are typically small molecules) include topoisomerase inhibitors (e.g., inhibitors of topoisomerase I or topoisomerase II. Topoisomerase I inhibitors such as irinotecan (CPT-II), aminocamptothecin, camptothecin, DX-8951f, and topotecan. Topoisomerase II inhibitors include etoposide (VP-16), and teniposide (VM-26)), cyclophosphamide, Thiotepa, bysulfan, melphalan, dacarbazine, cytosine arabinoside, cyclophosphamide, actinomycin-D, methotrexate, gemcitabine, oxyplatin, fluorouracil (5-FU), leucourin (LU), cisplatin, irinotecan (CPT-II), paclitaxel, docetaxel, vinblastine, epothilone, carboplatin, pegylated adriamycin, anthracyclines (e.g., daunomycin and doxorubicin), vindesine, neocarzinostatin, cis-platinum, chlorambucil, cytosine arabinoside, 5-fluorouridine, ibrutinib, and calicheamicin.
  • The present invention may now be described in accordance with the following, non-limiting working examples.
    • Working Examples Example 1. ASN002 Exhibits Anti-Tumor Activity in Ibrutinib-Resistant Lymphoma Cells
  • This activity of ASN002 was assessed using a diffuse large B-cell lymphoma (DLBCL) cell line, Pfeiffer (“Parental”); and an ibrutinib-resistant variant of the same cell line (“Ibrutinib-R”), which was developed by growing the cells in the presence of increasing concentrations of ibrutinib. Pools of ibrutinib-resistant cells were tested in this study. The drug idelalisib (which was approved by the FDA in July 2015 for the treatment of B-cell blood cancers) was used for comparison as a reference compound. The data are set forth in Table A (IC50 is the half maximal inhibitory concentration). They show that ASN002 was significantly more potent in inhibiting tumor cell proliferation than either ibrutinib or idelalisib, in the Pfeiffer cell line and, in particular, the ibrutinib-resistant cell line.
  • TABLE A
    Cell Proliferation IC50 (μM)
    Compound Parental Ibrutinib-R
    ASN002 0.08 0.32
    Ibrutinib 0.27 4.5
    Idelalisib 0.13 >10
    • Example 2. The Anti-Cancer Activity of ASN002 was Also Evaluated in Many Solid Tumor Cell Lines. IC50 Values for the Antiproliferative Activity of ASN002 in these Cell Lines are Set Forth in TABLE B
  • TABLE B
    Cell Line Tumor Type IC50 (uM)
    HT1376 Bladder 0.09
    LoVo Colon 0.15
    HepG2 Liver 0.24
    HT29 Colon 0.30
    Caki1 Kidney 0.33
    TCCSUP Bladder 0.34
    H1581 Lung 0.38
    MFM-223 Breast 0.40
    CAOV3 Ovary 0.42
    5637 Bladder 0.42
    ZR75 Breast 0.42
    HCT116 Colon 0.43
    T24 Bladder 0.44
    SCaBER Bladder 0.45
    A549 Lung 0.46
    MDAMB361 Breast 0.49
    C33A Cervical 0.50
    HT1197 Bladder 0.54
    SW480 Colon 0.60
    MCF7 Breast 0.60
    Colo205 Colon 0.61
    A375 Melanoma 0.61
    Hec1A Endometrial 0.66
    BxPC3 Pancreas 0.66
    SKOV3 Ovarian 0.73
    HeLa Cervical 0.77
    MDA-MB-231 Breast 0.77
    HUG1N Gasrtic 0.81
    AsPC1 Pancreas 0.84
    H1975 Lung 0.85
    CFPac1 Pancreas 0.85
    KE39 Gastric 0.86
    MKN1 Gastric 0.88
    MFE296 Endometrial 0.88
    H460 Lung 0.91
    DU145 Prostate 0.99
    SKMEL2 Melanoma 1.03
    LNCaP Prostate 1.07
    MDAMB468 Breast 1.46
    SW1990 Pancreas 1.62
    HCC1806 Breast 1.63
    MDAMB453 Breast 1.74
    EAhy296 Endothelial 1.80
    PC3 Prostate 1.98
    BT20 Breast 2.13
    UMUC3 Bladder 2.28
    J82 Bladder 2.75
    MIAPACA2 Pancreas 2.77
    BT474 Breast >10
    H1299 Lung >10
    HCC1937 Breast >10
    HCC1954 Breast >10
    JEG3 Placenta >10
    SKHEP1 Endothelial >10
    SKMEL28 Melanoma >10
    SW780 Bladder >10
    U87MG Glioblastoma >10
    Y79 Retiblastoma >10
  • All patent publications and non-patent publications are indicative of the level of skill of those skilled in the art to which this invention pertains. All these publications are herein incorporated by reference to the same extent as if each individual publication were specifically and individually indicated as being incorporated by reference.
  • Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present invention as defined by the appended claims.

Claims (28)

1. A method of treating a cancer subject, comprising administering to a cancer subject in need thereof, a therapeutically effective amount of a compound of Formula (I):
Figure US20190070182A1-20190307-C00375
wherein:
R1 is NR4R5, optionally substituted C1 to C6 alkoxy, optionally substituted C6 to C14 aryl, optionally substituted heteroaryl, optionally substituted 3-10 membered monocyclic or bicyclic cycloalkyl, or optionally substituted 3-10 membered monocyclic or bicyclic heterocyclyl, wherein:
(i) 3-4 membered cycloalkyl and heterocyclyl are saturated;
(ii) hydrogen atoms on the same carbon atom of said cycloalkyl or heterocyclyl are optionally replaced with an optionally substituted 3-6 membered cycloalkyl or heterocyclyl to form a spirocycloalkyl or spiroheterocyclyl; and
(iii) hydrogen atoms on the same atom of said cycloalkyl or heterocyclyl are optionally replaced with O to form an oxo substituent;
R2 is optionally substituted phenyl, —O—(C1 to C6 alkyl)-optionally substituted phenyl, or optionally substituted 5-6 membered heteroaryl, with the proviso that when R2 is 4-pyridyl, the 4-pyridyl lacks a carbonyl substituent at the 2nd position;
R4 and R5 are:
(a) independently selected from the group consisting of H, C1 to C6 alkyl, C1 to C6 hydroxyalkyl, C3 to C8 cycloalkyl, and —(C1 to C6 alkyl)N(C1 to C6 alkyl)(C1 to C6 alkyl);
(b) joined to form an optionally substituted 3-8 membered heterocyclyl,
wherein;
(bi) hydrogen atoms on the same carbon atom of said heterocyclyl are optionally replaced with an optionally substituted 3-6 membered cycloalkyl or heterocyclyl to form a spirocycloalkyl or spiroheterocyclyl; and
(bii) hydrogen atoms on the same atom of said heterocyclyl (b), cycloalkyl (bi), or heterocyclyl (bi), are optionally replaced with O to form an oxo substituent;
or a pharmaceutically acceptable salt or ester thereof.
2. The method of claim 1, wherein the compound is:
4-(4-morpholinophenylamino)-2-phenylpyrimido[4,5-d]pyridazin-5(6H)-one;
methyl 4-(5-oxo-4-(4-(piperazin-1-ylmethyl)phenylamino)-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)benzoate hydrochloride;
2-morpholino-4-(4-(piperazin-1-ylmethyl)phenylamino)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
4-(4-(morpholinomethyl)phenylamino)-2-phenylpyrimido[4,5-d]pyridazin-5(6H)-one;
4-(4-(4-ethylpiperazin-1-yl)phenylamino)-2-phenylpyrimido[4,5-d]pyridazin-5(6H)-one;
4-(4-((4-ethylpiperazin-1-yl)methyl)phenylamino)-2-phenylpyrimido[4,5-d]pyridazin-5(6H)-one;
2-phenyl-4-(4-(piperazin-1-ylmethyl)phenylamino)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
2-phenyl-4-(4-(piperazin-1-yl)phenylamino)pyrimido[4,5-d]pyridazin-5(6H)-one;
4-(4-(morpholine-4-carbonyl)phenylamino)-2-phenylpyrimido[4,5-d]pyridazin-5(6H)-one;
4-(4-(bis(2-hydroxyethyl)amino)phenylamino)-2-phenylpyrimido[4,5-d]pyridazin-5(6H)-one;
4-(4-(4-(2-aminoacetyl)piperazin-1-yl)phenylamino)-2-phenylpyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
2-(4-(4-(5-oxo-2-phenyl-5,6-dihydropyrimido[4,5-d]pyridazin-4-ylamino)phenyl)piperazin-1-yl)acetic acid;
1-(4-(5-oxo-2-phenyl-5,6-dihydropyrimido[4,5-d]pyridazin-4-ylamino)phenyl)piperidine-4-carboxylic acid;
4-(4-(4-(2-aminoacetyl)piperazin-1-yl)phenylamino)-2-phenylpyrimido[4,5-d]pyridazin-5(6H)-one;
N-(2-(dimethylamino)ethyl)-N-methyl-4-(5-oxo-2-phenyl-5,6-dihydropyrimido[4,5-d]pyridazin-4-ylamino)benzamide;
4-(4-(2-oxo-1,7-diazaspiro[3.5]nonan-7-yl)phenylamino)-2-phenylpyrimido[4,5-d]pyridazin-5(6H)-one;
4-(4-(2-oxa-7-azaspiro[3.5]nonan-7-yl)phenylamino)-2-phenylpyrimido[4,5-d]pyridazin-5(6H)-one;
4-(4-morpholinophenylamino)-2-(6-azaspiro[2.5]octan-6-yl)pyrimido[4,5-d]pyridazin-5(6H)-one;
6-(4-(5-oxo-2-phenyl-5,6-dihydropyrimido[4,5-d]pyridazin-4-ylamino)phenyl)-6-azaspiro[2.5]octane-1-carboxylic acid;
ethyl 6-(4-(5-oxo-2-phenyl-5,6-dihydropyrimido[4,5-d]pyridazin-4-ylamino)phenyl)-6-azaspiro[2.5]octane-1-carboxylate;
6-(4-(5-oxo-2-phenyl-5,6-dihydropyrimido[4,5-d]pyridazin-4-ylamino)benzyl)-6-azaspiro[2.5]octane-1-carboxylic acid;
sodium 6-(4-(5-oxo-2-phenyl-5,6-dihydropyrimido[4,5-d]pyridazin-4-ylamino)phenyl)-6-azaspiro[2.5]octane-1-carboxylate;
4-(4-(2-oxa-7-azaspiro[3.5]nonan-7-ylmethyl)phenylamino)-2-phenylpyrimido[4,5-d]pyridazin-5(6H)-one;
4-(4-(piperazin-1-ylmethyl)phenylamino)-2-(thiophen-3-yl)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
6-(5-oxo-4-(4-(piperazin-1-ylmethyl)phenylamino)-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)-6-azaspiro[2.5]octane-1-carboxylic acid hydrochloride;
4-(4-(4-ethylpiperazin-1-yl)phenylamino)-2-morpholinopyrimido[4,5-d]pyridazin-5(6H)-one;
4-(5-oxo-4-(4-(piperazin-1-ylmethyl)phenylamino)-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)benzoic acid hydrochloride;
4-(4-(4-ethylpiperazin-1-yl)phenylamino)-2-(4-(trifluoromethoxy)phenyl)pyrimido[4,5-d]pyridazin-5(6H)-one;
methyl 4-(4-(4-morpholinophenylamino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)benzoate;
4-(4-(piperazin-1-ylmethyl)phenylamino)-2-(piperidin-1-yl)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
2-(3-methoxyphenyl)-4-(4-(piperazin-1-ylmethyl)phenylamino)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
2-(piperazin-1-yl)-4-(4-(piperazin-1-ylmethyl)phenylamino)pyrimido[4,5-d]pyridazin-5(6H)-one dihydrochloride;
2-(benzo[d][1,3]dioxol-5-yl)-4-(4-(piperazin-1-ylmethyl)phenylamino)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
2-(1-(4-(5-oxo-2-phenyl-5,6-dihydropyrimido[4,5-d]pyridazin-4-ylamino)phenyl)piperidin-4-yl)acetic acid;
1-(4-(5-oxo-2-phenyl-5,6-dihydropyrimido[4,5-d]pyridazin-4-ylamino)benzyl)piperidine-4-carboxylic acid;
2-(2-methoxyphenyl)-4-(4-(piperazin-1-ylmethyl)phenylamino)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
4-(4-(4-ethylpiperazin-1-yl)phenylamino)-2-(thiophen-3-yl)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
9-(5-oxo-4-(4-(piperazin-1-ylmethyl)phenylamino)-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)-3,9-diazaspiro[5.5]undecane-2,4-dione hydrochloride;
6-(4-(5-oxo-2-(thiophen-3-yl)-5,6-dihydropyrimido[4,5-d]pyridazin-4-ylamino)phenyl)-6-azaspiro[2.5]octane-1-carboxylic acid;
2-(4-chlorophenyl)-4-(4-(piperazin-1-ylmethyl)phenylamino)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
2-(4-methoxyphenyl)-4-(4-(piperazin-1-ylmethyl)phenylamino)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
6-(4-((2-morpholino-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)-6-azaspiro[2.5]octane-1-carboxylic acid;
2-(1-(5-oxo-4-((4-(piperazin-1-ylmethyl)phenyl)amino)-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetic acid hydrochloride;
2-(1-oxidothiomorpholino)-4-((4-(piperazin-1-ylmethyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
2-(4-methylpiperazin-1-yl)-4-((4-(piperazin-1-ylmethyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
6-(4-((2-(4-methoxyphenyl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)-6-azaspiro[2.5]octane-1-carboxylic acid;
6-(4-((2-(3-methoxyphenyl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)-6-azaspiro[2.5]octane-1-carboxylic acid;
4-((4-(piperazin-1-ylmethyl)phenyl)amino)-2-(pyrrolidin-1-yl)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
2-(dimethylamino)-4-((4-(piperazin-1-ylmethyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
2-ethoxy-4-((4-(piperazin-1-ylmethyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
1-(5-oxo-4-((4-(piperazin-1-ylmethyl)phenyl)amino)-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidine-4-carboxylic acid hydrochloride;
2-(azepan-1-yl)-4-((4-(piperazin-1-ylmethyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
6-(4-((2-(2-methoxyphenyl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)-6-azaspiro[2.5]octane-1-carboxylic acid;
2-(diisopropylamino)-4-((4-(piperazin-1-ylmethyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
2-(4-(morpholinomethyl)phenyl)-4-((4-(piperazin-1-ylmethyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
1-(5-oxo-4-((4-(piperazin-1-ylmethyl)phenyl)amino)-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidine-4-carbonitrile hydrochloride;
2-(4-ethylpiperazin-1-yl)-4-((4-(piperazin-1-ylmethyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
4-((1-(2-morpholinoethyl)-1H-pyrazol-4-yl)amino)-2-phenylpyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1,4-diazepan-1-yl)-4-((4-(piperazin-1-ylmethyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one dihydrochloride;
2-(azepan-1-yl)-4-((4-morpholinophenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-methoxy-4-((4-(piperazin-1-ylmethyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
6-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)-6-azaspiro[2.5]octane-1-carboxylic acid;
2-phenyl-4-((1-(2-(piperazin-1-yl)ethyl)-1H-pyrazol-4-yl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
4-((1-(2-(4-methylpiperazin-1-yl)ethyl)-1H-pyrazol-4-yl)amino)-2-phenylpyrimido[4,5-d]pyridazin-5(6H)-one;
4-((1-(2-(4-ethylpiperazin-1-yl)ethyl)-1H-pyrazol-4-yl)amino)-2-phenylpyrimido[4,5-d]pyridazin-5(6H)-one;
6-(4-((2-(4-(cyanomethyl)piperidin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)-6-azaspiro[2.5]octane-1-carboxylic acid;
2-(azepan-1-yl)-4-((3,4,5-trimethoxyphenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(azepan-1-yl)-4-((4-(morpholine-4-carbonyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-4-yl)acetic acid;
2-(1-(4-((2-(4-(cyanomethyl)piperazin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-4-yl)acetic acid;
2-(1-(4-((2-(4-(cyanomethyl)piperidin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-4-yl)acetic acid;
6-(4-((2-(1,4-diazepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)-6-azaspiro[2.5]octane-1-carboxylic acid hydrochloride;
6-(4-((2-(4-(cyanomethyl)piperazin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)-6-azaspiro[2.5]octane-1-carboxylic acid;
6-(4-((2-(4-cyanopiperidin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)-6-azaspiro[2.5]octane-1-carboxylic acid;
2-(1-(4-((2-(4-cyanopiperidin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-4-yl)acetic acid;
1-(4-((2-(4-cyanopiperidin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)benzyl)piperidine-4-carboxylic acid;
2-(1-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)benzyl)piperidin-4-yl)acetic acid;
1-(4-((2-(4-(cyanomethyl)piperidin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)benzyl)piperidine-4-carboxylic acid;
6-(4-((2-cyclohexyl-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)-6-azaspiro[2.5]octane-1-carboxylic acid;
2-(1-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-4-yl)acetonitrile;
6-(4-((2-cycloheptyl-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)-6-azaspiro[2.5]octane-1-carboxylic acid;
2-(1-(4-((5-oxo-2-phenyl-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-4-yl)acetonitrile;
4-((4-((4-(2-hydroxy-2-methylpropanoyl)piperazin-1-yl)methyl)phenyl)amino)-2-phenylpyrimido[4,5-d]pyridazin-5(6H)-one;
2-(azepan-1-yl)-4-((4-((4-(2-hydroxy-2-methylpropanoyl)piperazin-1-yl)methyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(azepan-1-yl)-4-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(4-(4-((5-oxo-2-phenyl-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-1-yl)acetic acid;
2-(4-(4-((5-oxo-2-phenyl-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)cyclohexyl)acetic acid;
2-(1-(4-((2-(azocan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-4-yl)acetic acid;
2-(azepan-1-yl)-4-((4-(2-(piperazin-1-yl)ethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
2-(1-(4-((2-cycloheptyl-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-4-yl)acetic acid;
2-(4-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)cyclohexyl)acetic acid;
4-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenoxy)butanoic acid;
2-(azepan-1-yl)-4-((4-(2-morpholinoethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
4-((4-(2-morpholinoethoxy)phenyl)amino)-2-phenylpyrimido[4,5-d]pyridazin-5(6H)-one;
2-(azepan-1-yl)-4-((4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(2-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenoxy)ethyl)piperidin-4-yl)acetic acid;
2-(1-(5-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)pyridin-2-yl)piperidin-4-yl)acetonitrile;
1-(2-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenoxy)ethyl)piperidine-4-carboxylic acid;
2-(1-(5-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)pyridin-2-yl)piperidin-4-yl)acetamide;
2-(1-(4-((2-(4-(2-cyanopropan-2-yl)piperidin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-4-yl)acetic acid;
2-(1-(5-((5-oxo-2-phenyl-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)pyridin-2-yl)piperidin-4-yl)acetonitrile;
2-(1-(5-((5-oxo-2-phenyl-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)pyridin-2-yl)piperidin-4-yl)acetamide;
2-(1-(5-((2-(4-(cyanomethyl)piperidin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)pyridin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(piperazine-1-carbonyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
2-(1-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-4-yl)acetamide;
2-(4-(2-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenoxy)ethyl)piperazin-1-yl)acetic acid;
2-(azepan-1-yl)-4-((4-(2-(piperazin-1-yl)ethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(5-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)pyridin-2-yl)piperidin-4-yl)acetic acid;
2-(1-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-4-yl)-N-(2-hydroxyethyl)acetamide;
2-(azepan-1-yl)-4-((4-(((2S,5S)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(4-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperazin-1-yl)-2-methylpropanenitrile;
2-(4-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperazin-1-yl)-2-methylpropanamide;
2-(1-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-4-yl)acetonitrile;
2-(1-(5-((2-(4-(cyanomethyl)piperidin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)pyridin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(2-(4-(2-hydroxy-2-methylpropanoyl)piperazin-1-yl)ethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(5-((2-(4-(cyanomethyl)piperidin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)pyridin-2-yl)piperidin-4-yl)acetic acid;
2-(1-(4-((2-(3,5-dimethylpiperidin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-4-yl)acetic acid;
2-(1-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-4-yl)-N,N-bis(2-hydroxyethyl)acetamide;
2-methyl-2-(1-(4-((5-oxo-2-phenyl-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-4-yl)propanenitrile;
2-(4-(2-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenoxy)ethyl)piperazin-1-yl)-2-methylpropanenitrile;
2-(1-(4-((2-(2,6-dimethylmorpholino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-4-yl)acetic acid;
4-((4-(((2S,5S)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methoxy)phenyl)amino)-2-phenylpyrimido[4,5-d]pyridazin-5(6H)-one;
2-((1S,4S)-4-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)cyclohexyl)acetic acid;
(2R,5S)-5-((4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenoxy)methyl)-1,4-dioxane-2-carboxylic acid;
2-(4-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperazin-1-yl)acetic acid;
2-(1-(3-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenoxy)propyl)piperidin-4-yl)acetic acid;
6-(4-((2-(cyclohexylamino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)spiro[2.5]octane-1-carboxylic acid;
6-(4-((5-oxo-2-(piperidin-1-yl)-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)spiro[2.5]octane-1-carboxylic acid;
2-((1R,4R)-4-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)cyclohexyl)acetic acid;
3-(1-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-4-yl)propanoic acid;
2-(1-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-4-yl)cyclopropanecarboxylic acid;
3-(1-(4-((5-oxo-2-phenyl-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-4-yl)propanoic acid;
6-(4-((2-(4-fluorophenyl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)-6-azaspiro[2.5]octane-1-carboxylic acid;
6-(5-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)pyridin-2-yl)-6-azaspiro[2.5]octane-1-carboxylic acid;
6-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)-2-fluorophenyl)-6-azaspiro[2.5]octane-1-carboxylic acid;
2-(azepan-1-yl)-4-((4-(3-(piperazin-1-yl)propoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
6-(5-((5-oxo-2-phenyl-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)pyridin-2-yl)-6-azaspiro[2.5]octane-1-carboxylic acid;
6-(4-((5-oxo-2-(pyridin-4-yl)-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)-6-azaspiro[2.5]octane-1-carboxylic acid;
2-(azepan-1-yl)-4-((4-(4-(2-hydroxypropan-2-yl)piperidin-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(4-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperazin-1-yl)-2-methylpropanoic acid;
6-(4-((2-(azocan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)-6-azaspiro[2.5]octane-1-carboxylic acid;
2-(1-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-4-yl)-2-methylpropanoic acid;
2-methyl-2-(1-(4-((5-oxo-2-phenyl-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-4-yl)propanoic acid;
2-(4-(5-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)pyridin-2-yl)piperazin-1-yl)acetic acid;
2-(4-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)-1,4-diazepan-1-yl)acetic acid;
2-(1-(4-((4-(4-(2-hydroxypropan-2-yl)piperidin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
3-(1-(4-((2-(4-(cyanomethyl)piperidin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-4-yl)propanoic acid;
6-(5-((2-(4-(cyanomethyl)piperidin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)pyridin-2-yl)-6-azaspiro[2.5]octane-1-carboxylic acid;
1-(5-oxo-4-((4-(2-(piperazin-1-yl)ethoxy)phenyl)amino)-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidine-4-carbonitrile;
2-(1-(5-oxo-4-((4-(2-(piperazin-1-yl)ethoxy)phenyl)amino)-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(2-(4-ethylpiperazin-1-yl)ethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-phenyl-4-((4-(2-(piperazin-1-yl)ethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
4-((4-(2-(piperazin-1-yl)ethoxy)phenyl)amino)-2-(piperidin-1-yl)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(4-(4-((5-oxo-2-(piperidin-1-yl)-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)-1,4-diazepan-1-yl)acetic acid;
6-(4-((2-(4-methylpiperidin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)-6-azaspiro[2.5]octane-1-carboxylic acid;
2-(4-methylpiperidin-1-yl)-4-((4-(2-(piperazin-1-yl)ethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
2-(azepan-1-yl)-4-((4-(2-(3-oxopiperazin-1-yl)ethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
6-(2-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenoxy)ethyl)-6-azaspiro[2.5]octane-1-carboxylic acid;
2-(azepan-1-yl)-4-((4-(2-(diethylamino)ethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(cyclohexyl(methyl)amino)-4-((4-(2-(piperazin-1-yl)ethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((2-(cyclohexyl(methyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-4-yl)acetic acid;
2-(4-(4-((2-(4-(cyanomethyl)piperidin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperazin-1-yl)acetic acid;
2-(1-(4-((2-(3-methoxyphenyl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-4-yl)acetonitrile;
4-((4-(2-(1,4-diazepan-1-yl)ethoxy)phenyl)amino)-2-(azepan-1-yl)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(azepan-1-yl)-4-((4-(3-oxopiperazin-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(3-methoxyphenyl)-4-((4-(2-(piperazin-1-yl)ethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(azepan-1-yl)-4-((4-(2-(dimethylamino)ethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(azepan-1-yl)-4-((4-(2-(piperidin-4-yl)ethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(5-oxo-4-((4-(2-(piperidin-4-yl)ethoxy)phenyl)amino)-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
6-(4-((2-(cyclohexyl(methyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)-6-azaspiro[2.5]octane-1-carboxylic acid;
4-((4-(2-(1,4-diazepan-1-yl)ethoxy)phenyl)amino)-2-(piperidin-1-yl)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(azepan-1-yl)-4-((4-(2-(4-hydroxypiperidin-1-yl)ethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(azepan-1-yl)-4-((4-(3-(piperazin-1-yl)propyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(5-oxo-4-((4-(3-(piperazin-1-yl)propyl)phenyl)amino)-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(4-ethyl-3-oxopiperazin-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-morpholino-4-((4-(2-(piperazin-1-yl)ethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(2,6-dimethylmorpholino)-4-((4-(2-(piperazin-1-yl)ethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(4-ethyl-3-oxopiperazin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(3-(4-hydroxypiperidin-1-yl)propyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(azepan-1-yl)-4-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
4-((6-(2-(piperazin-1-yl)ethoxy)pyridin-3-yl)amino)-2-(piperidin-1-yl)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(azepan-1-yl)-4-((6-(2-(piperazin-1-yl)ethoxy)pyridin-3-yl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
4-((4-(2-(4-hydroxypiperidin-1-yl)ethoxy)phenyl)amino)-2-(piperidin-1-yl)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(azepan-1-yl)-4-((4-(2-(4-hydroxy-4-methylpiperidin-1-yl)ethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(2-(4-hydroxy-4-methylpiperidin-1-yl)ethoxy)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(4-hydroxypiperidin-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(4-ethylpiperazin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(2-(diisopropylamino)ethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(4-hydroxypiperidin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(piperazin-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(5-oxo-4-((4-(piperazin-1-yl)phenyl)amino)-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(4-(3-hydroxypropyl)piperidin-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(azepan-1-yl)-4-((4-(4-(2-hydroxyethyl)piperidin-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(4-(2-hydroxyethyl)piperidin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(1-(4-((4-(2-(4-ethylpiperazin-1-yl)ethyl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(2-(piperazin-1-yl)ethyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
4-((4-(2-aminoethoxy)phenyl)amino)-2-(azepan-1-yl)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(2-aminoethoxy)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(2-(4-hydroxypiperidin-1-yl)ethyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(azepan-1-yl)-4-((4-(4-(hydroxymethyl)piperidin-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(azepan-1-yl)-4-((4-(2-(4-(hydroxymethyl)piperidin-1-yl)ethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(2-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)piperidin-1-yl)ethyl)piperidin-4-yl)acetonitrile;
2-(1-(4-((4-(4-(3-hydroxypropyl)piperidin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(4-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperazin-1-yl)acetonitrile;
2-(1-(4-((4-(4-(cyanomethyl)piperazin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
3-(4-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperazin-1-yl)propanoic acid;
2-(azepan-1-yl)-4-((4-(2-(4-ethylpiperazin-1-yl)ethyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(azepan-1-yl)-4-((4-(2-(4-hydroxy-4-methylpiperidin-1-yl)ethyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(azepan-1-yl)-4-((4-(2-(4-(2-hydroxyethyl)piperazin-1-yl)ethyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(2-(4-(2-hydroxyethyl)piperazin-1-yl)ethyl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(4-(4-((2-(4-(cyanomethyl)piperidin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperazin-1-yl)-2-methylpropanoic acid;
2-(azepan-1-yl)-4-((4-(4-(2-hydroxy-2-methylpropanoyl)piperazin-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
3-(4-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperazin-1-yl)-3-oxopropanenitrile;
2-(1-(4-((4-(4-(hydroxymethyl)piperidin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((6-(4-hydroxypiperidin-1-yl)pyridin-3-yl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(2-(4-(hydroxymethyl)piperidin-1-yl)ethoxy)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
(phosphonooxy)methyl 6-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)-6-azaspiro[2.5]octane-1-carboxylate;
3-(4-(4-((2-(4-(cyanomethyl)piperidin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperazin-1-yl)propanoic acid;
2-(azepan-1-yl)-4-((6-(piperazin-1-yl)pyridin-3-yl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(azepan-1-yl)-4-((4-(2-(2-hydroxyethyl)-2H-tetrazol-5-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(4-(2-hydroxy-2-methylpropanoyl)piperazin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(1-(4-((4-(2-(diethylamino)ethoxy)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(2-ethyl-2H-tetrazol-5-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(2-ethyl-2H-tetrazol-5-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
4-((4-(2H-tetrazol-5-yl)phenyl)amino)-2-(azepan-1-yl)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((6-(4-ethylpiperazin-1-yl)pyridin-3-yl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((6-(4-ethylpiperazin-1-yl)pyridin-3-yl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(4-(5-oxo-4-((4-(2-(piperazin-1-yl)ethoxy)phenyl)amino)-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperazin-1-yl)acetonitrile;
2-(1-(5-oxo-4-((6-(piperazin-1-yl)pyridin-3-yl)amino)-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(1-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-3-yl)acetic acid;
2-(1-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-3-yl)acetic acid;
3-(4-(5-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)pyridin-2-yl)piperazin-1-yl)-3-oxopropanenitrile;
2-(5-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)-2H-tetrazol-2-yl)acetic acid;
2-(azepan-1-yl)-4-((6-(4-(2-hydroxyethyl)piperidin-1-yl)pyridin-3-yl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
3-(4-(5-((2-(4-(cyanomethyl)piperidin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)pyridin-2-yl)piperazin-1-yl)-3-oxopropanenitrile;
2-(azepan-1-yl)-4-((6-(4-(2-hydroxy-2-methylpropanoyl)piperazin-1-yl)pyridin-3-yl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(azepan-1-yl)-4-((4-(2-(4-(2-hydroxyethyl)piperazin-1-yl)ethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
3-(4-(4-((2-(4-(cyanomethyl)piperidin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperazin-1-yl)-3-oxopropanenitrile;
2-(5-(4-((2-(4-(cyanomethyl)piperidin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)-2H-tetrazol-2-yl)acetic acid;
2-(azepan-1-yl)-4-((6-(4-methylpiperazin-1-yl)pyridin-3-yl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((6-(4-methylpiperazin-1-yl)pyridin-3-yl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
4-((4-(4-((2H-tetrazol-5-yl)methyl)piperidin-1-yl)phenyl)amino)-2-(azepan-1-yl)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(2H-tetrazol-5-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(1-(4-((4-(4-((2H-tetrazol-5-yl)methyl)piperidin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(1-(5-((2-(4-(cyanomethyl)piperidin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)pyridin-2-yl)piperidin-3-yl)acetic acid;
2-(1-(4-((2-(4-(cyanomethyl)piperidin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)piperidin-3-yl)acetic acid;
2-(1-(4-((6-(4-(2-hydroxy-2-methylpropanoyl)piperazin-1-yl)pyridin-3-yl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
4-((6-(4-((2H-tetrazol-5-yl)methyl)piperidin-1-yl)pyridin-3-yl)amino)-2-(azepan-1-yl)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((6-(4-((2H-tetrazol-5-yl)methyl)piperidin-1-yl)pyridin-3-yl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(4-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenoxy)piperidin-1-yl)acetic acid;
2-(azepan-1-yl)-4-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(1-(4-((4-(4-(2-aminoethyl)piperazin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(1-(hydroxymethyl)-6-azaspiro[2.5]octan-6-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(1-(hydroxymethyl)-6-azaspiro[2.5]octan-6-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(4-(3-hydroxypropyl)piperazin-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(4-(3-hydroxypropyl)piperazin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(4-(4-((2-(4-(cyanomethyl)piperidin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenoxy)piperidin-1-yl)acetic acid;
2-(azepan-1-yl)-4-((4-(4-(2-hydroxyethyl)-1,4-diazepan-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(4-(2-hydroxyethyl)-1,4-diazepan-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(4-(1-hydroxy-2-methylpropan-2-yl)piperazin-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(4-(1-hydroxy-2-methylpropan-2-yl)piperazin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(4-(2-(dimethylamino)ethyl)piperazin-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(4-(2-(dimethylamino)ethyl)piperazin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(2-(4-ethylpiperazin-1-yl)-2-oxoethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(2-(4-ethylpiperazin-1-yl)-2-oxoethoxy)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(1-(4-((4-(2-(4-methylpiperazin-1-yl)-2-oxoethoxy)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(3-(2-hydroxyethyl)piperidin-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(azepan-1-yl)-4-((4-(4-(2,3-dihydroxypropyl)piperazin-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(4-(2,3-dihydroxypropyl)piperazin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(4-(2-fluoroethyl)piperazin-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(4-(2-fluoroethyl)piperazin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((6-(3-hydroxypiperidin-1-yl)pyridin-3-yl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((6-(3-hydroxypiperidin-1-yl)pyridin-3-yl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(4,4-difluoropiperidin-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(4,4-difluoropiperidin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(3-hydroxypiperidin-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(3-hydroxypiperidin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(2-(4-methylpiperazin-1-yl)-2-oxoethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(3-(hydroxymethyl)piperidin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(3-(hydroxymethyl)piperidin-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(3-(2-hydroxyethyl)piperidin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(1-(4-((4-(4-methoxypiperidin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(4-methoxypiperidin-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(azepan-1-yl)-4-((4-(4-fluoropiperidin-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(4-fluoropiperidin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(1-(4-((4-((1-(2-hydroxyethyl)piperidin-4-yl)oxy)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(piperidin-4-yloxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one hydrochloride;
2-(1-(4-((4-(2-hydroxyethoxy)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(2-hydroxyethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(3-hydroxypropoxy)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(3-hydroxypropoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(4-(1-hydroxy-2-methylpropan-2-yl)-1,4-diazepan-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(4-(2-fluoroethyl)piperidin-1-yl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(4-(2-fluoroethyl)piperidin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(1-(4-((3,5-dimethoxyphenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(1-(5-oxo-4-((4-(trifluoromethoxy)phenyl)amino)-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((3,5-dimethoxyphenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(azepan-1-yl)-4-((4-(trifluoromethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
3-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)propanoic acid;
3-(4-((2-(4-(cyanomethyl)piperidin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenyl)propanoic acid;
2-(azepan-1-yl)-4-((4-(bis(2-hydroxyethyl)amino)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(bis(2-hydroxyethyl)amino)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(3-hydroxypropyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(3-hydroxypropyl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((3-(hydroxymethyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((3-(hydroxymethyl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(1-(4-((4-fluorophenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-fluorophenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(azepan-1-yl)-4-((4-((1-hydroxy-2-methylpropan-2-yl)oxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-((1-hydroxy-2-methylpropan-2-yl)oxy)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(4-((2-(azepan-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenoxy)-2-methylpropanoic acid;
2-(4-((2-(4-(cyanomethyl)piperidin-1-yl)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-4-yl)amino)phenoxy)-2-methylpropanoic acid;
2-(azepan-1-yl)-4-((3,4-dimethoxyphenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((3,4-dimethoxyphenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((3-methoxyphenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((3-methoxyphenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(2-hydroxyethyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(2-hydroxyethyl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(2-methoxyethoxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(2-methoxyethoxy)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(1-(5-oxo-4-((3,4,5-trimethoxyphenyl)amino)-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-(benzo[d][1,3]dioxol-5-ylamino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-(benzo[d][1,3]dioxol-5-ylamino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-((1-(2-hydroxyethyl)piperidin-4-yl)oxy)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
sodium (2-(4-(cyanomethyl)piperidin-1-yl)-4-((4-(4-hydroxypiperidin-1-yl)phenyl)amino)-5-oxopyrimido[4,5-d]pyridazin-6(5H)-yl)methyl phosphate;
2-(azepan-1-yl)-4-((4-(hydroxymethyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((4-(hydroxymethyl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(1-(4-((4-(methylsulfonyl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(azepan-1-yl)-4-((4-(methylsulfonyl)phenyl)amino)pyrimido[4,5-d]pyridazin-5(6H)-one;
2-(1-(4-((1H-benzo[d][1,2,3]triazol-5-yl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(1-(5-oxo-4-((2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)amino)-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(1-(4-((4-(3-fluoropropyl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile;
2-(1-(4-((4-(difluoromethoxy)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile; or
4-((1H-benzo[d][1,2,3]triazol-5-yl)amino)-2-(azepan-1-yl)pyrimido[4,5-d]pyridazin-5(6H)-one.
3. The method of claim 1, wherein the compound is a salt of an acid and the acid is selected from the group consisting of acetic, propionic, lactic, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, phthalic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, napthalenesulfonic, benzenesulfonic, toluenesulfonic, trifluoroacetic, and camphorsulfonic.
4. The method of claim 1, wherein the ester is selected from the group consisting of acetyl, propionyl and benzoyl esters.
5. The method of claim 1, wherein the cancer is a hematopoietic cancer.
6. The method of claim 5, wherein the hematopoietic cancer is lymphoma.
7. The method of claim 6, wherein the lymphoma is diffuse large B-cell lymphoma.
8. The method of claim 6, wherein the lymphoma is mantle cell lymphoma.
9. The method of claim 6, wherein the lymphoma is follicular lymphoma.
10. The method of claim 5, wherein the hematopoietic cancer is leukemia.
11. The method of claim 10, wherein the leukemia is acute myeloid leukemia (AML).
12. The method of claim 11, wherein the AML is human erythroleukemia.
13. The method of claim 5, wherein the hematopoietic cancer is multiple myeloma.
14. The method of claim 5, wherein the cancer is refractory to Ibrutinib.
15. The method of claim 1, wherein the cancer is characterized by a solid tumor.
16. The method of claim 15, wherein the cancer is bladder cancer.
17. The method of claim 15, wherein the cancer is liver cancer.
18. The method of claim 15, wherein the cancer is colon cancer.
19. The method of claim 15, wherein the cancer is lung cancer.
20. The method of claim 1, wherein the compound of formula (I) is 2-(1-(4-((4-(4-hydroxypiperidin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile, or a pharmaceutically acceptable salt or ester thereof.
21. The method of claim 1, wherein the subject is a mammal.
22. The method of claim 21, wherein the mammal is human.
23. The method of claim 1, wherein the compound is administered orally.
24. The method of claim 1, wherein the compound is administered parenterally.
25. The method of claim 24, wherein the compound is administered via injection.
26. The method of claim 1, wherein the compound of formula (I) is formulated in a dosage form further comprising a pharmaceutically acceptable carrier.
27. A method of inhibiting growth and proliferation of cancer cells in vitro or in vivo, comprising contacting the cancer cells with an amount of the compound of formula (I) effective to inhibit the growth or proliferation of the cancer cells.
28. A method of inhibiting tumor growth, comprising contacting the tumor with an amount of the compound of formula (I) effective to inhibit the growth of the tumor.
US16/179,274 2015-12-04 2018-11-02 Uses of pyrimido-pyridazinones to treat cancer Abandoned US20190070182A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/179,274 US20190070182A1 (en) 2015-12-04 2018-11-02 Uses of pyrimido-pyridazinones to treat cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562263398P 2015-12-04 2015-12-04
US15/365,222 US10188654B2 (en) 2015-12-04 2016-11-30 Uses of pyrimido-pyridazinones to treat cancer
US16/179,274 US20190070182A1 (en) 2015-12-04 2018-11-02 Uses of pyrimido-pyridazinones to treat cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/365,222 Continuation US10188654B2 (en) 2015-12-04 2016-11-30 Uses of pyrimido-pyridazinones to treat cancer

Publications (1)

Publication Number Publication Date
US20190070182A1 true US20190070182A1 (en) 2019-03-07

Family

ID=57570591

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/365,222 Active US10188654B2 (en) 2015-12-04 2016-11-30 Uses of pyrimido-pyridazinones to treat cancer
US16/179,274 Abandoned US20190070182A1 (en) 2015-12-04 2018-11-02 Uses of pyrimido-pyridazinones to treat cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US15/365,222 Active US10188654B2 (en) 2015-12-04 2016-11-30 Uses of pyrimido-pyridazinones to treat cancer

Country Status (15)

Country Link
US (2) US10188654B2 (en)
EP (1) EP3383399A1 (en)
JP (1) JP2018535995A (en)
KR (1) KR20180084983A (en)
CN (1) CN108601785A (en)
AR (1) AR106830A1 (en)
AU (1) AU2016365215A1 (en)
BR (1) BR112018011196A2 (en)
CA (1) CA3006762A1 (en)
IL (1) IL259781A (en)
MX (1) MX2018006776A (en)
RU (1) RU2018124289A (en)
TW (1) TW201726141A (en)
WO (1) WO2017095898A1 (en)
ZA (1) ZA201803593B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190092779A1 (en) * 2011-08-23 2019-03-28 Asana Biosciences, Llc Pyrimido-pyridazinone compounds and methods of use thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111961035B (en) * 2019-05-20 2022-11-01 南京科技职业学院 Compound containing hydroxyisoquinoline structure, pharmaceutical composition and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009145856A1 (en) * 2008-04-16 2009-12-03 Portola Pharmaceuticals, Inc. 2, 6-diamino-pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors
US8383635B2 (en) * 2008-08-12 2013-02-26 Glaxosmithkline Llc Chemical compounds
CA2779105C (en) * 2009-10-29 2016-08-16 Hong Woo Kim Kinase inhibitors
US8796289B2 (en) 2011-07-19 2014-08-05 Abbvie Inc. Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
ES2690971T3 (en) * 2011-08-23 2018-11-23 Asana Biosciences, Llc Pyrimido-pyridazinone compounds and their use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190092779A1 (en) * 2011-08-23 2019-03-28 Asana Biosciences, Llc Pyrimido-pyridazinone compounds and methods of use thereof
US10647720B2 (en) * 2011-08-23 2020-05-12 Asan BioSciences, LLC Pyrimido-pyridazinone compounds and methods of use thereof

Also Published As

Publication number Publication date
RU2018124289A (en) 2020-01-14
EP3383399A1 (en) 2018-10-10
KR20180084983A (en) 2018-07-25
CA3006762A1 (en) 2017-06-08
MX2018006776A (en) 2018-08-15
CN108601785A (en) 2018-09-28
ZA201803593B (en) 2019-04-24
AU2016365215A1 (en) 2018-07-05
WO2017095898A1 (en) 2017-06-08
JP2018535995A (en) 2018-12-06
US10188654B2 (en) 2019-01-29
AR106830A1 (en) 2018-02-21
BR112018011196A2 (en) 2018-11-21
TW201726141A (en) 2017-08-01
US20170157126A1 (en) 2017-06-08
IL259781A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
US20220241261A1 (en) Combinations of inhibitors of irak4 with inhibitors of btk
USRE49556E1 (en) Compounds and compositions as protein kinase inhibitors
US10144706B2 (en) Compounds useful as immunomodulators
RU2687060C2 (en) Pharmaceutical compounds
US10745382B2 (en) Compounds useful as immunomodulators
RU2632907C2 (en) Dyetered diaminopyrimidine compounds and pharmaceutical compositions containing such connections
AU2016391377B2 (en) 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (Chk1) inhibitors, and their preparations and applications
CN110772640B (en) Synergistic antitumor effect of Bcl-2 inhibitors in combination with rituximab and/or bendamustine or with CHOP
US20190263804A1 (en) Azabenzimidazole derivatives as pi3k beta inhibitors
US11285132B2 (en) Uses of indolinone compounds
ES2952281T3 (en) Deuterated compounds for use in cancer treatment
US20190070182A1 (en) Uses of pyrimido-pyridazinones to treat cancer
US20200268728A1 (en) Drug targeting cancer stem cell
US20220041588A1 (en) Substituted imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JP2012255038A (en) Pyrimidine derivative for treatment of abnormal cell growth
ES2295605T3 (en) 2,5-DIONA-3- (1-METHYL-1H-INDOL-3-IL) -4-1 (PIRIDIN-2-ILMETIL) PIPERIDIN-4-IL-1H-INDOL-3-IL-1H CRYSTAL MONOCLORHYDRATE -PIRROL.
CN112888441A (en) Treatment of B cell malignancies
JP2013525290A5 (en)
CA2891900C (en) Derivatives of indole for the treatment of cancer, viral infections and lung diseases
CN108473504B (en) Novel dihydropyranopyrimidinone derivatives and uses thereof
US20220144776A1 (en) Analogues of pentamidine and uses therefor
CN115279754A (en) Isoxazole derivatives targeting TACC3 as anticancer agents
WO2019131794A1 (en) Anticancer agent
US20110281896A1 (en) Optically pure quinazoline compounds
US10351540B2 (en) 1,2-dithiolane and dithiol compounds useful in treating mutant EGFR-mediated diseases and conditions

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

AS Assignment

Owner name: ASANA BIOSCIENCES, LLC, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:REDDY, SANJEEVA P.;GUPTA, SANDEEP;SMITH, ROGER ASTBURY;REEL/FRAME:051010/0481

Effective date: 20160104

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION